# Patent

## Title
Neuropathy improvers containing nitrogenous compounds as the active ingredient

## Abstract

A compound represented by the Formula below, and an agent for the remedy of neural damage having the said compound as the active ingredient.




[Here, G represents G1 shown below





R4 represents, hydrogen atoms and acyl groups, W represents single bonds and alkylenes, m represents 0 or 1, R5 and R6 represent hydrogen atoms, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, aromatic hydrocarbon groups and heterocyclic groups, and R7 represents hydrogen atoms, acyl groups and alkoxycarbonyl groups. A2 represents, single bonds, —O—, —NR3—, and —S(═O)n—, A1 and A3 represent single bonds, aliphatic hydrocarbon groups, alicyclic hydrocarbon groups, heterocyclic groups and phenylene groups, and A4 represents single bonds, carbonyl groups and aliphatic hydrocarbon groups. R1 and R2 represent hydrogen atoms, alkyl groups, cycloalkyl groups, phenyl groups and heterocyclic groups. The previously mentioned functional groups may be substituted.]

## Background
TECHNICAL FIELD
The present invention relates to an agent for the remedy of neural damage wherein the active ingredient is a nitrogen-containing compound having a prostacyclin analog structure and an amido group or an amino group at the extremity of the α-chain, as well as pharmaceutical compositions thereof. In addition, the invention relates to a nitrogen-containing compound having a prostacyclin analog structure and an amino group at the extremity of the α-chain, as well as salts thereof.
TECHNICAL BACKGROUND
In the nervous system, neurons perform their function once they have formed a network through synapses between neurons by extending neurites (either axon or dendrite). In addition, such intercellular communication allows the cells to maintain their own existence through a mutual exchange of transmitters and nutritional factors. Therefore, even if the neurons themselves do not suffer fatal damage, if the neural network is damaged, neural functions decrease and, further, may lead to the death of the neurons themselves. Such neural network damage is thought to be what takes place first, not only in cases such as in external injuries where axons are disrupted, but also in many disorders causing neural damage, or in the surroundings of the damaged site. Therefore, a drug agent having a capability such as restoring neural network damage is thought to be both a drug agent capable of controlling the cellular death of neurons and an extremely active drug agent for the remedy of many disorders due to neural damage as well as lesion of nerves due to external injuries.
The following may be cited as disorders caused by neural damage: 1) Neuro-degenerative disorders such as Alzheimer's disease, Pick's disease, Lewy body disease, Parkinson's disease, Huntington's chorea, spinocerebellar degeneration and amyotrophic lateral sclerosis, 2) demyelinating disorders such as acute disseminated encephalomyelitis and multiple sclerosis, 3) metabolic disorders such as brain lipidosis and Wilson's Disease, 4) infectious disorders such as meningitis and Creutzfeld-Jacob disease, 5) peripheral neural disorders such as polyneuritis and Guillain-Barre Syndrome, 6) cerebrovascular disorder such as cerebral infarction and transient ischemia, 7) nervous disorders (neuropathies) associated with diabetes and renal diseases and 8) brain tumors.
Among the previously mentioned disorders which cause neural damage, Alzheimer's disease is the most representative, and constitutes a serious social issue together with the increase in the population of the elderly. In the past, the drug agents used for treating Alzheimer's disease could be roughly divided into those classified as activators of brain circulation and metabolism, and those classified as cholinergic nervous system activators. However, the activities of these drug agents are not sufficient.
In other words, activators of brain circulation and metabolism are drugs that are used to treat cerebrovascular damage and their after-effects, do not aid recovery directly from neural damage and therefore have a low efficacy against dementia which is the core disorder in Alzheimer's disease. In addition, activators of the cholinergic nervous system were developed based on the pathological findings that Alzheimer's disease patients had notable damage in the cholinergic nervous system. However, in Alzheimer's disease, cholinergic nervous systems are actually not the only ones that are damaged, therefore, the effects of such drugs are thought to be limited.
Given the situation, development of drugs based on novel drug effects for the treatment of Alzheimer's disease are strongly in demand. Among others, drug agents having an activity such as restoring neural network damage, as mentioned above, are anticipated to display extremely high efficacy for the treatment of Alzheimer's disease, if put into practical application.
In the past, for the development of drugs for the treatment of Alzheimer's disease, the models used for evaluating the drug's efficacy at the animal level were mainly models where the cholinergic nervous system was specifically damaged by methods such as administration of scoporamine or electric destruction, or models where damage was produced by cerebral ischemia or hypoxic stress due to carbon dioxide. Although many of these evaluation systems are reasonable as evaluation systems for the activators of the cholinergic nervous system or activators of brain circulation and metabolism, they are pathogenetically and pathologically distant from actual Alzheimer's disease, and are therefore not suited to the evaluation of novel drugs for the treatment of Alzheimer disease.
One important characteristic of Alzheimer's disease is the formation of senile plaques in the brain. β-amyloid proteins, which are the main constituents of these senile plaques, agglutinate in the brain to form amyloids and while being deposited in the brain tissue, exhibit their neurotoxicity, which is thought to be the main cause for Alzheimer's disease. Based on this, an animal model of Alzheimer's disease was made, wherein a mini-osmotic pump is implanted under the dorsal skin of a rat, for a continuous intracerebroventricular administration of β-amyloid proteins to lower the ability of learning and memory (Neuroscience Letters, vol. 170, pp. 63–66, 1994). In this model, deposition of the β-amyloid proteins could be recognized in the periphery of the cerebral ventricle. However, no clear neural cell death could be observed, therefore, there is a high possibility that the disorder of learning and memory observed in this model are due to damage in the neural network. Therefore, this model is an extremely rational system for screening and evaluating novel drugs for the treatment of Alzheimer's disease, and at the same time, is an adequate system for screening and evaluating novel drugs for the treatment of neural lesion due to a whole range of diseases causing neural damage, or due to injuries.
On the other hand, prostaglandin (PG) compounds are known to have multiple physiological activities such as strong platelet aggregation inhibition activity, vasodilatation and the associated hypotension activities, gastric acid secretion inhibition activity, smooth muscle contraction activity, cell protection activity, and diuretic activity. Based on such physiological activities, a number of attempts have been made to develop medicine from natural PG present in vivo, or from PG derivatives synthesized to serve as its agonists, and some of these attempts actually reached the market.
Prostacyclin, which is a PG, has the structure represented by the formula below (PGI2),




(in the formula, the numbers are identification numbers for the carbon atoms in prostacyclin) which is a substance containing a structure called α-chain comprising the carbon chain from 1 to 7, and a structure called ω-chain from carbon 13 to 20. In vivo it is known as a local hormone, mainly made in the vascular endothelium, and attempts were made to use its strong physiological activities, for example, platelet aggregation inhibition, smooth muscle contraction, hypotension, gastric acid secretion inhibition, peripheral vasodilatation and bronchodilatation, to provide it directly as a medicine (P. J. Lewis, J. O. Grady, Clinical Pharmacology of Prostaglandin).

However, because a prostacyclin molecule has a highly hydrolizable enol-ether bond, it is easily inactivated under neutral or acidic conditions, which makes it problematic in compounds to be used as medicines. Therefore, synthetic research was carried out on a compound having a prostacyclin analog structure, displaying the same activity as prostacyclin and being chemically stable (Synthesis, 1984, p. 449). In other words, this objective was achieved mainly by modifying the bicyclo[3.3.0]octane ring structure of from carbon 5 to 12 in prostacyclin. For example, the oxygen atoms bridging position 6 to 9 may be substituted with a methene group (—CH═) to synthesize the compound 9(O)-methano-Δ6(9α)-prostaglandin I1 (Isocarbacyclin) indicated by the formula below (Isocarbacyclin),




which is a compound having a prostacyclin analog structure fully satisfying the chemical stability (Japanese patent publication Sho. 59-210044). This compound displayed biological activities comparable to those of prostacyclin such as strong platelet aggregation inhibitory activity and vasodilatory-hypotensive activities (Japanese patent publication Sho. 59-210044 and Japanese patent publication Sho. 61-197518).

In the past, development of PG compounds to be used as medicine was mainly carried out in the field of obstetrics and gynecology, circulation or digestion. In the nerve field, there are no examples of these compounds commercialized as medicine, although there have been reports on the possibility of using PG compounds in nervous systems.
The following are known examples describing in particular the effect of compounds having a prostacyclin analog structure and which remedy neural damage: 1) in Japanese patent publication Sho. 61-129146, a compound having an isocarbacyclin analog structure was used for the prevention of or the treatment of the brain for disorders such as cerebral oxygen deficiency, 2) in Japanese patent publication Hei. 2-167227, a compound having an isocarbacyclin analog structure was used for the treatment of diabetic neuropathy, 3) in Japanese patent publication Hei. 8-245498, Japanese patent publication Hei. 10-101610, Japanese patent publication Hei. 11-5764 and patent No. EP-911314, a compound having an isocarbacyclin analog structure was used as a drug for the treatment of central nervous system disease, via the prostacyclin receptor of the central nervous system 4) in patent No. WO89/03387, 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivative was used as a drug for the treatment of cerebral ischemia 5) in Japanese patent publication Hei. 2-262519, beraprost was used for the treatment of diabetic neuropathy, 6) in Japanese patent publication Sho. 63-141927, treatment and prevention of cerebral thrombosis and cerebral infarction.
In the previously mentioned examples, however, the efficacy is described for compounds with a carboxyl group at position 1 of the prostacyclin or an ester thereof. Only in the compounds having a prostacyclin analog structure described in the above mentioned 6), a compound having a prostacyclin analog structure wherein the carboxyl group at position 1 is substituted by an amide group is described. However, there is no concrete description related to its pharmacological activity. Therefore, the usability of a compound having a prostacyclin analog structure wherein the carboxyl group at position 1 is substituted with an amide group, as a drug for the remedy of neural damage, was not known.
On the other hand, most of the compounds of the past known to have a prostaglandin analog activity, are compounds having a prostacyclin analog structure with, at position 1, a carboxyl group which is thought to be important for expressing the activity, or a chemical structure that can be easily substituted with a carboxyl group in vivo. Therefore, there are only few publicly known substances having a prostacyclin analog structure with an amino group at the extremity of the α-chain. For example, the compound below, described in the (East) German patent No. DD266102,




(in the formula, the symbol  indicates the E or the Z configuration with respect to the attached double-bond and TBDMS represents a t-butyl-dimethylsilyl group). However, it is positioned as a synthetic intermediate, and a description of its activity is not available.

In addition, in the U.S. patent publication No. U.S. Pat. No. 4,226,984, the compounds having the structure indicated below




and their substituted versions on the (o-chain are described as having a stimulatory effect on smooth muscles. However, no concrete example is given.

In addition, in the Japanese patent publication Sho. 54-117450, a synthesis of the compound having the structure below




is described. However, no description on its activity is given.

In addition, in the Japanese patent publication Sho. 62-67046, the compounds of the scheme below







(in the scheme, THP represents tetrahydropyrane-2-yl group and TBDMS represents a t-butyl-dimethylsilyl group.) and their substituted versions on the ω-chain are described. However, no description of their activity is given.

In addition, in the Japanese patent publication Hei. 9-67285, the 4 compounds below




are described. However, no description of their activity is given.

In addition, in the detailed description of WO00/24727, only a description of the anti-helicobacter activity is given, of a derivative of the compound having an amino group at the extremity of the α-chain, comprising the compound indicated by the formula below,




and being a compound with a prostacyclin analog structure.

Therefore, most of the compounds having a prostacyclin analog structure with an amino group at the extremity of the α-chain were novel substances with no known usability.
DISCLOSURE OF THE INVENTION
The problem to be solved by the present invention is to provide a novel agent for the remedy of neural damage which can act against disorders due to neural damage, or against neural lesions due to external injuries. Here, disorders caused by neural damage, or disorders caused by neural lesions due to external injuries may be cited as disorders in which the agent for the remedy of neural damage of the present invention can be used. Concretely, the following may be cited as disorders caused by neural damage: 1) Neuro-degenerative disorders such as Alzheimer's disease, Pick's disease, Lewy body disease, Parkinson's disease, Huntington's chorea, spinocerebellar degeneration and amyotrophic lateral sclerosis, 2) demyelinating disorders such as acute disseminated encephalomyelitis and multiple sclerosis, 3) metabolic disorders such as brain lipidosis and Wilson's Disease, 4) infectious disorders such as meningitis and Creutzfeld-Jacob disease, 5) peripheral neuropathies such as polyneuritis and Guillain-Barre Syndrome, 6) cerebrovascular disorder such as cerebral infarction and transient ischemia, 7) nervous disorders (neuropathies) associated with diabetes and renal diseases and 8) brain tumors.
In addition, when attempting to develop PG compounds to serve as a medicine in the cerebral nerve field, two problems have to be considered. The first problem is that the diversity of activities that PG compound has may cause adverse events. In order to solve this problem, it is necessary to use compounds that are active as specifically on the cerebral nervous system as possible, with low influences on other parts such as circulatory organs. The second problem is that, in contrast to the vascular system in peripheral organs, in the vascular system of the brain, the vascular endothelial cells are associated by tight junctions, which results in a limitation of the delivery of substances from the circulating blood to the parenchymal tissue of the brain, that is, a so-called blood brain barrier exists. Therefore, in order to develop drug agents for the cerebral nervous system, it is necessary to obtain drugs with a high permeability across the blood brain barrier.
After performing extensive research on the above-mentioned problems employing neuroid cells to evaluate the promotion activity on the neurite outgrowth, an evaluation system using an animal model for Alzheimer type dementia wherein β-amyloid protein is continuously injected, and a system to evaluate the decrease of blood pressure, the inventors of the present application found that the nitrogen-containing compound in the formula (1) shown below, having a prostacyclin analog structure and an amido group or an amino group at the extremity of the α-chain, had the activity of promoting the neurite outgrowth, as well as the activity of remedying disorders of learning and memory provoked by the β-amyloid protein. In addition, the above-mentioned compounds showed that they have only a low influence on the peripheral circulatory system, that their activity displays a high specificity for the brain, and that the above mentioned compound has a high permeability across blood brain barriers, allowing the present invention to be completed.
In other words, the present invention is an agent for the remedy of nerve disorders having as the active ingredient the compound represented by the formula (1) shown below.




[In Formula (1), the symbol  represents a single bond or a double bond.

G represents one functional group chosen from the group consisting of the Formulae (G1), (G2), (G3), (G4), (G5), (G6), (G7), (G8), (G9), (G10), (G11) and (G12) shown below.










(In Formula G1), Formula (G2), Formula (G3), Formula (G4), Formula (G5), Formula (G6), Formula (G7), Formula (G8), Formula (G9), Formula (G10), Formula (G11) and Formula (G12),

the symbol  represents the site of linkage with A1.

R4 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group or a functional group forming the acetal bond together with the oxygen atom bonded to R4.
W represents a single bond, —CH2—, —(CH2)2—, —(CH2)3—, —CH═CH—, —CH═CHCH2—, —C═C— or —C═CCH2—.

    
    
        m may be either 0 or 1. However, when W is a single bond, m is equal to 1.
        R5 and R6 are either identical or different and, either represents one functional group chosen from the following items 1) to 5), i.e.,
    
    
    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    or, when R5 and R6 are bonded to each other, they represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, an acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


R7 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, a functional group forming the acetal bond together with the oxygen atom bound to R7, or, when R7 and R5 are bonded to each other, it represents one portion of the bond forming the carbonyl group together with the carbon atom bonded to R5 and the oxygen atom bonded to R7.
A2 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below.




(In the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.)





(In the formula, n represents 0, 1, or 2.)

A1 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges G and A2 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A3 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges A2 and A4 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A4 represents either of the items 1) to 4) below

    1) a single bond
    2) a carbonyl group
    3) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R1 and R2, and A3 through an identical atom or through different atoms.
    4) when A4 and R1 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A4 or R1 and the nitrogen atom they are bonded to are bonded through a double bond, R2 represents the bond between A4 or R1 and the nitrogen atom.)


However, in the combination of A1, A2, A3 and A4, A1, A2, A3 and A4 may not simultaneously represent bonds. In addition, when A2 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A2 and the nitrogen atom bonded to R1 and R2 must be bonded with more than two carbon atoms in between.
R1 and R2 are either identical or different, and either represent one functional group chosen from the following items 1) to 7), i.e.,

    1) a hydrogen atom,
    2) a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, phenyl group, and, heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms) may be cited as substituents),
    3) a substituted or an unsubstituted cycloalkyl group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted phenyl group (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms, and, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    6) an acyl group having 1 to 10 carbon atoms when A4 is not a carbonyl group,
    7) a sulfonyl group having 1 to 8 carbon atoms when A4 is not a carbonyl group (however, when either R1 or R2 represents a sulfonyl group having 1 to 8 carbon atoms, the other may be neither an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms), or, when R1 and R2 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to (for said cyclic amino group having 4 to 8 carbon atoms, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents)].


In addition, the present invention is a nitrogen-containing compound represented by Formula (2) below or a salt thereof.




[In Formula (2), the symbol  represents a single bond or a double bond. G represents one functional group chosen from the group consisting of the Formulae (G1), (G2), (G3), (G4), (G5), (G6), (G7), (G8), (G9), (G10), (G11) and (G12) shown above. (In Formula (G1), Formula (G2), Formula (G3), Formula (G4), Formula (G5), Formula (G6), Formula (G7), Formula (G8), Formula (G9), Formula (G10), Formula (G11) and Formula (G12), the symbol  represents the site of linkage with A10.

R4, W, m, R5, R6 and R7 have the same definitions as above.
A20 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below.




(In the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.)





(In the formula, n represents 0, 1, or 2.)

A10 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges G and A20 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A30 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges A20 and A40 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A40 represents any of the items 1) to 3) below

    1) a single bond
    2) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R10 and R20, and A30 through an identical atom or through different atoms.
    3) when A40 and R10 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A40 or R10 and the nitrogen atom they are bonded to are bonded through a double bond, R20 represents the bond between A40 or R10 and the nitrogen atom.)


However, in the combination of G, A10, A20, A30, and A40, when G represents the Formula (G1), and either of A10 or A30 is a phenylene group, A20 may not be a single bond and when A20 represents a single bond, then G and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between. In addition, when A20 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A20 and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between.
R10 and R20 are either identical or different, and either represent one functional group chosen from the following items 1) to 7), i.e.,

    1) a hydrogen atom (however, when R10 and R20 both represent a hydrogen atom, only in the case where G is equal to Formula (G1)),
    2) when G is not equal to Formula (G7), a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, phenyl group, and, heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms) may be cited as substituents),
    3) when G is not equal to Formula (G7), a substituted or an unsubstituted cycloalkyl group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) when G is not equal to Formula (G7), a substituted or an unsubstituted phenyl group (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms, and, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    6) when G is not equal to Formula (G7), an acyl group having 1 to 10 carbon atoms
    7) when G is not equal to Formula (G7), a sulfonyl group having 1 to 8 carbon atoms (however, when either R10 or R20 represents a sulfonyl group having 1 to 8 carbon atoms, the other may neither be an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms),
    or, when R10 and R20 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to (for said cyclic amino group having 4 to 8 carbon atoms, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents)]




PREFERRED EMBODIMENTS
In the following, the present invention will be explained in detail.
In Formula (1) above, the symbol  represents a single bond or a double bond. G1, G2, G5, G6, G8, G10, G11 and G12 may be cited as acceptable G for forming a double bond with such a bonding site.
In other words, Formula (1) above, in combination with G, forms one of the Formulae (1-G1), (1-G2), (1-G3), (1-G4), (1-G5), (1-G6), (1-G7), (1-G8), (1-G9), (1-G10), (1-G11) or (1-G12), below.










[In Formula (1-G1), Formula (1-G2), Formula (1-G3), Formula (1-G4), Formula (1-G5), Formula (1-G6), Formula (1-G7), Formula (1-G8), Formula (1-G9), Formula (1-G10), Formula (1-G11) and Formula (1-G12), the symbol  , A1, A2, A3, A4, R1, R2, R4, R5, R6, R7, m and W, have the same definitions as above.]

G1, G2, G3, G4, G5, G6 and G7 may be cited as such a preferred functional group for G. Among them G1, G3 and G7 are more preferred and G1 is especially preferred.
Each of the above Formulae (1-G1), (1-G2), (1-G3), (1-G4), (1-G5), (1-G6), (1-G7), (1-G8), (1-G9), (1-G10), (1-G11) and (1-G12) have a preferred spatial configuration and the ones represented by the Formulae (1-G1E), (1-G2E), (1-G3E), (1-G4E), (1-G5E), (1-G6E), (1-G7E), (1-G8E), (1-G9E), (1-G10E), (1-G11E) and (1-G12E) below may be cited.










[In Formula (1-G1E), Formula (1-G2E), Formula (1-G3E), Formula (1-G4E), Formula (1-G5E), Formula (1-G6E), Formula (1-G7E), Formula (1-G8E), Formula (1-G9E), Formula (1-G10E), Formula (1-G11E) and Formula (1-G12E), the symbol , A1, A2, A3, A4, R1, R2, R4, R5, R6, R7, m, and W have the same definitions as above. The symbol  indicates that the bond is in the βposition with respect to the carbon atom forming the cyclic structure it is bonded to. The symbol  indicates that the bonds are in the a position with respect to the carbon atoms forming the cyclic structure they are bonded to.]

In the above Formula (1), R4 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group or a functional group forming the acetal bond together with the oxygen atom bonded to R4.
As examples of such R4 which are acyl groups having 2 to 10 carbon atoms, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group, and a cinnamoyl group may be cited. However, an acetyl group and a benzoyl group may be cited as preferred examples.
In addition, as examples of a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, a trimethylsilyl group, a triethylsilyl group, a dimethylisopropylsilyl group, a dimethylhexylsilyl group, a t-butyldimethylsilyl group, a triisopropylsilyl group, a t-butyldiphenylsilyl group, and a tribenzylsilyl group may be cited. However, a trimethylsilyl group, a triethylsilyl group, and a t-butyldimethylsilyl group may be cited as preferred examples.
In addition, as examples of functional groups forming the acetal bond together with the oxygen atom bonded to R4, a methoxymethyl group, a 1-ethoxyethyl group, a 1-methoxy-1-methylethyl group, a 2-ethoxy-1-methylethyl group, a 2-methoxyethoxymethyl group, a tetrahydropyrane-2-yl group and a 6,6-dimethyl-3-oxa-2-oxo-bicyclo[3.1.0]hexane-4-yl group may be cited. However, a methoxymethyl group, a 2-methoxyethoxymethyl group, and a tetrahydropyran-2-yl group may be cited as preferred examples.
As particularly preferred examples of such R4, a hydrogen atom; an acetyl group, a t-butyldimethylsilyl group and a tetrahydropyran-2-yl group may be cited.
In the above formula (1), W represents one of: a single bond, —CH2—, —(CH2)2—, —(CH2)3—, —CH═CH—, —CH═CHCH2—, —C≡C— or —C≡CCH2—. For said W, —CH═CH— or —CH═CHCH2— may be cited as preferred examples.
R5 and R6 are either identical or different and, either represents one functional group chosen from the following items 1) to 5), i.e.,

    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    or, when R5 and R6 are bonded to each other, they represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


R7 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, a functional group forming the acetal bond together with the oxygen atom bound to R7, or, when R7 and R5 are bonded to each other, R7 represents one portion of the bond forming the carbonyl group together with the carbon atom bonded to R5 and the oxygen atom bonded to R7.
In the partial structure represented by the Formula (W1) below, of the above Formula (1),




m may be either 0 or 1. However, when W is a single bond, m is equal to 1. When m equals 1, the above Formula (1) represents Formula (W1A) below,





[In the formula, the symbol  indicates that R51 is in the β position with respect to the carbon atom it is bonded to. The symbol  indicates that the oxygen atom is in the α position with respect to the carbon atom it is bonded to.

R51 and R61 are either identical or different and, either represents one functional group chosen from the following items 1) to 5), i.e.,

    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    or, when R51 and R61 are bonded to each other, they represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


R71 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, and a functional group forming the acetal bond together with the oxygen atom bound to R71.]
Formula (W1B) below,




[In the formula, R51, R61 and R71 have the same definitions as above. The symbol  indicates that the oxygen is in the β position with respect to the carbon atom it is bonded to. The symbol  indicates that R51 is in the α position with respect to the carbon atom it is bonded to.] or Formula (W1C) below,





[In the formula, R62 represents a functional group chosen from the following items 1] to 5], i.e.,

    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents)].


If m equals to 0 the above Formula (W1) represents the Formula (W1D) below




[In the formula, R62 has the same definition as above.]

When the above Formula (W1) represents the above Formula (W1A) or (W1B), these may be combined in any proportion.
In the above formulae(W1A), (W1B), (W1C) or (W1D), R51, R61 and R62 represent one of the items 1) to 5):

    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 0.1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


As examples of such R51, R61 or R62 which are unsubstituted aliphatic hydrocarbon groups having 1 to 10 carbon atoms, alkyl groups such as a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl group, a t-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a 4-methylpentyl group, a hexyl group, a heptyl group, a 2-methylhexyl group, a 1,1-dimethylpentyl group, an octyl group, a 3,7-dimethyloctyl group, a nonyl group, and a decyl group, alkenyl groups such as a vinyl group, a 1-methylvinyl group, a 1-ethylvinyl group, a 1-propenyl group, a 2-propenyl group, a 2-methyl-1-propenyl group, a 1-butenyl group, a 2-butenyl group, a 2-methyl-1-butenyl group, a 1,3-butadienyl group, a 1-pentenyl group, a 2-pentenyl group, a 4-methyl-1-pentenyl group, a 1-hexenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 5-hexenyl group, a 1,5-hexadienyl group, a 2-heptenyl group, a 2-octenyl group, a 2-nonenyl group, and a 2-decenyl group, and alkynyl groups such as an ethynyl group, a 1-propynyl group, a 2-propynyl group, a 1-butynyl group, a 2-methyl-1-butynyl group, a 3,3-dimethyl-1-butynyl group, a 1-pentynyl group, a 2-pentynyl group, a 3-pentynyl group, a 1-hexynyl group, a 2-hexynyl group, a 3-hexynyl group, a 4-hexynyl group, a 1-methyl-3-pentynyl group, a 1-methyl-3-hexynyl group, a 2-heptynyl group, a 2-octynyl group, a 2-nonynyl group and a 2-decynyl group may be cited. As preferred examples, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, a 2-methylhexyl group, a 1,1-dimethylpentyl group, a 1-propenyl group, a 1-butenyl group, a 2-pentenyl group, a 1-octenyl group and a 1-methyl-3-pentynyl group may be cited.
As examples of such R51, R61 or R62 which are unsubstituted alicyclic hydrocarbon groups having 3 to 8 carbon atoms, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a 1-cyclopentenyl group, a cyclohexyl group, a 1-cyclohexenyl group, a 3-cyclohexenyl group, a 4-cyclohexenyl group, a cycloheptyl group, a 1-cycloheptenyl group, and a cyclooctyl group may be cited. As preferred examples, the cyclopentyl group and the cyclohexyl group may be cited.
As examples of such R51, R61 or R62 which are unsubstituted aromatic hydrocarbon groups having 6 to 10 carbon atoms, a phenyl group, a 1-naphthyl group and a 2-naphthyl group may be cited. As a preferred example, a phenyl group may be cited.
As examples of such R51, R61 or R62 which are unsubstituted heterocyclic groups having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle, monocyclic or bicyclic groups such as a furyl group, a thiophenyl group, a pyrrolyl group, an oxazolyl group, an isooxazolyl group, a thiazolyl group, an isothiazolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a pyranyl group, a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a benzofuranyl group, an indolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a quinolyl group, an isoquinolyl group, a quinazolyl group, a purinyl group, a pteridinyl group, an azetidinyl group, a pyrrolidinyl group, a morpholino group, a piperidino group and a piperazinyl group may be cited. As a preferred example, a pyridyl group may be cited.
As examples of substitution groups when R51, R61 or R62 is a substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, alkoxy groups having 1 to 4 carbon atoms which are a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an s-butoxy group and a t-butoxy group, aryloxy groups having 6 to 10 carbon atoms which are a phenoxy group, a 1-naphthoxy group and a 2-naphthoxy group, aralkoxy groups having 7 to 9 carbon atoms such as a benzyloxy group, an α-phenethyloxy group, a β-phenethyloxy group, a phenylpropyloxy group and a cinnamyloxy group, acyloxy groups having 2 to 10 carbon atoms such as an acetoxy group, a trifluoroacetoxy group, a propionyloxy group, an isopropionyloxy group, a butyryloxy group, an isobutyryloxy group, an s-butyryloxy group, a valeryloxy group, an isovaleryloxy group, a hexanoyloxy group, a heptanoyloxy group, an octanoyloxy group, a nonanoyloxy group, a decanoyloxy group, a benzoyloxy group, a phenylacetyloxy group, a cinnamoyloxy group, a cyclopentylcarboxy group, a cyclohexylcarboxy group and a cycloheptylcarboxy group, sulfonyloxy groups having 1 to 8 carbon atoms such as a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, an ethanesulfonyloxy group, a butanesulfonyloxy group, a t-butanesulfonyloxy group, a nonafluorobutanesulfonyloxy group, a benzenesulfonyloxy group, a p-bromobenzenesulfonyloxy group, a p-toluenesulfonyloxy group, a benzylsulfonyloxy group, an α-phenethylsulfonyloxy group and a β-phenethylsulfonyloxy group, an oxo group, a carboxyl group, alkoxycarbonyl groups having 2 to 10 carbon atoms such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, an s-butoxycarbonyl group, a t-butoxycarbonyl group, a phenoxycarbonyl group, a 1-naphthoxycarbonyl group, a 2-naphthoxycarbonyl group, a benzyloxycarbonyl group, an α-phenethyloxycarbonyl group, a β-phenethyloxycarbonyl group, carbamoyl groups having 1 to 15 carbon atoms such as a carbamoyl group, an N-methylcarbamoyl group, an N-ethylcarbamoyl group, an N-propylcarbamoyl group, an N-isopropylcarbamoyl group, an N-butylcarbamoyl group, an N-isobutylcarbamoyl group, an N–s-butylcarbamoyl group, an N-t-butylcarbamoyl group, an N-pentylcarbamoyl group, an N-hexylcarbamoyl group, an N-phenylcarbamoyl group, an N-benzylcarbamoyl group, an N-phenethylcarbamoyl group, an N-cyclopropylcarbamoyl group, an N-cyclobutylcarbamoyl group, an N-cyclopentylcarbamoyl group, an N-cyclohexylcarbamoyl group, an N-cycloheptylcarbamoyl group, an N-cyclopropanemethylcarbamoyl group, an N,N-dimethylcarbamoyl group, an N,N-ethylmethylcarbamoyl group, an N,N-diethylcarbamoyl group, an N,N-dipropylcarbamoyl group, an N,N-dibutylcarbamoyl group, an N,N-dicyclohexylcarbamoyl group, an N,N-diphenylcarbamoyl group, and an N,N-dibenzylcarbamoyl group, amino groups having 0 to 14 carbon atoms such as an amino group, a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, an s-butylamino group, a t-butylamino group, a pentylamino group, an hexylamino group, an heptylamino group, an octylamino group, a nonylamino group, a decylamino group, a phenylamino group, a benzylamino group, a phenethylamino group, a cyclopropylamino group, a cyclobutylamino group, a cyclopentylamino group, a cyclohexylamino group, a cycloheptylamino group, a cyclooctylamino group, a cyclopropanemethylamino group, a dimethylamino group, an N-methylamino group, a diethylamino group, an N-methylpropylamino group, an N-methylisopropylamino group, an N-methylbutylamino group, an N-methyl-t-butylamino group, an N-ethylisopropylamino group, a dipropylamino group, a diisopropylamino group, an ethylbutylamino group, an N-methylhexylamino group, a dibutylamino group, a dipentylamino group, a dicyclohexylamino group, a diphenylamino group, a dibenzylamino group a piperidino group and a morpholino group, acylamino groups having 1 to 10 carbon atoms such as a formylamino group, an acetylamino group, a trifluoroacetylamino group, a propionylamino group, a butyrylamino group, an isobutyrylamino group, a valerylamino group, an hexanoylamino group, a benzoylamino group, a phenylacetylamino group, a phenylpropionylamino group, and a cinnamoylamino group, sulfonylamino groups having 1 to 8 carbon atoms such as a methanesulfonylamino group, a trifluoromethanesulfonylamino group, an ethanesulfonylamino group, a butanesulfonylamino group, a t-butanesulfonylamino group, a nonafluorobutanesulfonylamino group, a benzenesulfonylamino group, a p-bromobenzenesulfonylamino group, a p-toluenesulfonylamino group, a benzylsulfonylamino group, an α-phenethylsulfonylamino group and a β-phenethylsulfonylamino group, imino groups having 1 to 10 carbon atoms such as a methylimino group, an ethylimino group, a propylimino group, an isopropylimino group, a butylimino group, an isobutylimino group, a pentylimino group, an hexylimino group, an heptylimino group, an octylimino group, a nonylimino group, a decylimino group, a phenylimino group, a benzylimino group, a phenethylimino group, a cyclopropylimino group, a cyclobutylimino group, a cyclopentylimino group, a cyclohexylimino group, and a cycloheptylimino group, a cyano group, a nitro group, sulfide groups having 1 to 6 carbon atoms such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, an s-butylthio group, a t-butylthio group, a pentylthio group, an hexylthio group, a phenylthio group, a cyclopentylthio group and a cyclohexylthio group, sulfinyl groups having 1 to 6 carbon atoms such as a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, a butylsulfinyl group, an isobutylsulfinyl group, an s-butylsulfinyl group, a t-butylsulfinyl group, a pentylsulfinyl group, a hexylsulfinyl group, a phenylsulfinyl group, a cyclopentylsulfinyl group, and a cyclohexylsulfinyl group, sulfonyl groups having 1 to 6 carbon atoms such as a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, an s-butylsulfonyl group, a t-butylsulfonyl group, a pentylsulfonyl group, a hexylsulfonyl group, a phenylsulfonyl group, a cyclopentylsulfonyl group and a cyclohexylsulfonyl group, a substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (in addition to the same examples as the examples chosen among the examples indicated as examples of substitution group in the case of the previously-mentioned aliphatic hydrocarbon group having 1 to 10 carbon atoms, aliphatic hydrocarbon groups having 1 to 6 carbon atoms which are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl group, an t-butyl group, a pentyl group, a hexyl group, a 2-propenyl group, a 1-butenyl group, a 2-butenyl group, a 2-pentenyl group, a 3-pentenyl group, a 2-hexenyl group, a 3-hexenyl group, a 4-hexenyl group, a 2-butynyl group, a 2-pentynyl group, a 3-pentynyl group, a 2-hexynyl group and a 3-hexynyl group, acyl groups having 1 to 10 carbon atoms such as a formyl group, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group and a cinnamoyl group may be cited as examples of substitution groups for such an alicyclic hydrocarbon group having 3 to 8 carbon atoms), a substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (in addition to the same examples as the examples chosen among the examples indicated as examples of substitution groups in the case of the previously-mentioned aliphatic hydrocarbon group having 1 to 10 carbon atoms, and in the case of the previously-mentioned alicyclic hydrocarbon group having 3 to 8 carbon atoms, alkyl groups having 1 to 4 carbon atoms which are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl group and a t-butyl group may be cited as substitution examples for such aromatic hydrocarbon groups having 6 to 10 carbon atoms), a substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (the same examples as the examples chosen among the examples indicated as examples of substitution groups in the case of the previously-mentioned aliphatic hydrocarbon group having 1 to 10 carbon atoms, and in the case of the previously-mentioned alicyclic hydrocarbon group having 3 to 8 carbon atoms may be cited as substitution examples of such a heteocyclic group) may be cited. As preferred examples of such substitution groups for aliphatic hydrocarbon groups having 1 to 10 carbon atoms, a fluorine atom, a hydroxyl group, a phenyl group, a tolyl group, a 4-methoxyphenyl group, a 4-dimethylaminophenyl group, a phenoxy group, a 3,5-dichlorophenoxy group, a cyclopentyl group, a cyclohexyl group, a 3-ethylcyclopentyl group and a phenylsulfonyl group may be cited.
As examples of substitution groups when R51, R61 or R62 are substituted alicyclic hydrocarbon groups having 3 to 8 carbon atoms, the same example as the examples chosen among the examples given for the above-mentioned substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms may be cited. As preferred examples of substitution groups for such alicyclic hydrocarbon groups having 3 to 8 carbon atoms, a methyl group, an ethyl group, a propyl group, a hydroxyl group, a methoxy group and an ethoxy group may be cited.
As examples of substitution groups when R51, R61 or R62 are substituted aromatic hydrocarbon groups having 6 to 10 carbon atoms, the same example as the examples chosen among the examples given for the above-mentioned substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms may be cited. As preferred examples of substitution groups for aromatic hydrocarbon groups having 6 to 10 carbon atoms, a methyl group, an ethyl group, a propyl group, a hydroxyl group, a methoxy group, an ethoxy group, a fluorine atom, a chlorine atom, a bromine atom and an iodine atom may be cited.
As examples of substitution groups when R51, R61 or R62 are substituted heterocyclic groups having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle, the same examples as the examples chosen among the examples given for the above-mentioned substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms may be cited. As preferred examples of substitution groups for such heterocyclic groups having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle, a methyl group, an ethyl group, a propyl group, a hydroxyl group, a methoxy group and an ethoxy group may be cited.
In addition, in the above Formula (W1A) or Formula (W1B), R51 and R61 are bonded to each other, and represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).
As examples of such unsubstituted alicyclic hydrocarbon chains having 4 to 7 carbon atoms, tetramethylene group, pentamethylene group, hexamethylene group and heptamethylene group may be cited. As preferred examples the tetramethylene group and the pentamethylene group may be cited.
As examples of substitution groups wherein R51 and R61 are bonded to each other and form a substituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms, the same examples as the examples chosen among the examples given for the above-mentioned substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms may be cited. As preferred examples of substitution groups for such groups forming an alicyclic hydrocarbon chain having 4 to 7 carbon atoms, a methyl group, an ethyl group, a propyl group, a hydroxyl group, a methoxy group and an ethoxy may be cited.
In the above Formula (W1A) or Formula (W1B), R71 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, a functional group forming the acetal bond together with the oxygen atom bound to R71.
As examples of such acyl groups having 2 to 10 carbon atoms, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group and a cinnamoly group may be cited. As preferred examples an acetyl group and a benzoyl group may be cited. As examples of tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, a trimethylsilyl group, a triethylsilyl group, a dimethylisopropyls group, a dimethylhexylsilyl group, a t-butyldimethylsilyl group, a triisopropylsilyl group, a t-butyldiphenylsilyl group and a tribenzylsilyl group may be cited. As preferred examples, a trimethylsilyl group, a triethylsilyl group and a t-butyldimethylsilyl group may be cited.
As examples of alkoxycarbonyl groups having 2 to 5 carbon atoms, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, a s-butoxycarbonyl group and a t-butoxycarbonyl group may be cited. As preferred examples, a methoxycarbonyl group and an ethoxycarbonyl group may be cited.
As examples of sulfonyl groups having 1 to 8 carbon atoms, a methanesulfonyl group, a trifluoromethanesulfonyl group, an ethanesulfonyl group, a butanesulfonyl group, a t-butanesulfonyl group, a nonafluorobutanesulfonyl group, a benzenesulfonyl group, a p-bromobenzenesulfonyl group, a p-toluenesulfonyl group, a benzylsulfonyl group, an α-phenethylsulfonylamino group, and a β-phenethylsulfonylamino group may be cited. As preferred examples a methanesulfonyl group and a trifluoromethanesulfonyl group may be cited.
As examples of functional groups forming the acetal bond together with the oxygen atom bound to R71 a methoxymethyl group, a 1-ethoxyethyl group, a 1-methoxy-1-methylethyl group, a 2-ethoxy-1-methylethyl group, a 2-methoxyethoxymethyl group, a tetrahydropyrane-2-yl group, a 6,6-dimethyl-3-oxa-2-oxo-bicyclo[3.1.0]hexane-4-yl group may be cited. As preferred examples, a methoxymethyl group, a 2-methoxyethoxymethyl group and a tetrahydropyran-2-yl group may be cited. As particularly preferred such functional groups for R71, a hydrogen atom, an acetyl group, a trimethylsilyl group, a t-butyldimethylsilyl group and a tetrahydropyran-2-yl may be cited.
As such preferred examples of the above Formula (W1), the items 1) to 6) shown below may be cited.

    1) a hydrogen atom,
    2) a hydroxymethy group, a formyl group, a methanesulfonyloxymehyl group, a methoxycarbonyloxymethyl group, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, a heptyl group, an octyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a phenyl group, an o-tolyl group, an m-tolyl group, a p-tolyl group, a 4-methoxyphenyl group, an 4-N,N-dimethylaminophenyl group, a 3-chlorophenyl group, a 4-chlorophenyl group, a 4-fluorophenyl group, a 4-bromophenyl group, 3,5-dichlorophenyl group, a benzyl group, an α-phenethyl group, a β-phenethyl group, an o-tolylmethyl group, an m-tolylmethyl group, a p-tolylmethyl group, a 3-ethylphenyl group, a 4-ethylphenyl group, a 3-propylphenyl group, a 2-(o-tolyl)ethyl group, a 2-(m-tolyl)ethyl group, a 2-(p-tolyl)ethyl group, a 3-(o-tolyl)propyl group, a 3-(m-tolyl)propyl group, a 3-(p-tolyl)propyl group, a 1,1-bis(phenylsulfonyl)-2-(o-tolyl)ethyl group, a 1,1-bis(phenylsulfonyl)-2-(m-tolyl)ethyl group, a 1,1-bis(phenylsulfonyl)-2-(p-tolyl)ethyl group, a 1,1-bis(phenylsulfonyl)-2-(o-tolyl)propyl group, a 1,1-bis(phenylsulfonyl)-2-(m-tolyl)propyl group, a 1,1-bis(phenylsulfonyl)-2-(p-tolyl)propyl group,
    3) a 1-hydroxypentyl group, a 1-hydroxyhexyl group, a 1-hydroxyheptyl group, a 1-hydroxyoctyl group, a 1-hydroxy-1-methylpentyl group, a 1-hydroxy-1-ethylpentyl group, a 1-hydroxy-1-vinylpentyl group, a 1-hydroxy-1-methylhexyl group, a 1-hydroxy-1-ethylhexyl group, a 1-hydroxy-3-methylhexyl group, 1-hydroxy-2-butyl-2-propene group, a 1-hydroxy-2-methylhexyl group, a 1-hydroxy-2-fluorohexyl group, a 1-hydroxy-2,2-dimethylhexyl group, a 1 hydroxy-3-ethoxy-2,2-dimethylpropane group, a 1-hydroxy-2,2-difluorohexyl group, a 1-hydroxy-2,2,6-trimethylheptyl group, a 1-hydroxy-2-fluoro-1-methyloctyl group, a 1-hydroxyhexa-3-enyl group, a 1-hydroxy-5-methylhexa-4-enyl group, a 1-hydroxy-2,5-dimethylhexa-4-enyl group, a 1-hydroxy-3,7-dimethylhexa-4-enyl group, a 1-hydroxy-2,2,5-trimethylhexa-4-enyl group, 1-hydroxy-2,2-dimethylpenta-3-ynyl group, a 1-hydroxy-2,2-dimethylpenta-3-ynyl group, a 1-hydroxyhexa-4-ynyl group, a 1-hydroxy-2-methylhexa-4-ynyl group, a 1-hydroxy-2,2-dimethylhexa-4-ynyl group, a 1-hydroxy-2-methylhepta-4-ynyl group, a 1-hydroxy-4-cyclopropyl-2-methylbutyl group, a 1-hydroxy-2-cyclopentylethyl group, a 1-hydroxy-2-cyclohexylethyl group, a 1-hydroxy-2-phenylethyl group, a 1-hydroxy-2-phenylpropy group, a 1-hydroxy-1-(o-tolyl)methyl group, a 1-hydroxy-1-(m-tolyl)methyl group, a 1-hydroxy-1-(p-tolyl)methyl group, a 1-hydroxy-1-(3-ethylphenyl)methyl group, a 1-hydroxy-1-(4-ethylphenyl)methyl group, a 1-hydroxy-1-(3-propylphenyl)methyl group, a 1-hydroxy-2(o-tolyl)ethyl group, a 1-hydroxy-2-(m-tolyl)ethyl group, a 1-hydroxy-2-(p-tolyl)ethyl group, a 1-hydroxy-3-(o-tolyl)propyl group, a 1-hydroxy-3-(m-tolyl)propyl group, a 1-hydroxy-3-(p-tolyl)propyl group, a 1-hydroxy-4-(o-tolyl)butyl group, a 1-hydroxy-4-(m-tolyl)butyl group, a 1-hydroxy-4-(p-tolyl)butyl group, a 1-hydroxy-2-(3-chlorophenyl)ethyl group, a 1-hydroxy-2-phenoxyethyl group, a 1-hydroxy-2-(4-fluorophenoxy)ethyl group, a 1-hydroxy-2-(3-chloropheoxyl)ethyl group, a 1-hydroxy-1-cyclopentylmethyl group, a 1-hydroxy-1-cyclohexylmethyl group, a 1-hydroxy-1-cyclopentylethyl group, a 1-hydroxy-[(4-cyclohexenyl)methyl group, a 1-hydroxy-1-(3-ethylcyclopentyl)methyl group, a 1-hydroxy-1-(2-methylcyclopentyl)methyl group, a 1-hydroxy-1-(2-methylcyclohexyl)methyl group, a 1-hydroxy-1-(3-methylcyclohexyl)methyl group, a 1-hydroxy-1-(4-methylcyclohexyl)methyl group, a 1-hydroxy-1-(2,2,4-trimethylcyclohexyl)methyl group, a 1-hydroxy-1-(1-(2-butynyl) cyclobutyl)methyl group, a 1-hydroxy-1-(1-(2-pentynyl)cyclobutyl)methyl group, a 1-hydroxy-1-phenylmethyl group, a 1-hydroxy-1-(4-chlorophenyl)methyl group, a 1-hydroxy-1-(4-bromophenyl)methyl group, a 1-hydroxy-1-(3-chlorophenyl)methyl group, a 1-hydroxy-1-(4-methoxyphenyl)methyl group, a 1-hydroxy-1-(4-N,N-dimetylaminophenyl)methyl group, a 1-hydroxy-1-(1-naphthyl)methyl group, a 1-hydroxy-1-(2-naphthyl)methyl group,
    4) a functional group described in 3) above, wherein the hydroxy group has been substituted for an acetyloxy group, a benzoyloxy group, a trimethylsilyloxy group, a t-butyldimethylsilyloxy group, a tetrahydropyrane-2-yloxy group or a methanesulfonyloxy group,
    5) a pentanoyl group, a hexanoyl group, a heptanoyl group, an octanoyl group, a 3-methylhexanoyl group, a 2-methylhexanoyl group, a 2,2-dimethylhexanoyl group, a 2,2,6-trimethylheptanoyl group, a 3-hexenoyl group, a 5-methyl-4-hexenoyl group, a 2,5-dimethyl-4-hexenoyl group, a 3,7-dimethyl-6-octenoyl group, a 2,2,5-trimethyl-4-hexenoyl group, a 3-pentynoyl group, a 2,2-dimethyl-3-pentynoyl group, a 4-hexynoyl group, a 2-methyl-4-hexynoyl group, a 2,2-dimethyl-4-hexynoyl group, a 2-methyl-4-heptynoyl group, a 4-cyclopropyl-2-methylbutanoyl group, a cyclopentylacetyl group, a cyclohexylacetyl group, a 2-phenylacetyl group, a 3-phenylpropanoyl group, a 2-methylbenzoyl group, a 3-methylbenzoyl group, a 4-methylbenzoyl group, a 3-ethylbenzoyl group, a 4-ethylbenzoyl group, a 3-propylbenzoyl group, an (o-tolyl)acetyl group, an (m-tolyl)acetyl group, a (p-tolyl)acetyl group, 3-(o-tolyl)propanoyl group, a 3-(m-tolyl)propanoyl group, a 3-(p-tolyl)propanoyl group, a 4-(o-tolyl)butanoyl group, a 4-(m-tolyl)butanoyl group, a 4-(p-tolyl)butanoyl group, a (3-chlorophenyl)acetyl group, a cyclopentylcarbonyl group, a cyclohexylcarbonyl group, a 3-ethylcyclopentylcarbonyl group, a 2-methylcyclopentylcarbonyl group, a 2-methylcyclohexylcarbonyl group, a 3-methylcyclohexylcarbonyl group, a 4-methylcyclohexylcarbonyl group, a benzoyl group, a 4-chlorobenzoyl group, a 4-bromobenzoyl group, a 3-chlorobenzoyl group, a 4-methoxybenzoyl group, a 4-N,N-dimethylaminobenzoyl group, a 1-naphthylcarbonyl group, a 2-naphthylcarbonyl group,
    6) a 1-pentenyl group, a 1-hexenyl group, a 1-heptenyl group, a 1-octenyl group, a 2-methylhexene-1-yl group, a 2-ethylhexene-1-yl group, a 2-methylheptene-1-yl group, a 2-ethylheptene-1-yl group, a 1-methylhexene-1-yl group, a 1-ethylhexene-1-yl group, a 3-methylhexene-1-yl group, a 1,3-hexadiene-1-yl group, a 5-methyl-1,4-hexadiene-1-yl group, a 2,5-dimethyl-1,4-hexadiene-1-yl group, a 3,7-dimethyl-1,6-octadiene-1-yl group, a penta-3-yn-1-en-1-yl group, a hexa-4-yn-1-en-1-yl group, a 2-methylhexa-4-yn-1-en-1-yl group, a 2-methylhepta-4-yn-1-en-1-yl group, a 4-cyclopropyl-2-methyl-1-butene-1-yl group, a 2-cyclopentylvinyl group, a 2-cyclohexylvinyl group, a 2-phenylvinyl, a 3-phenyl-1-propene-1-yl group, a 2-(o-tolyl)vinyl group, a 2-(m-tolyl)vinyl group, a 2-(p-tolyl)vinyl group, a 3-(o-tolyl)-1-propene-1-yl group, a 3-(m-tolyl)-1-propene-1-yl group, a 3-(p-tolyl)-1-propene-1-yl group, a 4-(o-tolyl)-1-butene-1-yl group, a 4-(m-tolyl)-1-butene-1-yl group, a 4-(p-tolyl)-1-butene-1-yl group, a 2-(3-ethylphenyl)vinyl group, a 2-(4-ethylphenyl)vinyl group, a 2-(3-propylphenyl)vinyl group, a 2-(3-chlorophenyl)vinyl group, a 2-(4-chlorophenyl)vinyl group, a 2-(4-methoxyphenyl)vinyl group, a 2-(4-N,N-dimethylaminophenyl)vinyl group.


In the above Formula (1) A2 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below.




[In the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.]





[In the formula, n represents 0, 1, or 2.]

In the above Formula (A2B), R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.
As examples of R3 which are alkyl groups having 1 to 4 carbon atoms, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl group and a t-butyl group may be cited. As examples of R3 which are acyl groups having 1 to 10 carbon atoms, a formyl group, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group and a cinnamoly group may be cited. As preferred examples of such an R3, a hydrogen atom, a methyl group, a formyl group and an acetyl group may be cited.
In the above Formula (A2C), n represents 0, 1, or 2. However, 0 may be cited as the preferred value for n.
A single bond, —O—, —NH—, —N(CH3)— and —S— may be cited as such preferred functional groups for A2.
In the above Formula (1), A1 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges G and A2 through an identical atom or through different atoms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


Examples of such A1 which are aliphatic hydrocarbon groups having 1 to 3 carbon atoms, are functional groups derived by removing hydrogen atoms from the same carbon atom or two different carbon atoms of a methane, an ethene, a propane, an ethene, a propene, an acetylene or a propyne: when G and A1 are bonded through a single bond, A1 is a bivalent functional group derived by removing one hydrogen atom for each bond; when G and A1 are bonded through a double bond, A1 is a trivalent functional group derived by removing one hydrogen atom for one bond and two hydrogens for the other bond. As preferred examples of such bivalent functional groups, —CH2—, —(CH2)2—, —CH(CH3)—, —(CH2)3—, —C(CH3)2—, —CH═CH—, —CH═CHCH2—, —CH═C(CH3)—, —C═C— and —C═CCH2— may be cited, and as preferred examples of such trivalent functional groups, ═CH—, =CHCH2—, =C(CH3)—, =CH(CH2)2—, =CHCH═CH— and ═CH—CH(CH3)— may be cited.
As examples of A1 which are alicyclic hydrocarbon groups having 3 to 8 carbon atoms, are functional groups derived from a cyclopropane, a cyclobutane, a cyclopentane, a cyclopentene, a cyclohexane, a cyclohexene, a cycloheptane and a cyclooctane by removing hydrogen atoms on the same carbon atom or two different carbon atoms: when G and A1 are bonded through a single bond, A1 is a bivalent functional group derived by removing one hydrogen atom for each bond; when G and A1 are bonded through a double bond, A1 is a trivalent functional group derived by removing one hydrogen atom for one bond and two hydrogens for the other bond. As preferred examples of such bivalent functional groups, a 1,2-cyclopropylene group, a cyclopropylydene group, a 1,2-cyclopentylene group, a 1,3-cyclopentylene group, a 1,2-cyclohexylene group, a 1,3-cyclohexylene group, a 1,4-cyclohexylene may be cited, and as a preferred example of such a trivalent functional group, a 1-cyclohexyl-4-ylidedene group may be cited.
As examples of A1 which are heterocyclic groups having between 1 and 2 oxygen atoms, nitrogen atoms, or sulfur atoms, bivalent functional groups derived by removing one hydrogen atom from each of two different carbon atoms such as a furan cycle, a thiofuran cycle, a pyrrole cycle, an oxazole cycle, an isooxazole cycle, a thiazole cycle, an isothioazole cycle, an imidazole cycle, a pyrazole cycle, a pyran group, a pyridine cycle, a pyrazine cycle, a pyrimidine cycle, a pyridazine cycle, an azetidine cycle, a pyrrolidine cycle, a piperidine cycle, a piperazine cycle and a morpholine cycle may be cited. As preferred functional group for such an A1, the bond representing a single bond, —CH2—, —(CH2)2—, ═CH— and ═CHCH2— may be cited.
In the above Formula (1), A3 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges A2 and A4 through an identical atom or through different atoms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


As examples of such A3 which are aliphatic hydrocarbon groups having 1 to 3 carbon atoms, alicyclic hydrocarbon groups having 3 to 8 carbon atoms, or heterocycles and which have heterocyclic groups having between 1 and 2 oxygen atoms, nitrogen atoms, or sulfur atoms, among the examples given in the above-mentioned A1, the examples given as bivalent functional groups may be may be cited. As particularly preferred functional groups for such A3, the bond representing a single bond; —CH2—, —(CH2)2—, —CH═CH— and a phenylene group may be cited.
In the above Formula (1), A4 represents either of the items 1) to 4) below

    1) a single bond
    2) a carbonyl group
    3) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R1 and R2, and A3 through an identical atom or through different atoms.
    4) when A4 and R1 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A4 or R1 and the nitrogen atom they are bonded to are bonded through a double bond, R2 represents the bond between A4 or R1 and the nitrogen atom.)


When A4 represents an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R1 and R2, and A3 through an identical atom or through different atoms, such as an aliphatic hydrocarbon group having 1 to 3 carbon atoms is a bivalent functional group derived by removing one hydrogen atom for each bond, from the same carbon atom or two different carbon atoms of a methane, a methene, a propane or a propene. As preferred examples of such A4 which are aliphatic hydrocarbon groups having 1 to 3 carbon atoms, —CH2—, —(CH2)2—, —CH(CH3)—, —(CH2)3—, —C(CH3)2— and —CH═CHCH2— may be cited.
When A4 represents a functional group wherein A4 and R1 are bonded to each other forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to, as examples of such functional groups forming 5 to 8 membered rings, monovalent functional groups derived by removing one hydrogen atom from one carbone atom of a pyrrole cycle, an oxazole cycle, an isooxazole cycle, a thiazole cycle, an isothioazole cycle, a pyrazole cycle, a pyridine cycle, a pyrazine cycle, a pyrimidine cycle, a pyridazine cycle, an azetidine cycle, a pyrrolidine cycle, a piperidine cycle, a piperazine cycle and a morpholine cycle may be cited. When A4 or R1 and the nitrogen atom they are bonded to are bonded through a double bond, in other words, when forming a cycle, for example, such as an oxazole cycle, an isooxazole cycle, a thiazole cycle, an isothioazole cycle, an imidazole cycle, a pyrazole cycle, a pyridine cycle, a pyrazine cycle, a pyrimidine cycle and a pyridazine cycle with A4, R1 and the nitrogen atom they are bonded to, R2 represents a bond between A4 or R1, and the nitrogen atom. As preferred examples of such functional groups forming 5 to 8 membered rings, a 2-pyrrolidinyl group, a 2-piperidinyl group, a 3-piperidinyl group, a 4-piperidinyl group, a 2-piperazinyl group, a 2-morpholinyl group, a 2-pyridyl group, a 3-pyridyl group and a 4-pyridyl group may be cited.
As particularly preferred examples of such a functional group for A4, the bond representing a single bond, a carbonyl group, —CH2— and —(CH2)2— may be cited. In addition, when representing a functional group wherein A4 and R1 are bonded to each other forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to, as particularly preferred examples, a 2-pyridyl group, a 4-pyridyl group and a 4-piperidinyl group may be cited.
In the above Formula (1), the combination of functional groups A1, A2, A3 and A4, represented by Formula (A) below,




[In Formula (A), A1, A2, A3, A4, and the symbol  have the same definition as above.]A1, A2, A3 and A4 may not simultaneously represent bonds. In addition, when A2 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A2 and the nitrogen atom bonded to R1 and R2 must be bonded with more than two carbon atoms in between. As preferred examples of such functional groups, —(CH2)3—, —(CH2)4—, —(CH2)5—, ═CH(CH2)2—, ═CH(CH2)3—, ═CH(CH2)4—, —CH2CH═CHCH2—, —NH(CH2)2—, —NH(CH2)3—, —NH(CH2)4—, —N(CH3)(CH2)3—, —CH2NH(CH2)2—, —O(CH2)3—, —CH2O(CH2)2—, —S(CH2)3—, —CH2S(CH2)2—, -(o-phenylene)-, -(m-phenylene)-, -(p-phenylene)-, —CH2— (o-phenylene)-, —CH2—(m-phenylene)-, —CH2—(p-phenylene)-, —(CH2)2-(o-phenylene)-, —(CH2)2-(m-phenylene)-, —(CH2)2-(p-phenylene)-, -(o-phenylene)-CH2—, -(m-phenylene)-CH2—, -(p-phenylene)-CH2—, -(o-phenylene)-(CH2)2—, -(m-phenylene)-(CH2)2—, -(p-phenylene)-(CH2)2—, —CH2— (o-phenylene)-CH2—, —CH2— (m-phenylene)-CH2—, —CH2—(p-phenylene)-CH2—, —(CH2)2CO—, —(CH2)3CO—, —(CH2)4CO—, ═CHCH2CO—, ═CH(CH2)2CO—, ═CH(CH2)3CO—, —CH2CH═CHCO—, —NHCH2CO—, —NH(CH2)2CO—, —NH(CH2)3CO—, —N(CH3)(CH2)2CO—, —CH2NHCH2CO—, —O(CH2)2CO—, —CH2OCH2CO—, —S(CH2)2CO—, —CH2SCH2CO—, -(o-phenylene)-CO—, -(m-phenylene)-CO—, -(p-phenylene)-CO—, —CH2— (o-phenylene)-CO—, -(o-phenylene)-CH2CO—, -(m-phenylene)-CH2CO—, -(p-phenylene)-CH2CO—, —CH2— (m-phenylene)-CO— and —CH2— (p-phenylene)-CO— may be cited.

In the above Formula (1), R1 and R2 may be identical or different and represent one of the items 1) to 7) shown below.

    1) a hydrogen atom,
    2) a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, phenyl group, and, heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents)
    6) an acyl group having 1 to 10 carbon atoms when A4 is not a carbonyl group,
    7) a sulfonyl group having 1 to 8 carbon atoms when A4 is not a carbonyl group (however, when either R1 or R2 represents a sulfonyl group having 1 to 8 carbon atoms, the other may neither be an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms), or, when R1 and R2 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to (for said cyclic amino group having 4 to 8 carbon atoms, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


As examples of such R1 and R2 which are unsubstituted alkyl groups having 1 to 10 carbon atoms, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl group, an t-butyl group, a pentyl group, an isopentyl group, a neopentyl group, a hexyl group, a heptyl group, an octyl group, a nonyl group and a decyl group may be cited.
As examples of unsubstituted cycloalkyl groups having 3 to 8 carbon atoms, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group and a cyclooctyl group may be cited.
As examples of unsubstituted heterocycles, monocyclic or bicyclic functional groups such as a furyl group, a thiophenyl group, a pyrrolyl group, an oxazolyl group, an isooxazolyl group, a thiazolyl group, an isothiazolyl group, an imidazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a pyranyl group, a pyridyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, a benzofuranyl group, an indolyl group, a benzimidazolyl group, a benzothiazolyl group, a benzoxazolyl group, a quinolyl group, an isoquinolyl group, a quinazolyl group, a purinyl group, a pteridinyl group, an azetidinyl group, a pyrrolidinyl group, a morpholino group, a piperidino group and pyperazinyl may be cited.
As examples of substitution groups when R51, R61 or R62 is a substituted aliphatic hydrocarbon group having 1 to 10 carbon atoms, a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a hydroxyl group, alkoxy groups having 1 to 4 carbon atoms which are a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an s-butoxy group and a t-butoxy group, aryloxy groups having 6 to 10 carbon atoms which are a phenoxy group, a 1-naphthoxy group and a 2-naphthoxy group, aralkoxy groups having 7 to 9 carbon atoms such as a benzyloxy group, an α-phenethyloxy group, a β-phenethyloxy group, a phenylpropyloxy group and a cinnamyloxy group, acyloxy groups having 2 to 10 carbon atoms such as an acetoxy group, a trifluoroacetoxy group, a propionyloxy group, an isopropionyloxy group, a butyryloxy group, an isobutyryloxy group, an s-butyryloxy group, a valeryloxy group, an isovaleryloxy group, a hexanoyloxy group, a heptanoyloxy group, an octanoyloxy group, a nonanoyloxy group, a decanoyloxy group, a benzoyloxy group, a phenylacetyloxy group, a cinnamoyloxy group, a cyclopentylcarboxy group, a cyclohexylcarboxy group and a cycloheptylcarboxy group, sulfonyloxy groups having 1 to 8 carbon atoms such as a methanesulfonyloxy group, a trifluoromethanesulfonyloxy group, an ethanesulfonyloxy group, a butanesulfonyloxy group, a t-butanesulfonyloxy group, a nonafluorobutanesulfonyloxy group, a benzenesulfonyloxy group, a p-bromobenzenesulfonyloxy group, a p-toluenesulfonyloxy group, a benzylsulfonyloxy group, an α-phenethylsulfonyloxy group and a β-phenethylsulfonyloxy group, an oxo group, a carboxyl group, alkoxycaobonyl groups having 2 to 10 carbon atoms such as a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a butoxycarbonyl group, an isobutoxycarbonyl group, an s-butoxycarbonyl group, a t-butoxycarbonyl group, a phenoxycarbonyl group, a 1-naphthoxycarbonyl group, a 2-naphthoxycarbonyl group, a benzyloxycarbonyl group, an α-phenethyloxycarbonyl group and a β-phenethyloxycarbonyl group, carbamoyl groups having 1 to 15 carbon atoms such as a carbamoyl group, an N-methylcarbamoyl group, an N-ethylcarbamoyl group, an N-propylcarbamoyl group, an N-isopropylcarbamoyl group, an N-butylcarbamoyl group, an N-isobutylcarbamoyl group, an N-s-butylcarbamoyl group, an N-t-butylcarbamoyl group, an N-pentylcarbamoyl group, an N-hexylcarbamoyl group, an N-phenylcarbamoyl group, an N-benzylcarbamoyl group, an N-phenethylcarbamoyl group, an N-cyclopropylcarbamoyl group, an N-cyclobutylcarbamoyl group, an N-cyclopentylcarbamoyl group, an N-cyclohexylcarbamoyl group, an N-cycloheptylcarbamoyl group, an N-cyclopropanemethylcarbamoyl group, an N,N-dimethylcarbamoyl group, an N,N-ethylmethylcarbamoyl group, an N,N-diethylcarbamoyl group, an N,N-dipropylcarbamoyl group, an N,N-dibutylcarbamoyl group, an N,N-dicyclohexylcarbamoyl group, an N,N-diphenylcarbamoyl group, an N,N-dibenzylcarbamoyl group, a piperidinocarbonyl group, and a morpholinocarbonyl group, amino groups having 0 to 14 carbon atoms such as an amino group, a methylamino group, an ethylamino group, a propylamino group, an isopropylamino group, a butylamino group, an isobutylamino group, an s-butylamino group, a t-butylamino group, a pentylamino group, an hexylamino group, an heptylamino group, an octylamino group, a nonylamino group, a decylamino group, a phenylamino group, a benzylamino group, a phenethylamino group, a cyclopropylamino group, a cyclobutylamino group, a cyclopentylamino group, a cyclohexylamino group, a cycloheptylamino group, a cyclooctylamino group, a cyclopropanemethylamino group, a dimethylamino group, an N-ethylmethylamino group, a diethylamino group, an N— methylpropylamino group, an L N-methylisopropylamino group, an N-meth ylbutylamino group, an N-methyl-t-butylamino group, an N-ethylisopropylamino group, a dipropylamino group, a diisopropylamino group, an ethylbutylamino group, an N-methylhexylamino group, a dibutylamino group, a dipentylamino group, a dicyclohexylamino group, a diphenylamino group, a dibenzylamino group, a piperidino group and a morpholino group, acylamino groups having 1 to 10 carbon atoms such as a formylamino group, an acetylamino group, a trifluoroacetylamino group, a propionylamino group, a butyrylamino group, an isobutyrylamino group, a valerylamino group, an hexanoylamino group, a benzoylamino group, a phenylacetylamino group, a phenylpropionylamino group, and a cinnamoylamino group, sulfonylamino groups having 1 to 8 carbon atoms such as a methanesulfonylamino group, a trifluoromethanesulfonylamino group, an ethanesulfonylamino group, a butanesulfonylamino group, a t-butanesulfonylamino group, a nonafluorobutanesulfonylamino group, a benzenesulfonylamino group, a p-bromobenzenesulfonylamino group, a p-toluenesulfonylamino group, a benzylsulfonylamino group, an c-phenethylsulfonylamino group and a β-phenethylsulfonylamino group, imino groups having 1 to 10 carbon atoms such as a methylimino group, an ethylimino group, a propylimino group, an isopropylimino group, a butylimino group, an isobutylimino group, a pentylimino group, an hexylimino group, an heptylimino group, an octylimino group, a nonylimino group, a decylimino group, a phenylimino group, a benzylimino group, a phenethylimino group, a cyclopropylimino group, a cyclobutylimino group, a cyclopentylimino group, a cyclohexylimino group, and a cycloheptylimino group, a cyano group, a nitro group, sulfide groups having 1 to 6 carbon atoms such as a methylthio group, an ethylthio group, a propylthio group, an isopropylthio group, a butylthio group, an isobutylthio group, an s-butylthio group, a t-butylthio group, a pentylthio group, an hexylthio group, a phenylthio group, a cyclopentylthio group and a cyclohexylthio group, sulfinyl groups having 1 to 6 carbon atoms such as a methylsulfinyl group, an ethylsulfinyl group, a propylsulfinyl group, an isopropylsulfinyl group, a butylsulfinyl group, an isobutylsulfinyl group, an s-butylsulfinyl group, a t-butylsulfinyl group, a pentylsulfinyl group, a hexylsulfinyl group, a phenylsulfinyl group, a cyclopentylsulfinyl group, and a cyclohexylsulfinyl group, sulfonyl groups having 1 to 6 carbon atoms such as a methylsulfonyl group, an ethylsulfonyl group, a propylsulfonyl group, an isopropylsulfonyl group, a butylsulfonyl group, an isobutylsulfonyl group, an s-butylsulfonyl group, a t-butylsulfonyl group, a pentylsulfonyl group, a hexylsulfonyl group, a phenylsulfonyl group, a cyclopentylsulfonyl group and a cyclohexylsulfonyl group, a substituted or unsubstituted cycloalkyl group having 3 to 8 carbon atoms (in addition to the same examples as the examples chosen among the examples indicated as examples of substitution groups in the case of the previously mentioned alkyl group having 1 to 10 carbon atoms, alkyl groups having 1 to 4 carbon atoms which are a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, an s-butyl and a t-butyl group, acyl groups having 1 to 10 carbon atoms such as a formyl group, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group and a cinnamoyl group may be cited as examples of such cycloalkyl groups having 3 to 8 carbon atoms), a substituted or unsubstituted phenyl group (as examples of substitution groups for such a pheyl group, the substitution groups given in the case of the previously-mentioned alkyl group having 1 to 10 carbon atoms and the same examples as the examples chosen among the examples indicated as examples of substitution groups in the case of the previously-mentioned cycloalkyl groups having 3 to 8 carbon atoms may be cited), a substituted or unsubstituted heterocyclic group (include 1 to 4 oxygen atoms, nitrogen atoms or sulfur atoms. As examples of substitution groups for such a heterocyclic group, the same examples as the examples chosen among the examples indicated as examples of substitution groups in the case of the previously-mentioned alkyl group having 1 to 10 carbon atoms and in the case of the previously-mentioned cycloalkyl groups having 3 to 8 carbon atoms may be cited) may be cited.
When R1 or R2 represents an acyl group having 1 to 10 carbon atoms, as examples of such an acyl group having 1 to 10 carbon atoms, a formyl group, an acetyl group, a trifluoroacetyl group, a propionyl group, a butyryl group, an isobutyryl group, a valeryl group, an hexanoyl group, a benzoyl group, a phenylacetyl group, a phenylpropionyl group and a cinnamoyl group may be cited.
When R1 or 2 represents a solfonyl group having 1 to 8 carbon atoms, as examples of such a solfonyl group having 1 to 8 carbon atoms, a methanesulfonyl group, a trifluoromethanesulfonyl group, an ethanesulfonyl group, a butanesulfonyl group, a t-butanesulfonyl group, a nonafluorobutanesulfonyl group, a benzenesulfonyl group, a p-bromobenzenesulfonyl group, a p-toluenesulfonyl group, a benzylsulfonyl group, an α-phenethylsulfonyl group, β-phenethylsulfonyl group may be cited. As preferred examples of such R1 and R2, a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a t-butyl group, a 2-hydroxyethyl group, a carboxymethyl group, a carboxyethyl group, a methoxycarbonylethyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopropylmethyl group, a phenyl group, a tolyl group, a benzyl group, a phenethyl group, a pyridyl group, a 4-pyridyl group, a formyl group, an acetyl group, a propanoyl group, a benzoyl group, a methanesulfonyl group, a benzenesulfonyl group and a p-toluenesulphonyl may be cited.
When representing a functional group wherein R1 and R2 are bonded to each other and form an amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to, as examples of functional groups forming such an amino group having 4 to 8 carbon atoms, an azetidinyl group, a pyrrolidinyl group, a piperidino group, a morpholino group, a piperazinyl group and a perhydroazepinyl group may be cited.
As preferred examples of such amino groups formed by R1, R2 and the nitrogen atom they are bonded to, an amino group, a methylamino group, an ethylamino group, a propylamino group, a butylamino group, a dimethylamino group, an N-methylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group, an N-methylamino group, a cyclohexylamino group, a phenylamino group, a benzylamino group, a tolylamino group, a (4-pyridylmethyl)amino group, a 2-pyridylamino group, a 1-pyrrolidinyl group, a piperidino group, a morpholino group, a 4-N-methylpiperadin-1-yl group, a carboxymethylamino group, a 1-carboxyethylamino group, a 2-hydroxyethylamino group, a 3-hydroxyethylamino group and a 2-methoxycarbonylethyl group may be cited.
In the above Formula (1), the compound represented by the Formula (2) below is a novel substance.




[In Formula (2), the symbol  represents a single bond or a double bond.

G represents one functional group chosen from the group consisting of the Formulae (G1), (G2), (G3), (G4), (G5), (G6), (G7), (G8), (G9), (G10), (G11) and (G12) shown below.










(In Formula G1), Formula (G2), Formula (G3), Formula (G4), Formula (G5), Formula (G6), Formula (G7), Formula (G8), Formula (G9), Formula (G10), Formula (G11) and Formula (G12), the symbol  represents the site of linkage with A10.

R4 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group or a functional group forming the acetal bond together with the oxygen atom bonded to R4.
W represents a single bond, —CH2—, —(CH2)2—, —(CH2)3—, —CH═CH—, —CH═CHCH2—, —C═C— or —C≡CCH2—.
m may be either 0 or 1. However, when W is a single bond, m is equal to 1.
R5 and R6 are either identical or different and, either represent one functional group chosen from the following items 1) to 5), i.e.,

    1) a hydrogen atom,
    2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents, substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (aliphatic hydrocarbon group having 1 to 6 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents), and, substituted or unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents) may be cited as substituents),
    3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group having 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms in the cycle (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    or, when R5 and R6 are bonded to each other, they represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


R7 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, a functional group forming the acetal bond together with the oxygen atom bound to R7, or, when R7 and R5 are bonded to each other, it represents one portion of the bond forming the carbonyl group together with the carbon atom bonded to R5 and the oxygen atom bonded to R7.
A20 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below.




(In the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.)





(In the formula, n represents 0, 1, or 2.)

A10 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges G and A20 through an identical atom or through different a toms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A30 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges A20 and A40 through an identical atom or through different atoms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


A40 represents any of the items 1) to 3) below

    1) a single bond
    2) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R10 and R20, and A30 through an identical atom or through different atoms.
    3) when A40 and R10 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A40 or R10 and the nitrogen atom they are bonded to are bonded through a double bond, R20 represents the bond between A40 or R10 and the nitrogen atom.)


However, in the combination of G, A10, A20, A30, and A40 of the above Formula (2), when G represents the Formula (G1), and either of A10 or A30 is a phenylene group, A20 may not be a single bond. In addition, when A20 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A20 and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between.
R10 and R20 are either identical or different, and either represent one functional group chosen from the following items 1) to 7), i.e.,

    1) a hydrogen atom (however, when R10 and R20 both represent a hydrogen atom, only in the case where G is equal to Formula (G1)),
    2) when G is not equal to Formula (G7), a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, phenyl group, and, heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms) may be cited as substituents),
    3) when G is not equal to Formula (G7), a substituted or an unsubstituted cycloalkyl group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) when G is not equal to Formula (G7), a substituted or an unsubstituted phenyl group (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms, and, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    6) when G is not equal to Formula (G7), an acyl group having 1 to 10 carbon atoms
    7) when G is not equal to Formula (G7), a sulfonyl group having 1 to 8 carbon atoms (however, when either R10 or R20 represents a sulfonyl group having 1 to 8 carbon atoms, the other may be neither an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms),
    or, when R10 and R20 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to (for said cyclic amino group having 4 to 8 carbon atoms, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents)].


The same examples given for G in the above Formula (1) may be cited as preferred examples for G in the above Formula (2).
In the above Formula (2), A20 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below.




[In the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms.]





[In the formula, n represents 0, 1, or 2.]

The same examples given as concrete examples for R3 in the above Formula (1) may be cited as concrete examples for R3 in the above Formula (A2B).
In the above Formula (A2C), n represents 0, 1, or 2. However, 0 may be cited as the preferred value for n.
A single bond, —O—, —NH—, —N(CH3)— and —S— may be cited as such preferred functional groups for A20.
A10 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges G and A20 through an identical atom or through different atoms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


The same examples given as concrete examples for A1 in the above Formula (1) may be cited as such concrete examples for A10. A bond representing a single bond, —CH2—, —(CH2)2—, =CH— and ═CHCH2— may be cited as particularly preferred functional groups.
In the above Formula (2), A30 represents the items 1) or 2) below

    1) a single bond
    2) a functional group which bridges A20 and A40 through an identical atom or through different atoms, and chosen from a group consisting of an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group f having 1 or 2 oxygen atoms, nitrogen atoms, or sulfur atoms, and a phenylene group.


The same examples given as concrete examples for A3 in the above Formula (1) may be cited as concrete examples for A30. A bond representing a single bond, —CH2—, —(CH2)2— and —CH═CH— may be cited as particularly preferred functional groups.
In the above Formula (2), A40 represents any of the items 1) to 3) below

    1) a single bond
    2) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R10 and R20, and A30 through an identical atom or through different atoms.
    3) when A40 and R10 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A40 or R10 and the nitrogen atom they are bonded to are bonded through a double bond, R20 represents the bond between A40 or R10 and the nitrogen atom.). The same examples given as concrete examples for A4 in the above Formula (1) may be cited as such concrete examples for A40. A bond representing a single bond, —CH2— and —(CH2)2— may be cited as particularly preferred functional groups. In addition, when A40 and R10 are bonded to each other, to represent a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to, 2-pyridyl, 4-pyridyl and 4-piperidinyl may be cited as particularly preferred examples.


However, in the combination of G, A10, A20, A30, and A40, when G represents the Formula (G1), and either of A10 or A30 is a phenylene group, A20 may not be a single bond. In addition, when A20 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A20 and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between.
In the above Formula (2), as preferred examples of functional groups represented by the Formula (A0) below,




[In Formula (A0), A10, A20, A30, A40, and the symbol  have the same definition as above.]

    —(CH2)3—, —(CH2)4—, —(CH2)5—, =CH(CH2)2—, =CH(CH2)3—, =CH(CH2)4—, —CH2CH═CHCH2—, —NH(CH2)2—, —NH(CH2)3—, —NH(CH2)4—, —N(CH3)(CH2)3—, —CH2NH(CH2)2—, —O(CH2)3—, —CH2O(CH2)2—, —S(CH2)3— and —CH2S(CH2)2— may be cited.


In the above Formula (2), R10 and R20 are either identical or different, and either represent one functional group chosen from the following items 1) to 7), i.e.,

    1) a hydrogen atom (however, when R10 and R20 both represent a hydrogen atom, only in the case where G is equal to Formula (G1)),
    2) when G is not equal to Formula (G7), a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms (fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, phenyl group, and, heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms) may be cited as substituents),
    3) when G is not equal to Formula (G7), a substituted or an unsubstituted cycloalkyl group having 3 to 8 carbon atoms (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    4) when G is not equal to Formula (G7), a substituted or an unsubstituted phenyl group (alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    5) a substituted or an unsubstituted heterocyclic group (containing 1 to 4 oxygen atoms, nitrogen atoms, or sulfur atoms, and, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents),
    6) when G is not equal to Formula (G7), an acyl group having 1 to 10 carbon atoms
    7) when G is not equal to Formula (G7), a sulfonyl group having 1 to 8 carbon atoms (however, when either R10 or R20 represents a sulfonyl group having 1 to 8 carbon atoms, the other may neither be an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms),
    or, when R10 and R20 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to (for said cyclic amino group having 4 to 8 carbon atoms, alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms may be cited as substituents).


As concrete examples of R10 and R20, the same examples as the examples given in the above Formula (1) as concrete examples may be cited, and, as particularly preferred examples, a hydrogen atom, a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a t-butyl group, a 2-hydroxyethyl group, a 3-hydroxyethyl group, a carboxymethyl group, a carboxyethyl group, a methoxycarbonylethyl group, a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopropylmethyl group, a phenyl group, a tolyl group, a benzyl group, a phenethyl group, a pyridyl group, a 4-pyridyl group, a formyl group, an acetyl group, a propanoyl group, a benzoyl group, a methanesulfonyl group, a benzenesulfonyl group and a p-toluenesulfonyl may be cited.
When representing a functional group wherein R1 and R2 are bonded to each other and form an amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to, as examples of functional groups forming such an amino group having 4 to 8 carbon atoms, the same examples as the examples given in the above Formula (1) as concrete examples of R1 and R2 may be cited.
As preferred examples of such amino groups formed by R10, R20 and the nitrogen atom they are bonded to, an amino group, a methylamino group, an ethylamino group, a propylamino group, a butylamino group, a dimethylamino group, an N-methylamino group, a diethylamino group, a dipropylamino group, a diisopropylamino group, a dibutylamino group, an N-methylamino group, a cyclohexylamino group, a phenylamino group, a benzylamino group, a tolylamino group, a (4-pyridylmethyl)amino group, a 2-pyridylamino group, a 1-pyrrolidinyl group, a piperidino group, a morpholino group, a 4-N-methylpiperidin-1-yl group, a carboxymethylamino group, a 1-carboxyethylamino group, a 2-hydroxyethylamino group, and a 3-hydroxyethylamino group may be cited.
There are instances where the nitrogen-containing compound represented by the above Formula (1) may form salts. No particular restriction exists for such salts provided they are pharmacologically accepted. Concretely, mineral acid salts such as hydrochlorides, hydrobromates, hydroiodates, phosphates, nitrates, and sulfates, organic sulfonates such as methane sulfonates, 1-hydroxyethane sulfonates, and p-toluenesulfonates, and, organic carboxylates such as acetates, trifluoroacetates, propionates, oxalates, malonates, succinates, glutarates, adipinates, tartrates, maleates, malates and mendelates may be included as added acidic salts, and, salts formed with inorganic bases such as sodium salts, potassium salts, magnesium salts, calcium salts, inorganic salt groups such as aluminium salts, and, salts formed with organic bases such as methylamine salts, ethylamine salts, lysine salts, and ornithin salts may be cited as salts made with bases.
Concrete examples of the nitrogen-containing compounds represented by the above Formula (1) provided by the present invention will be given in the following. However, the invention is not limited to these examples.

    1) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    2) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    3) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    4) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    5) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    6) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    7) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    8) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    9) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    10) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    11) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    12) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    13) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    14) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    15) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    16) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    17) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    18) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    19) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    20) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    21) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    22) (1S,5S,6R,7R)-3-(47N,N-dibutylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    23) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    24) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    25) (1S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    26) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    27) (1S,5S,6R,7R)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    28) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    29) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    30) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    31) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    32) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    33) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    34) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    35) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    36) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    37) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    38) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    39) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    40) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    41) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    42) (1S,5S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    43) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-1-pentenyl-]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    44) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    45) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-1-bicyclo[3.3.0]-2-octene
    46) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    47) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    48) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    49) (1S,5S,6R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    50) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    51) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    52) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)-N-methylaminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    53) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    54) (1S,5S,6R,7R)-3-[N-(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    55) (1S,5S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    56) (1S,5S,6 R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]haminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    57) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    58) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    59) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    60) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    61) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    62) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    63) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    64) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    65) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    66) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    67) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    68) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    69) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    70) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    71) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    72) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    73) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    74) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    75) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl]thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    76) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    77) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    78) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    79) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    80) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    81) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    82) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    83) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    84) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    85) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    86) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    87) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    88) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
    89) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    90) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    91) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    92) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    93) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,5 S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    94) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    95) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    96) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    97) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    98) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    99) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    100) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    101) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    102) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    103) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    104) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    105) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    106) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    107) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    108) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    109) (1S,5S,6R,7R)-3-(4-N,N-dibutylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    110) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    111) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    112) (1S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    113) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    114) (1S,5S,6R,7R)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    115) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    116) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    117) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    118) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    119) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    120) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    121) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    122) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    123) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    124) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    125) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    126) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    127) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    128) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    129) (1S,5S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    130) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-1-pentenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    131) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    132) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    133) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    134) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbamoylethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    135) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    136) (1S,5S,6 R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    137) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    138) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(3S,5S,8E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    139) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)-N-methylaminomethyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    140) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    141) (1S,3S,6R,7R)3-[N—(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    142) (1S,5S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    143) (1S,5S,6R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    144) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    145) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    146) (1S,3S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    147) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    148) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    149) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    150) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    151) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    152) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    153) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    154) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    155) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    156) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    157) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    158) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    159) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    160) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    161) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    162) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl]thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    163) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    164) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    165) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    166) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    167) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    168) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]thioethyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    169) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    170) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    171) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    172) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    173) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    174) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    175) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    176) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-1-octenyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    177) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    178) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    179) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    180) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    181) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    182) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    183) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    184) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    185) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(4S, E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    186) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    187) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    188) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    189) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    190) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]7-hydroxybicyclo[3.3.0]-2-octene
    191) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    192) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    193) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    194) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    195) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    196) (1S,5S,6R,7R)-3-(4-N,N-dibutylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    197) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(4S,1 E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    198) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    199) (1S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    200) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    201) (1S,5S,6R,7R)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    202) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    203) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    204) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    205) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    206) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    207) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    208) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    209) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    210) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoylpentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo (3.3.0]-2-octene
    211) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    212) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    213) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(4S, E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    214) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    215) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    216) (1S,5S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    217) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-1-pentenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    218) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    219) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    220) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    221) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbarmoylethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    222) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    223) (1S,5S,6R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    224) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    225) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    226) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoyethyl)-N-methylaminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    227) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    228) (1S,5S,6R,7R)-3-[N—(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    229) (1S,5S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    230) (1S,5S,6R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    231) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    232) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    233) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    234) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    235) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    236) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    237) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    238) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    239) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    240) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    241) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    242) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(4S,4E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    243) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    244) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    245) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    246) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    247) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    248) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    249) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl]thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    250) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    251) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    252) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    253) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    254) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    255) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl] thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    256) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    257) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    258) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    259) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    260) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    261) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    262) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[33.0]-2-octene
    263) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    264) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    265) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    266) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    267) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    268) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    269) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    270) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    271) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    272) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    273) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    274) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    275) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    276) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    277) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    278) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    279) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    280) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    281) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(3S, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    282) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    283) (1S,5S,6R,7R)-3-(4-N,N-dibutylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    284) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    285) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    286) (1S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    287) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    288) (1S,5S,6R,7R)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    289) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    290) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    291) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    292) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    293) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    294) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    295) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    296) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    297) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoylpentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    298) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    299) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(3S, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    300) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    301) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    302) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    303) (1S,5S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3S, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    304) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-1-pentenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    305) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    306) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    307) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    308) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbamoylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    309) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    310) (1S,5S,6R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    311) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    312) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    313) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)-N-methylaminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    314) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    315) (1S,5S,6R,7R)-3-[N—(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    316) (1S,3S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    317) (1S,5S,6R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    318) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    319) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    320) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    321) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    322) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    323) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    324) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    325) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    326) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    327) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    328) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    329) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    330) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    331) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    332) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    333) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    334) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    335) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    336) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl] thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    337) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    338) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    339) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    340) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    341) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    342) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    343) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    344) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    345) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    346) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    347) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    348) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    349) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    350) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    351) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    352) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    353) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    354) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene 355) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    356) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    357) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    358) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    359) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    360) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    361) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    362) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    363) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    364) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    365) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    366) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3R, E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    367) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    368) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    369) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    370) (1S,5S,6R,7R)-3-(4-N,N-dibutylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    371) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    372) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    373) (1S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    374) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    375) (1S,5S,6R,7R)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    376) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    377) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    378) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    379) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    380) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    381) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    382) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    383) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    384) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoy8-pentyl)-6-[(3R, E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    385) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    386) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    387) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    388) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    389) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    390) (1S,5S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    391) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-pentenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    392) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    393) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    394) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(3R,9E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    395) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbamoylethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    396) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    397) (1S,5S,6R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    398) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    399) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    400) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)-N-methylaminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    401) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    402) (1S,5S,6R,7R)-3-[N—(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    403) (1S,5S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    404) (1S,5S,6R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    405) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    406) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    407) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    408) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    409) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    410) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    411) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    412) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    413) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    414) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    415) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    416) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    417) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    418) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    419) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    420) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    421) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    422) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    423) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl] thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    424) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    425) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    426) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    427) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    428) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    429) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    430) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    431) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    432) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    433) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    434) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    435) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    436) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    437) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    438) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    439) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    440) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    441) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    442) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    443) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(E)-4-(m-tolyl)—butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    444) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    445) (1S,5S,6R,7R)-3-(4-N-methylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    446) (1S,5S,6R,7R)-3-(4-N-ethylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    447) (1S,5S,6R,7R)-3-(4-N-propylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    448) (1S,5S,6R,7R)-3-(4-N-isopropylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    449) (1S,5S,6R,7R)-3-(4-N-butylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    450) (1S,5S,6R,7R)-3-(4-N-t-butylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    451) (1S,5S,6R,7R)-3-(4-N-phenylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    452) (1S,5S,6R,7R)-3-(4-N-benzylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    453) (1S,5S 6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    454) (1S,5S,6R,7R)-3-[4-(4-N-methyl-1-piperazinyl)carbonylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    455) (1S,5S,6R,7R)-3-[4-N-(2-pyridyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    456) (1S,5S,6R,7R)-3-(4-N,N-dipropylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    457) (1S,5S,6R,7R)-3-(4-N,N-dibutylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    458) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    459) (1S,5S,6R,7R)-3-[4-N-(2-hydroxyethyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    460) (1S,5S,5S,6R,7R)-3-[4-N-(3-hydroxypropyl)carbamoylbutyl]-6-[(E)-4-(m-tolyl)—butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    461) (1S,5S,6R,7R)-3-(3-carbamoylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    462) (1S,5S,6R,7%)-3-(3-N,N-dimethylcarbamoylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    463) (1S,5S,6R,7R)-3-(3-N,N-diisopropylcarbamoylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    464) (1S,5S,6R,7R)-3-(3-N-t-butyl-N-methylcarbamoylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    465) (1S,5S,6R,7R)-3-[3-(1-pyrrolidinyl)carbonylpropyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    466) (1S,5S,6R,7R)-3-(3-piperidinocarbonylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    467) (1S,5S,6R,7R)-3-(3-morpholinocarbonylpropyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    468) (1S,5S,6R,7R)-3-(5-carbamoylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    469) (1S,5S,6R,7R)-3-(5-N,N-dimethylcarbamoylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    470) (1S,5S,6R,7R)-3-(5-N,N-diisopropylcarbamoylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    471) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylcarbamoylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    472) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)carbonylpentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    473) (1S,5S,6R,7R)-3-(5-piperidinocarbonylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    474) (1S,5S,6R,7R)-3-(5-morpholinocarbonylpentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    475) (1S,5S,6R,7R)-3-[(1Z)-3-N,N-dimethylcarbamoyl-1-propenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    476) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    477) (1S,1S,6R,7R)-3-[(1E)-4-N,N-dimethylcarbamoyl-1-butenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    478) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylcarbamoyl-1-pentenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    479) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    480) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    481) (1S,5S,6R,7R)-3-[N-(2-N,N-diisopropylcarbamoylethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    482) (1S,5S,6R,7R)-3-[N-(2-N-t-butyl-N-methylcarbamoylethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    483) (1S,5S,6R,7R)-3-[N-[2-(1-pyrrolidinyl)carbonylethyl]aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    484) (1S,5S,6R,7R)-3-[N-(2-piperidinocarbonylethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    485) (1S,5S,6R,7R)-3-[N-(2-morpholinocarbonylethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    486) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylcarbamoylpropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    487) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylcarbamoylethyl)-N-methylaminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    488) (1S,5S,6R,7R)-3-[N—(N,N-dimethylcarbamoylmethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    489) (1S,5S,6R,7R)-3-[N—(N,N-diisopropylcarbamoylmethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    490) (1S,5S,6R,7R)-3-[N-(N-t-butyl-N-methylcarbamoylmethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    491) (1S,5S,6R,7R)-3-[2-N-[(1-pyrrolidinyl)carbonylmethyl]aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    492) (1S,5S,6R,7R)-3-[2-N-(piperidinocarbonylmethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    493) (1S,5S,6R,7R)-3-[2-N-(morpholinocarbonylmethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    494) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylcarbamoylethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    495) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    496) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    497) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    498) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinyl)carbonylethyl]oxymethyl]-6-[(E)-4-(m-tolyl) 1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    499) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    500) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    501) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    502) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    503) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    504) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    505) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    506) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    507) (1S,5S,6R,7R)-3-[(2-N,N-dimethylcarbamoylethyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    508) (1S,5S,6R,7R)-3-[(2-N,N-diisopropylcarbamoylethyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    509) (1S,5S,6R,7R)-3-[(2-N-t-butyl-N-methylcarbamoylethyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    510) (1S,5S,6R,7R)-3-[[2-(1-pyrrolidinylcarbonyl)ethyl]thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    511) (1S,5S,6R,7R)-3-[(2-piperidinocarbonylethyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    512) (1S,5S,6R,7R)-3-[(2-morpholinocarbonylethyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    513) (1S,5S,6R,7R)-3-[2-(N,N-dimethylcarbamoylmethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    514) (1S,5S,6R,7R)-3-[2-(N,N-diisopropylcarbamoylmethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    515) (1S,5S,6R,7R)-3-[2-(N-t-butyl-N-methylcarbamoylmethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    516) (1S,5S,6R,7R)-3-[2-[(1-pyrrolidinyl)carbonylmethyl]thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    517) (1S,5S,6R,7R)-3-[2-(piperidinocarbonylmethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    518) (1S,5S,6R,7R)-3-[2-(morpholinocarbonylmethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    519) (1S,5S,6R,7R)-3-[(2-carbamoylphenyl)methyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    520) (1S,5S,6R,7R)-3-[(4-carbamoylphenyl)methyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    521) (1S,5S,6R,7R)-3-[2-(3-carbamoylphenyl)ethyl]-6-[(E)-4-(m-tolyl)-2-butenyl-7-hydroxybicyclo[3.3.0]-2-octene
    522) (1S,5S,6R,7R)-3-[2-[3-(piperidinocarbonyl)phenyl]ethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    523) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    524) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    525) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    526) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    527) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    528) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    529) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    530) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    531) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    532) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,5R,1E)-3-hydroxy-5-methyl]-nonenyl group
    533) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    534) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    535) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    536) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    537) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(4R,1E)-4-hydroxy-4-methyl]-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    538) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    539) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    540) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    541) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    542) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group
    543) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]7-hydroxybicyclo[3.3.0]-2-octene
    544) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    545) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    546) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo [3.3.0]-2-octene
    547) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    548) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    549) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    550) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    551) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    552) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group
    553) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    554) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    555) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    556) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    557) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    558) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    559) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    560) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    561) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    562) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group
    563) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]- 7-hydroxybicyclo[3.3.0]-2-octene
    564) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1 propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    565) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1 propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    566) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    567) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    568) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    569) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    570) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    571) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    572) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group
    573) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    574) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    575) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    576) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    577) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    578) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    579) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    580) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    581) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    582) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group
    583) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    584) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    585) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    586) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    587) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    588) (S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    589) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    590) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    591) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    592) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group
    593) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    594) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R, 1E)-3-hydroxy-3-phenyl-1 propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    595) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3R,1E)—hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    596) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    597) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    598) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    599) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    600) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    601) (1S,5S,6 R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    602) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group
    603) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    604) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    605) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    606) (1S,5S,6R,7R)-3-[4-N-(2-methoxycarbonylethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    607) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    608) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    609) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    610) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    611) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    612) compounds of compound numbers 10 to 87 of the examples given bove, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group
    613) (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    614) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    615) (1S,5S,6R,7R)-3-(4-N,N-diethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    616) (1S,5S,6R,7R)-3-[4-N-(2-ethoxycarbonylethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    617) (1S,5S,6R,7R)-3-[4-N-(4-pyridylmethyl)carbamoylbutyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    618) (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    619) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)carbonylbutyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    620) (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    621) (1S,5S,6R,7R)-3-(4-morpholinocarbonylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    622) compounds of compound numbers 10 to 87 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-1-octenyl group
    623) (1S,5S,6R,7S)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    624) (1S,5S,6R,7S)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    625) (1R,5R,6S,7S)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    626) (1R,5R,6S,7S)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    627) (1R,5R,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    628) (1R,5R,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    629) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-hydroxy-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    630) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    631) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    632) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    633) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    634) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-hexenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    635) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-hexenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    636) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-heptenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    637) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-heptenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    638) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    639) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    640) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-decenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    641) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R; 1E)-3-hydroxy-1-decenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    642) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    643) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    644) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    645) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    646) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    647) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-(3-ethylcyclopentyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    648) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3(3-ethylcyclopentyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    649) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    650) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    651) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    652) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    653) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    654) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    655) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    656) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    657) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    658) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    659) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    660) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    661) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    662) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    663) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    664) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    665) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    666) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    667) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    668) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-5-(o-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    669) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-5-(o-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    670) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S, 1E)-3-hydroxy-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    671) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    672) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-5-(p-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    673) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-5-(p-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    674) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(4-methoxyphenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    675) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(4-methoxyphenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    676) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(4-N,N-dimethylaminophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    677) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(4-N,N-dimethylaminophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    678) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-(3-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    679) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(3-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    680) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3 hydroxy-4-1(4-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    681) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(4-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    682) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    683) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    684) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    685) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    686) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    687) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    688) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    689) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    690) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-3(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    691) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-3(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    692) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    693) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    694) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-3-methyl-5(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    695) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-3-methyl-5(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    696) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4,4-dimethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    697) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1 E)-3-hydroxy-4,4-dimethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    698) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E,5Z)-3-hydroxy-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    699) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E,5Z)-3-hydroxy-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    700) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    701) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    702) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl--6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    703) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl--6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    704) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4,4-dimethyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    705) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4,4-dimethyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    706) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl--6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    707) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    708) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    709) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    710) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    711) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-1-octynyl]-7-hydroxybicyclo [3.3.0]-2-octene
    712) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-1-octynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    713) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S, 1Z)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    714) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1Z)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    715) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxyoctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    716) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxyoctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    717) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-3-methyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    718) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-3-methyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    719) (1S,5 S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-4,4-dimethyloctyl]7-hydroxybicyclo[3.3.0]-2-octene
    720) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-4,4-dimethyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    721) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-3-phenylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    722) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-3-phenylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    723) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-4-phenylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    724) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-4-phenylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    725) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-4-(m-tolyl)butyl]-7-hydroxybicyclo[3.3.0]-2-octene
    726) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-4-(m-tolyl)butyl]-7-hydroxybicyclo[3.3.0]-2-octene
    727) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S)-3-hydroxy-3-cyclopentylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    728) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R)-3-hydroxy-3-cyclopentylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    729) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S, 1E)-4-hydroxy-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    730) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    731) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-hydroxy-4-butyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    732) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S, 1E)-4-hydroxy-4-butyl-1,5-hexadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    733) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R, 1E)-4-hydroxy-4-butyl-1,5-hexadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    734) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-cyclopentyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    735) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R, 1E)-4-hydroxy-4-cyclopentyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    736) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-cyclohexyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    737) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-cyclohexyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    738) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    739) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-4-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    740) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-(1-hydroxycyclopentyl)-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    741) (1S,5S 6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-(1-hydroxycyclohexyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    742) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    743) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-4-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    744) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-1-octenyl]-7 hydroxybicyclo[3.3.0]-2-octene
    745) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E)-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    746) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,5S)-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    747) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,5R)-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    748) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E,5S)-5-methyl-1,3-nonadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    749) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E,5R)-5-methyl-1,3-nonadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    750) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,4R)-5-methyl-1,3-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    751) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,4S)-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    752) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E)-4-methyl-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    753) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,5R)-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    754) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,4S)-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    755) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E)-4-ethyl-1,3-octadienyl j-7-hydroxybicyclo[3.3.0]-2-octene
    756) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-butyl-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    757) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,5Z)-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    758) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E,5Z)-1,3,5-octatrienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    759) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-cyclopentyliden-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    760) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-cyclohexyliden-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    761) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-2-phenylvinyl]-7-hydroxybicyclo[3.3.0]-2-octene
    762) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-2-(o-tolyl)vinyl]-7-hydroxybicyclo[3.3.0]-2-octene
    763) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-2-(m-tolyl)vinyl]-7-hydroxybicyclo[3.3.0]-2-octene
    764) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-2-(p-tolyl)vinyl]-7-hydroxybicyclo[3.3.0]-2-octene
    765) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    766) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    767) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E) 4-phenyl-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    768) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3t)-4-phenyl-3-methyl-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    769) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    770) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    771) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    772) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E)-4-(m-tolyl)-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    773) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    774) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(31E,3E)-5-(m-tolyl)-3-pentadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    775) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-4,4-bisphenylsufonyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-octene
    776) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E,3E)-5-(m-tolyl)-1,3-hexadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    777) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(4-phenoxybutyl)-7-hydroxybicyclo[3.3.0]-2-octene
    778) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    779) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-S-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    780) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    781) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-hexenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    782) (S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-heptenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    783) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    784) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    785) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-decenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    786) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-3-oxo-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    787) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4R,1E)-3-oxo-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    788) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4,4-dimethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    789) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(5S,1E)-3-oxo-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    790) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(5R,1E)-3-oxo-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    791) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    792) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1 E)-3-oxo-3-cyclohexyl-1 propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    793) (1S,5 S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    794) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    795) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-3-phenyl-propenyl]7-hydroxybicyclo[3.3.0]-2-octene
    796) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    797) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    798) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    799) (1S,5 S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    800) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    801) (1S,58,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    802) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    803) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    804) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-5-(o-tolyl)-1-pentenyl]7-hydroxybicyclo[3.3.0]-2-octene
    805) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    806) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1E)-3-oxo-5-(p-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    807) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-hydroxymethyl-7-hydroxybicyclo[3.3.0]-2-octene
    808) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R)-hydroxyethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    809) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S)-1-hydroxyethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    810) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R)-1-hydroxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    811) (1S,5S 6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S)-1-hydroxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    812) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R)-1-hydroxy-1-methylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    813) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S)-1-hydroxy-1-methylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    814) (1 S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R,2E)—hydroxy-2-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    815) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S,2E)-1-hydroxy-2-nonenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    816) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R,3S,2E)-1,3-dihydroxy-2-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    817) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S,3S,2E)-1,3-dihydroxy-2-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    818) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R,3S,2E)-1,3-dihydroxy-4-cyclopentyl-2-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    819) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S,3S,2E)-1,3-dihydroxy-4-cyclopentyl-2-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    820) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R,3S,2E)-1,3-dihydroxy-5-phenyl-2-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    821) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S,3S,2E)-1,3-dihydroxy-5-phenyl-2-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    822) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S)-1-hydroxy-2-pentynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    823) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R)-1-hydroxy-2-pentynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    824) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1R)-1-hydroxy-5-phenoxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    825) (1S,5S,6S,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(1S)-1-hydroxy-5-phenoxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    826) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxyphenylmethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    827) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxyphenylmethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    828) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(o-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    829) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(o-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    830) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(m-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    831) (1S,5S,6R,7R)-5-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(m-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    832) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(p-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    833) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(p-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    834) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(4-methoxyphenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    835) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(4-methoxyphenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    836) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(4-N,N-dimethylaminophenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    837) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(4-N,N-dimethylaminophenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    838) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(R)-hydroxy(3-chlorophenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    839) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(S)-hydroxy(3-chlorophenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    840) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-formyl-7-hydroxybicyclo[3.3.0]-2-octene
    841) (1S,3S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-acetyl-7-hydroxybicyclo[3.3.0]-2-octene
    842) (1 S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-benzoyl-7-hydroxybicyclo[3.3.0]-2-octene
    843) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(o-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    844) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(m-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    845) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(p-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    846) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(4-methoxyphenylcarbonyl)-7-hydroxybicyclo[3.3.0]-2-octene
    847) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-(4-N,N-dimethylaminophenyl carbonyl)-7-hydroxybicyclo[3.3.0]-2-octene
    848) (1S,5S,6R,7R)-3-(4-N,N-dimethyl carbamoylbutyl)-6-(3-chlorophenylcarbonyl)-7-hydroxybicyclo[3.3.0]-2-octene
    849) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-phenylvinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    850) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-(4-methoxyphenyl)vinyl carbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    851) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-(4-N,N-dimethylamino phenyl)vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    852) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-(3-chlorophenyl)vinyl carbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    853) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-(2-thienyl)vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    854) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(2E)-2-(4-pyridyl)vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    855) compounds of compound numbers 623 to 854 of the examples given above, wherein the 4-N,N-dimethylcarbamoylbutyl group, which is a substitution group at position 3 of the bicyclo[3.3.0]-2-octene cycle, has been replaced by either of the 4-carbamoylbutyl group, the 4-N,N-diethylcarbamoylbutyl group, the 4-N-(2-methoxycarbonylethyl)carbamoylbutyl group, the 4-N-(4-pyridylmethyl)carbamoylbutyl group, the 4-N,N-diisopropylcarbamoylbutyl group, the 4-(1-pyrrolidinyl)carbonylbutyl group, the 4-piperidinocarbonylbutyl group or the 4-morpholinocarbonylbutyl group
    856) (1S,2R,3R,5S)-7-[(E)-4-carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    857) (1S,2R,3R,5S)-7-[(E)-4-N-methylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    858) (1S,2R,3R,5S)-7-[(E)-4-N-ethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    859) (1S,2R,3R,5S)-7-[(E)-4-N-propylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    860) (1S,2R,3R,5S)-7-[(E)-4-N-isopropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    861) (1S,2R,3R,5S)-7-[(E)-4-N-butylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    862) (1S,2R,3R,5S)-7-[(E)-4-N-t-butylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    863) (1S,2R,3R,5S)-7-[(E)-4-N-phenylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    864) (1S,2R,3R,5S)-7-[(E)-4-N-benzylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    865) (1S,2R,3R,5S)-7-[(E)-4-N-(4-pyridylmethyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    866) (1S,2R,3R,5S)-7-[(E)-4-(1-pyrrolidinyl)carbonylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    867) (1S,2R,3R,5S)-7-[(E)-4-piperidinocarbonylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]3-hydroxybicyclo[3.3.0]octane
    868) (1S,2R,3R,5S)-7-[(E)-4-morpholinocarbonylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    869) (1S,2R,3R,5S)-7-[(E)-4-(4-N-methyl-1-piperazinyl)carbonylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    870) (1S,2R,3R,5S)-7-[(E)-4-N-(2-pyridyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    871) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S, 1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    872) (1S,2R,3R,5S)-7-[(E)-4-N,N-diethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    873) (1S,2R,3R,5S)-7-[(E)-4-N,N-dipropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo [3.3.0]octane
    874) (1S,2R,3R,5S)-7-[(E)-4-N,N-diisopropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    875) (1S,2R,3R,5S)-7-[(E)-4-N,N-dibutylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    876) (1S,2R,3R,5S)-7-[(E)-4-N-t-butyl-N-methylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    877) (1S,2R,3R,5S)-7-[(E)-4-N-(2-hydroxyethyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    878) (1S,2R,3R,5S)-7-[(E)-4-N-(3-hydroxypropyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    879) (1S,2R,3R,5S)-7-[(E)-3-carbamoylpropylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    880) (1S,2R,3R,5S)-7-[(E)-3-N,N-dimethylcarbamoylpropylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    881) (1S,2R,3R,5S)-7-[(E)-5-carbamoylpentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    882) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylcarbamoylpentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    883) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    884) (1S,2R,3R,5S)-7-[(E)-2-(N,N-diisopropylcarbamoylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    885) (1S,2R,3R,5S)-7-[(E)-2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    886) (1S,2R,3R,5S)-7-[(E)-2-[(1-pyrrolidinyl)carbonylmethyl]oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    887) (1S,2R,3R,5S)-7-[(E)-2-(piperidinocarbonylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    888) (1S,2R,3R,5S)-7-[(E)-2-(morpholinocarbonylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    889) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)thioethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    890) (1S,2R,3R,5S)-7-[(E)-2-N—(N,N-dimethylcarbamoylmethyl)aminoethylidene]-2-[(3S,1E)3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    891) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethoxymethylene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    892) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethylthiomethylene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    893) (1S,2R,3R,5S)-7-[(E)-N—(N,N-dimethylcarbamoylmethyl)aminomethylene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    894) (1S,2R,3R,5S)-7-[(E)-4-carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    895) (1S,2R,3R,5S)-7-[(E)-4-N-methylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    896) (1S,2R,3R,5S)-7-[(E)-4-N-ethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    897) (1S,2R,3R,5S)-7-[(E)-4-N-propylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    898) (1S,2R,3R,5S)-7-[(E)-4-N-isopropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    899) (1S,2R,3R,5S)-7-[(E)-4-N-butylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    900) (1S,2R,3R,5S)-7-[(E)-4-N-t-butylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-0.3-hydroxybicyclo[3.3.0]octane
    901) (1S,2R,3R,5S)-7-[(E)-4-N-phenylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    902) (1S,2R,3R,5S)-7-[(E)-4-N-benzylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    903) (1S,2R,3R,5S)-7-[(E)-4-N-(4-pyridylmethyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    904) (1S,2R,3R,5S)-7-[(E)-4-(1-pyrrolidinyl)carbonylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    905) (1S,2R,3R,5S)-7-[(E)-4-piperidinocarbonylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    906) (1S,2R,3R,5S)-7-[(E)-4-morpholinocarbonylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.6]octane
    907) (1S,2R,3R,5S)-7-[(E)-4-(4-N-methyl-1-piperazinyl)carbonylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    908) (1S,2R,3R,5S)-7-[(E)-4-N-(2-pyridyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    909) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    910) (1S,2R,3R,5S)-7-[(E)-4-N,N-diethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    911) (1S,2R,3R,5S)-7-[(E)-4-N,N-dipropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    912) (1S,2R,3R,5S)-7-[(E)-4-N,N-diisopropylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    913) (1S,2R,3R,5S)-7-[(E)-4-N,N-dibutylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    914) (1S,2R,3R,5S)-7-[(E)-4-N-t-butyl-N-methylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    915) (1S,2R,3R,5S)-7-[(E)-4-N-(2-hydroxyethyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    916) (1S,2R,3R,5S)-7-[(E)-4-N-(3-hydroxypropyl)carbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    917) (1S,2R,3R,5S)-7-[(E)-3-carbamoylpropylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    918) (1S,2R,3R,5S)-7-[(E)-3-N,N-dimethylcarbamoylpropylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    919) (1S,2R,3R,5S)-7-[(E)-5-carbamoylpentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    920) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylcarbamoylpentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    921) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    922) (1S,2R,3R,5S)-7-[(E)-2-(N,N-diisopropylcarbamoylmethyl)-oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0] octane
    923) (1S,2R,3R,5S)-7-[(E)-2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethylidene]-2-[(3S,1E)3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    924) (1S,2R,3R,5S)-7-[(E)-2-[(1-pyrrolidinyl)carbonylmethyl]oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0] octane
    925) (1S,2R,3R,5S)-7-[(E)-2-(piperidinocarbonylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    926) (1S,2R,3R,5S)-7-[(E)-2-(morpholinocarbonylmethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo(3.3.0]octane
    927) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)thioethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    928) (1S,2R,3R,5S)-7-[(E)-2-N—(N,N-dimethylcarbamoylmethyl)aminoethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    929) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethoxymethylene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    930) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethylthiomethylene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    931) (1S,2R 3R,5S)-7-[(E)-N—(N,N-dimethylcarbamoylmethyl)aminomethylene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    932) (1S,2R,3R,5S)-7-[(E)-4-carbamoylbutylidene]-2-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    933) (1S,2R,3R,5S)-7-[(E)-4-N-methylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    934) (1S,2R,3R,5S)-7-[(E)-4-N-ethylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    935) (1S,2R,3R,5S)-7-[(E)-4-N-propylcarbamoylbutylidene]-2-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    936) (1S,2R,3R,5S)-7-[(E)-4-N-isopropylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0] octane
    937) (1S,2R,3R,5S)-7-[(E)-4-N-butylcarbamoylbutylidene]-2-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    938) (1S,2R,3R,5S)-7-[(E)-4-N-t-butylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    939) (1S,2R,3R,5S)-7-[(E)-4-N-phenylcarbamoylbutylidene]-2-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    940) (1S,2R,3R,5S)-7-[(E)-4-N-benzylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    941) (1 S,2R,3R,5S)-7-[(E)-4-N-(4-pyridylmethyl)carbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    942) (1S,2R,3R,5S)-7-[(E)-4-(1-pyrrolidinyl)carbonylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    943) (1S,2R,3R,5S)-7-[(E)-4-piperidinocarbonylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    944) (1S,2R,3R,5S)-7-[(E)-4-morpholinocarbonylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    945) (1S,2R,3R,5S)-7-[(E)-4-(4-N-methyl-1-piperazinyl)carbonylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo [3.3.0]octane
    946) (1S,2R,3R,5S)-7-[(E)-4-N-(2-pyridyl)carbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    947) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    948) (1S,2R,3R,5S)-7-[(E)-4-N,N-diethylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    949) (1S,2R,3R,5S)-7-[(E)-4-N,N-dipropylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    950) (1S,2R,3R,5S)-7-[(E)-4-N,N-diisopropylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    951) (1S,2R,3R,5S)-7-[(E)-4-N,N-dibutylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    952) (1S,2R,3R,5S)-7-[(E)-4-N-t-butyl-N-methylcarbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    953) (1S,2R,3R,5S)-7-[(E)-4-N-(2-hydroxyethyl)carbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    954) (1S,2R,3R,5S)-7-[(E)-4-N-(3-hydroxypropyl)carbamoylbutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    955) (1S,2R,3R,5S)-7-[(E)-3-carbamoylpropylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0] octane
    956) (1S,2,R,3R,5S)-7-[(E)-3-N,N-dimethylcarbamoylpropylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    957) (1S,2R,3R,5S)-7-[(E)-5-carbamoylpentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    958) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylcarbamoylpentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    959) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    960) (1S,2R,3R,5S)-7-[(E)-2-(N,N-diisopropylcarbamoylmethyl)oxyethylidene]-2-[(3S,4S,1E)3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    961) (1S,2R,3R,5S)-7-[(E)-2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    962) (1S,2R,3R,5S)-7-[(E)-2-[(1-pyrrolidinyl)carbonylmethyl]oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    963) (1S,2R,3R,5S)-7-[(E)-2-(piperidinocarbonylmethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    964) (1S,2R,3R,5S)-7-[(E)-2-(morpholinocarbonylmethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    965) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)thioethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    966) (1S,2R,3R,5S)-7-[(E)-2-N-(N,N-dimethylcarbamoylmethyl)aminoethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    967) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethoxymethylene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    968) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethylthiomethylene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    969) (1S,2R,3R,5S)-7-[(E)-N—(N,N-dimethylcarbamoylmethyl)aminomethylene]-2-[(3S,4S, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    970) (1S,2R,3R,5S)-7-[(E)-4-carbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    971) (1S,2R,3R,5S)-7-[(E)-4-N-methylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    972) (1S,2R,3R,5S)-7-[(E)-4-N-ethylcarbamoylbutylidene]-2-[(3S,4R, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    973) (1S,2R,3R,5S)-7-[(E)-4-N-propylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0] octane
    974) (1S,2R,3R,5S)-7-[(E)-4-N-isopropylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    975) (1S,2R,3R,5S)-7-[(E)-4-N-butylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    976) (1S,2R,3R,5S)-7-[(E)-4-N-t-butylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo [3.3.0]octane
    977) (1S,2R,3R,5S)-7-[(E)-4-N-phenylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    978) (1S,2R,3R,5S)-7-[(E)-4-N-benzylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    979) (1S,2R,3R,5S)-7-[(E)-4-N-(4-pyridylmethyl)carbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    980) (1S,2R,3R,5S)-7-[(E)-4-(1-pyrrolidinyl)carbonylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    981) (1S,2R,3R,5S)-7-[(E)-4-piperidinocarbonylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    982) (1S,2R,3R,5S)-7-[(E)-4-morpholinocarbonylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    983) (1S,2R,3R,5S)-7-[(E)-4-(4-N-methyl-1-piperazinyl)carbonylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    984) (1S,2R,3R,5S)-7-[(E)-4-N-(2-pyridyl)carbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    985) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    986) (1S,2R,3R,5S)-7-[(E)-4-N,N-diethylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    987) (1S,2R,3R,5S)-7-[(E)-4-N,N-dipropylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    988) (1S,2R,3R,5S)-7-[(E)-4-N,N-diisopropylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    989) (1S,2R,3R,5S)-7-[(E)-4-N,N-dibutylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    990) (1S,2R,3R,5S)-7-[(E)-4-N-t-butyl-N-methylcarbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    991) (1S,2R,3R,5S)-7-[(E)-4-N-(2-hydroxyethyl)carbamoylbutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    992) (1S,2R,3R,5S)-7-[(E)-4-N-(3-hydroxypropyl)carbamoylbutyldene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    993) (1S,2R,3R,5S)-7-[(E)-3-carbamoylpropylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    994) (1S,2R,3R,5S)-7-[(E)-3-N,N-dimethylcarbamoylpropylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    995) (1S,2R,3R,5S)-7-[(E)-5-carbamoylpentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    996) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylcarbamoylpentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    997) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    998) (1S,2R,3R,5S)-7-[(E)-2-(N,N-diisopropylcarbamoylmethyl)oxyethylidene]-2[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    999) (1S,2R,3R,5S)-7-[(E)-2-(N-t-butyl-N-methylcarbamoylmethyl)oxyethylidene]-2[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-5-enyl]-3-hydroxybicyclo[3.3.0]octane
    1000) (1S,2R,3R,5S)-7-[(E)-2-[(1-pyrrolidinyl)carbonylmethyl]oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1001) (1S,2R,3R,5S)-7-[(E)-2-(piperidinocarbonylmethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1002) (1S,2R,3R,5S)-7-[(E)-2-(morpholinocarbonylmethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1003) (1S,2R,3R,5S)-7-[(E)-2-(N,N-dimethylcarbamoylmethyl)thioethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1004) (1S,2R,3R,5S)-7-[(E)-2-N—(N,N-dimethylcarbamoylmethyl)aminoethylidene]-2[(3S,4R, 1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1005) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethoxymethylene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1006) (1S,2R,3R,5S)-7-[(E)-N,N-dimethylcarbamoylmethylthiomethylene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1007) (1S,2R,3R,5S)-7-[(E)-N—(N,N-dimethylcarbamoylmethyl)aminomethylene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    1008) compounds of compound numbers 856 to 893 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group, or, the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group or the 2-(1-hydroxycyclohexyl)ethynyl group
    1009) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-carbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1010) (1R,2R,3aS,8bS)-2,3,3a, 8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N-methylcarbamoylpropyl)-1H-cyclopenta [b] benzofuran
    1011) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-ethylcarbamoylpropyl)-1H-cyclopenta [b]benzofuran
    1012) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-propylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1013) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-isopropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1014) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1015) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-t-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1016) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S, 1E)-3-hydroxy-1-octenyl]-5-(3-N-phenylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1017) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(3-N-benzylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1018) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-N-(4-pyridylmethyl)carbamoylpropyl]-1H-cyclopenta[b] benzofuran
    1019) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-(1-pyrrolidinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1020) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-piperidinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1021) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-morpholinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1022) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-(4-N-methyl-1-piperazinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1023) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-N-(2-pyridyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1024) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-dimethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1025) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-diethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1026) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-dipropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1027) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-diisopropylcarbamoylpropyl)-1H-cyclopenta [b]benzofuran
    1028) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-dibutylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1029) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N-t-butyl-N-methylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1030) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-N-(2-hydroxyethyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1031) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[3-N-(3-hydroxypropyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1032) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(2-carbamoylethyl)-1H-cyclopenta[b]benzofuran
    1033) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(2-N,N-dimethylcarbamoylethyl)-1H-cyclopenta[b]benzofuran
    1034) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-carbamoylbutyl)-1H-cyclopenta[b]benzofuran
    1035) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-dimethylcarbamoylbutyl)-1H-cyclopenta [b]benzofuran
    1036) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(2-N,N-dimethylcarbamoylethyloxy)-1H-cyclopenta[b]benzofuran
    1037) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-carbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1038) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-methylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1039) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-ethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1040) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-propylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1041) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-isopropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1042) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1043) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-t-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1044) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-phenylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1045) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-benzylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1046) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(4-pyridylmethyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1047) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-(1-pyrrolidinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1048) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-piperidinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1049) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-morpholinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1050) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-(4-N-methyl-1-piperazinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1051) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(2-pyridyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1052) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dimethylcarbamoylpropyl)-1H-cyclopenta[b] benzofuran
    1053) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-diethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1054) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dipropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1055) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-diisopropylcarbamoylpropyl)-1H-cyclopenta [b]benzofuran
    1056) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dibutylcarbamoylpropyl)-1H-cyclopenta[b] benzofuran
    1057) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-t-butyl-N-methylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1058) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(2-hydroxyethyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1059) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(3-hydroxypropyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1060) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-carbamoylethyl)-1H-cyclopenta [b]benzofuran
    1061) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-N,N-dimethylcarbamoylethyl)-1H-cyclopenta[b] benzofuran
    1062) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-carbamoylbutyl)-1H-cyclopenta[b]benzofuran
    1063) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dimethylcarbamoylbutyl)-1H-cyclopenta[b]benzofuran
    1064) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-N,N-dimethylearbamoylethyloxy)-1H-cyclopenta[b]benzofuran
    1065) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-carbamoylpropyl)-1H-cyclopenta (b]benzofuran
    1066) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-methylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1067) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-ethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1068) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-propylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1069) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-isopropylcarbamoylpropyl)-1H-cyclopenta [b] benzofuran
    1070) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1071) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-t-butylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1072) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-phenylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1073) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-benzylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1074) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(4-pyridylmethyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1075) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-(1-pyrrolidinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1076) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-piperidinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1077) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-morpholinocarbonylpropyl)-1H-cyclopenta[b]benzofuran
    1078) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-(4-N-methyl-1-piperazinyl)carbonylpropyl]-1H-cyclopenta[b]benzofuran
    1079) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(2-pyridyl)carbamoylpropyl]-1H-cyclopenta[b]benzofuran
    1080) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dimethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1081) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-diethylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1082) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dipropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1083) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-diisopropylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1084) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dibutylcarbamoylpropyl)-1H-cyclopenta [b] benzofuran
    1085) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N-t-butyl-N-methylcarbamoylpropyl)-1H-cyclopenta[b]benzofuran
    1086) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(2-hydroxyethyl)carbamoylpropyl]-01H-cyclopenta[b]benzofuran
    1087) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[3-N-(3-hydroxypropyl)carbamoylpropyl]-1H-cyclopenta [b]benzofuran
    1088) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-carbamoylethyl)-1H-cyclopenta [b]benzofuran
    1089) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-N,N-dimethylcarbamoylethyl)-1H-cyclopenta [b]benzofuran
    1090) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-carbamoylbutyl)-1H-cyclopenta[b]benzofuran
    1091) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dimethylcarbamoylbutyl)-1H-cyclopenta [b]benzofuran
    1092) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(2-N,N-dimethylcarbamoylethyloxy)-1H-cyclopenta[b]benzofuran
    1093) compounds of compound numbers 1009 to 1036 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group or the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group
    1094) (1S,2R,3R,5S)-7-[(Z)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1095) (1R,5S,7R,8R)-3-(4-N,N-dimethylcarbamoylbutyl)-8-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1096) (1S,2R,3R,5S,7R)-7-(4-N,N-dimethylcarbamoylbutyl)-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1097) (1S,2R,3R,5S,7R)-7-[2-(N,N-dimethylaminocarbamoylmethoxy)ethyl]-2-[(3R,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-3-hydroxybicyclo[3.3.0]octane
    1098) (1S,3S,5R,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-oxabicyclo[3.3.0]octane
    1099) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-oxabicyclo[3.3.0]-3-octen
    1100) (1S,5R,6R,7R)-3-[(Z)-4-N,N-dimethylcarbamoylbutylidene]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-4-oxo-2-oxabicyclo[3.3.0]octane
    1101) (1S,3S,5R,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-thiabicyclo[3.3.0]octane
    1102) (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-azabicyclo[3.3.0]-2-octene
    1103) (1S,3S,5R,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-azabicyclo[3.3.0]octane
    1104) compounds of compound numbers 1094 to 1103 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group, the (3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group, the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group or the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group
    1105) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,1E)-3-hydroxy-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1106) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1107) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1108) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1109) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1110) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1111) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1112) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1113) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1114) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1115) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1116) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1117) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1118) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1119) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1120) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1121) (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1122) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1123) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1124) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1125) (1S,5S,6R,7R)-3-(5-N,N- dibutylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1126) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1127) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]7-hydroxybicyclo[3.3.0]-2-octene
    1128) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1129) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1130) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1131) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1132) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylaminobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1133) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1134) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1135) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1136) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1137) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1138) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1139) (1S,5S,6R,7R)-3-(6-N-t-butyl-N-methylaminohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1140) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl)hexyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1141) (1S,5S,6R,7R)-3-(6-piperidinohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1142) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1143) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1144) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1145) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1146) (1S,5S,6R,7R)-3-[(1Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1147) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1148) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1149) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1150) (1S,5S,6R,7R)-3-[N-(3-N-t-butyl-N-methylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1151) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1152) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1153) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1154) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(3S,1E)-3-hydroxy 1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1155) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1156) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1157) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1158) (1S,5S,6R,7R)-3-[2-N-(2-N-t-butyl-N-methylaminoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1159) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1160) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1161) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1162) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1163) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1164) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1165) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1166) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1167) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1168) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1169) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo([3.3.0]-2-octene
    1170) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-76-hydroxybicyclo[3.3.0]-2-octene
    1171) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)oxyethyl]-6-[(3S, E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1172) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1173) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1174) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1175) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1176) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1177) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)thiomethyl]-6-[(3S, 1E)-3-hydroxy-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1178) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1179) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1180) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1181) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1182) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1183) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1184) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1185) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(3S, 1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1186) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1187) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1188) (1S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1189) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1190) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1191) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1192) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1193) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1194) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1195) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1196) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1197) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-octene
    1198) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(3S,5S,1 E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1199) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1200) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1201) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1202) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1203) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]7-hydroxybicyclo[3.3.0]-2-octene
    1204) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1205) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]7-hydroxybicyclo [3.3.0]-2-octene
    1206) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1207) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1208) (1S,5S,6R,7R)-3-(5-N-butylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1209) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1210) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1211 (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1212) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1213) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1214) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1215) (1S,5S,6R,7R)-3-(5-N,N-dibutylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1216) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1217) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1218) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1219) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1220) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1221) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1222) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylaminobutyl)-6-[(3S,5 S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1223) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1224) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1225) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1226) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1227) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1228) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1229) (1S,5S,6R,7R)-3-(6-N-t-butyl-N-methylaminohexyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1230) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl]hexyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1231) (1S,5S,6R,7R)-37(6-piperidinohexyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1232) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1233) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1234) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1235) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1236) (1S,5S,6R,7R)-3-[(1Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1237) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1238) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1239) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1240) (1S,5S,6R,7R)-3-[N-(3 N-t-butyl-N-methytaminopropyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1241) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1242) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1243) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1244) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1245) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1246) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1247) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1248) (1S,5S,6R,7R)-3-[2-N-(2-N-t-butyl-N-methylaminoethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1249) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1250) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1251) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1252) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1253) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1254) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1255) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1256) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1257) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1258) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl]-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1259) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[3S, 5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1260) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1261) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1262) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1263) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1264) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1265) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1266) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1267) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1268) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1269) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1270) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1271) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1272) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(3S,5S, 1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1273) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1274) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1275) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1276) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)thioethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1277) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1278) (1S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1279) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1280) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1281) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl]ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1282) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]7-hydroxybicyclo[3.3.0]-2-octene
    1283) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1284) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1285) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1286) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1287) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1288) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1289) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1290) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1291) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl-7-hydroxybicyclo[3.3.0]-2-octene
    1292) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1293) (1S, 5S,6R,7R)-3-(5-morpholinopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1294) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1295) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1296) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1297) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1298) (1S,5S,6R,7R)-3-(5-N-butylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1299) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1300) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1301) (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1302) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1303) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1304) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1305) (1S,5S,6R,7R)-3-(5-N,N-dibutylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1306) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1307) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1308) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1309) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1310) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1311) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1312) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylaminobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1313) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1314) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1315) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1316) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1317) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1318) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1319) (1S,5S,6R,7R)-3-(6-N-t-butyl-N-methylaminohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1320) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl)hexyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1321) (1S,5S,6R,7R)-3-(6-piperidinohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1322) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1323) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1324) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1325) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1326) (1S,5S,6R,7R)-3-[(1 Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1327) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1328) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1329) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1330) (1S,5S,6R,7R)-3-[N-(3-N-t-butyl-N-methylaminopropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1331) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1332) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1333) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1334) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1335) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(4S,1E)4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1336) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1337) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1338) (1S,5S,6R,7R)-3-[2-N-(2-N-t-butyl-N-methylaminoethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1339) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1340) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1341) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1342) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1343) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1344) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1345) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1346) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1347) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1348) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1349) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1350) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1351) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1352) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1353) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1354) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1355) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1356) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1357) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1358) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1359) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1360) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1361) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1362) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1363) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)thioethyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1364) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]thioethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1365) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1366) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)thioethyl]-6-[(4S, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1367) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1368) (1-S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1369) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1370) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1371) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl]ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1372) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1373) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1374) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1375) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1376) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1377) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1378) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1379) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1380) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1381) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1382) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,1E)-3-hydroxy-4-(M-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1383) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1384) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1385) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1386) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1387) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(3S,1 E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1388) (1S,5S,6R,7R)-3-(5-N-butylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1389) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1390) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1391) (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1392) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1393) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1394) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(3S, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1395) (1S,5S,6R,7R)-3-(5-N,N-dibutylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1396) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1397) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1398) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1399) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1400) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1401) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1402) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylaminobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1403) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1404) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1405) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1406) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene 1407) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1408) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1409) (1S,5S,6R,7R)-3-(6-N-t-butyl-N-methylaminohexyl)-6-[(3S,1 E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1410) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl)hexyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1411) (1S,5S,6R,7R)-3-(6-piperidinohexyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1412) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1413) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1414) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1415) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1416) (1S,5S,6R,7R)-3-[(1Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1417) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1418) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1419) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1420) (1S,5S,6R,7R)-3-[N-(3-N-t-butyl-N-methylaminopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1421) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1422) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1423) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1424) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1425) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1426) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1427) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(3S,7E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1428) (1S,5S,6R,7R)-3-[2-N-(2-N-t-butyl-N-methylaminoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1429) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1430) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1431) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1432) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1433) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1434) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1435) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1436) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1437) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1438) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1439) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1440) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1441) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1442) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1443) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1444) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1445) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1446) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1447) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1448) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1449) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1450) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1451) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1452) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1453) (1S,5S,6R,7R)-3-[2-(2-N-t-butyl-N-methylaminoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1454) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl] thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1455) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1456) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)thioethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1457) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1458) (1S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1459) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1460) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1461) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl]ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1462) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1463) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1464) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1465) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1466) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1467) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1468) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1469) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1470) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1471) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1472) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1473) (1S,5S,6R,1R)-3-(5-morpholinopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1474) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1475) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1476) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1477) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-hydroxybicyclo[3.3.0]-2-octene
    1478) (1S,5S,6R,7R)-3-(5-N-butylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1479) (1S,5S,6R,7R)-3-(5-N-t-butylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1480) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1481) (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1482) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1483) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1484) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1485) (1S,5S,6R,7R)-3-(5-N,N-dibutylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1486) (1S,5S,6R,7R)-3-(5-N-t-butyl-N-methylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
    1487) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1488) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1489) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1490) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1491) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1492) (1S,5S,6R,7R)-3-(4-N-t-butyl-N-methylaminobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1493) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1494) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1495) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1496) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1497) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1498) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1499) (1S,5S,6R,7R)-3-(6-N-t-butyl-N-methylaminohexyl)-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1500) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl)hexyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1501) (1S,5S,6R,7R)-3-(6-piperidinohexyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1502) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1503) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1504) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1505) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1506) (1S,5S,6R,7R)-3-[(1Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1507) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1508) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1509) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1510) (1S,5S,6R,7R)-3-[N-(3-N-t-butyl-N-methylaminopropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1511) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1512) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1513) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1514) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1515) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1516) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1517) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1518) (1S,5S,6R,7R)-3-[2-N-(2-N-t-butyl-N-methylaminoethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1519) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1520) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1521) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1522) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1523) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1524) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1525) (1S,5S,6R,7R)-3-[(3-N-t-butyl-N-methylaminopropyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1526) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1527) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1528) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1529) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1530) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1531) (1S,5S,6R,7R)-3-[2-(2-N—t-butyl-N-methylaminoethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1532) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1533) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1534) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1535) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1536) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1537) (1S,5S,6R,7R)-3-[(3-N—t-butyl-N-methylaminopropyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1538) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1539) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1540) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1541) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1542) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1543) (1S,5S,6R,7R)-3-[2-(2-N—t-butyl-N-methylaminoethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1544) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1545) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1546) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)thioethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1547) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1548) (1S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1549) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1550) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1551) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl]ethyl]-6-[(3R, 1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1552) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1553) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1554) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1555) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]2-octene
    1556) (1S,5 S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1557) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(E)-4-(m-tolyl)-1-buten yl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1558) (1S,5S,6R,7R)-3-[5-N-(2-methoxycarbonylethyl)aminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1559) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1560) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1561) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1562) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1563) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene.
    1564) (1S,5S,6R,7R)-3-(5-N-methylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1565) (1S,5S,6R,7R)-3-(5-N-ethylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1566) (1S,5S,6R,7R)-3-(5-N-propylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1567) (1S,5S,6R,7R)-3-(5-N-isopropylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1568) (1S,5S,6R,7R)-3-(5-N-butylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1569) (1S,5S,6R,7R)-3-(5-N—t-butylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1570) (1S,5S,6R,7R)-3-(5-N-phenylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1571) (1S,5S,6R,7R)-3-(5-N-benzylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1572) (1S,5S,6R,7R)-3-[5-(4-N-methyl-1-piperazinyl)pentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1573) (1S,5S,6R,7R)-3-[5-N-(2-pyridyl)aminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1574) (1S,5S,6R,7R)-3-(5-N,N-dipropylaminopentyl)-6-[(E)-4-(m-olyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1575) (1S,5S,6R,7R)-3-(5-N,N-dibutylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1576) (1S,5S,6R,7R)-3-(5-N—t-butyl-N-methylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1577) (1S,5S,6R,7R)-3-[5-N-(2-hydroxyethyl)aminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1578) (1 S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl-6-[(E)-4-(m-tolyl)—butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1579) (1S,5S,6R,7R)-3-(4-aminobutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]2-octene
    1580) (1S,5S,6R,7R)-3-(4-N,N-dimethylaminobutyl)-6-[(E)-4-(m-tolyl)-S-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1581) (1S,5S,6R,7R)-3-(4-N,N-diisopropylaminobutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1582) (1S,5S,6R,7R)-3-(4-N—t-butyl-N-methylaminobutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1583) (1S,5S,6R,7R)-3-[4-(1-pyrrolidinyl)butyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1584) (1S,5S,6R,7R)-3-(4-piperidinobutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1585) (1S,5S,6R,7R)-3-(4-morpholinobutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1586) (1S,5S,6R,7R)-3-(6-aminohexyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1587) (1S,5S,6R,7R)-3-(6-N,N-dimethylaminohexyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1588) (1S,5S,6R,7R)-3-(6-N,N-diisopropylaminohexyl)-6-[(E)-4-(m-tolyl)-8-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1589) (1S,5S,6R,7R)-3-(6-N—t-butyl-N-methylaminohexyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1590) (1S,5S,6R,7R)-3-[6-(1-pyrrolidinyl)hexyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1591) (1S,5S,6R,7R)-3-(6-piperidinohexyl)-6-[(E)-4-S(m-tolyl)—butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1592) (1S,5S,6R,7R)-3-(6-morpholinohexyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1593) (1S,5S,6R,7R)-3-[(1Z)-4-N,N-dimethylamino-1-butenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1594) (1S,5S,6R,7R)-3-[(1Z)-5-N,N-dimethylamino-1-pentenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1595) (1S,5S,6R,7R)-3-[(1E)-5-N,N-dimethylamino-1-pentenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1596) (1S,5S,6R,7R)-3-[(1Z)-6-N,N-dimethylamino-1-hexenyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1597) (1S,5S,6R,7R)-3-[N-(2-N,N-dimethylaminoethyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1598) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1599) (1S,5S,6R,7R)-3-[N-(3-N,N-diisopropylaminopropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1600) (1S,5S,6R,7R)-3-[N-(3-N—t-butyl-N-methylaminopropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1601) (1S,5S,6R,7R)-3-[N-[3-(1-pyrrolidinyl)propyl]aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1602) (1S,5S,6R,7R)-3-[N-(3-piperidinopropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1603) (1S,5S,6R,7R)-3-[N-(3-morpholinopropyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1604) (1S,5S,6R,7R)-3-[N-(4-N,N-dimethylaminobutyl)aminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1605) (1S,5S,6R,7R)-3-[N-(3-N,N-dimethylaminopropyl)-N-methylaminomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1606) (1S,5S,6R,7R)-3-[2-N-(2-N,N-dimethylaminoethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1607) (1S,5S,6R,7R)-3-[2-N-(2-N,N-diisopropylaminoethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1608) (1S,5S,6R,7R)-3-[2-N-(2-N—t-butyl-N-methylaminoethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1609) (1S,5S,6R,7R)-3-[2-N-[2-(1-pyrrolidinyl)ethyl]aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1610) (1S,5S,6R,7R)-3-[2-N-(2-piperidinoethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1611) (1S,5S,6R,7R)-3-[2-N-(2-morpholinoethyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1612) (1S,5S,6R,7R)-3-[2-N-(3-N,N-dimethylaminopropyl)aminoethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1613) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)oxymethyl]-6-[(E)-4-(m-tolyl)-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1614) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1615) (1S,5S,6R,7R)-3-[(3-N—t-butyl-N-methylaminopropyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1616) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1617) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1618) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)oxymethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1619) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1620) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1621) (1S,5S,6R,7R)-3-[2-(2-N—t-butyl-N-methylaminoethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1622) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1623) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1624) (1S,5S,6R,7R)-3-[2-(2-morpholinoethyl)oxyethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1625) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminopropyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1626) (1S,5S,6R,7R)-3-[(3-N,N-diisopropylaminopropyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1627) (1S,5S,6R,7R)-3-[(3-N—t-butyl-N-methylaminopropyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1628) (1S,5S,6R,7R)-3-[[3-(1-pyrrolidinyl)propyl]thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1629) (1S,5S,6R,7R)-3-[(3-piperidinopropyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1630) (1S,5S,6R,7R)-3-[(3-morpholinopropyl)thiomethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1631) (1S,5S,6R,7R)-3-[2-(2-N,N-dimethylaminoethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1632) (1S,5S,6R,7R)-3-[2-(2-N,N-diisopropylaminoethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1633) (1S,5S,6R,7R)-3-[2-(2-N—t-butyl-N-methylaminoethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1634) (1S,5S,6R,7R)-3-[2-[2-(1-pyrrolidinyl)ethyl]thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1635) (1S,5S,6R,7R)-3-[2-(2-piperidinoethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1636) (1S,5S,6R,7R)-3-[2-(Z-morpholinoethyl)thioethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1637) (1S,5S,6R,7R)-3-[(3-N,N-dimethylaminophenyl)methyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1638) (1S,5S,6R,7R)-3-[[2-(aminomethyl)phenyl]methyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1639) (1S,5S,6R,7R)-3-[[4-(aminomethyl)phenyl]methyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1640) (1S,5S,6R,7R)-3-[2-[3-(aminomethyl)phenyl]ethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1641) (1S,5S,6R,7R)-3-[2-[3-(piperidinomethyl)phenyl] ethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1642) (1S,5S,6R,7R)-3-[2-(4-piperidyl)ethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1643) (1S,5S,6R,7R)-3-[2-(4-pyridyl)ethyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo [3.3.0]-2-octene
    1644) (1S,5S,6R,7R)-3-[4-(2-pyridyl)butyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1645) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1646) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1647) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1648) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1649) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1650) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1651) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1652) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1653) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl]7-hydroxybicyclo[3.3.0]-2-octene
    1654) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group
    1655) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1656) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1657) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1658) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(4R,1E)-4-hydroxy-4-methyl]-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1659) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(4R, 1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1660) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1661) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(4R,1E)-4-hydroxy 4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1662) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1663) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(4R,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1664) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group
    1665) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1666) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1667) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1668) (1S,5S,6R,7R)-3-[S—N-(3-hydroxypropyl)aminopentyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1′-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1669) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1′-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1670) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1671) (S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1672) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1673) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1674) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group
    1675) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]7-hydroxybicyclo[3.3.0]-2-octene
    1676) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1677) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,4R, E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1678) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1679) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1680) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1681) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1682) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1683) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1684) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group
    1685) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1686) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1687) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1688) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1689) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1690) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl]-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1691) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1692) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicylo[3.3.0]-2-octene
    1693) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1694) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group
    1695) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1696) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1697) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1698) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1699) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1700) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1701) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1702) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1703) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1704) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group
    1705) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1706) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1707) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1708) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1709) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1710) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1711) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1712) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1713) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1714) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group
    1715) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1716) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1717) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1718) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1719) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1720) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1721) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1722) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1723) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3R,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1724) compounds of compound numbers-1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group
    1725) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1726) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1727) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1728) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1729) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1730) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1731) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1732) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1733) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3R,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1734) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group
    1735) (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1736) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1737) (1S,5S,6R,7R)-3-(5-N,N-diethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1738) (1S,5S,6R,7R)-3-[5-N-(3-hydroxypropyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1739) (1S,5S,6R,7R)-3-[5-N-(4-pyridylmethyl)aminopentyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1740) (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1741) (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1742) (1S,5S,6R,7R)-3-(5-piperidinopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1743) (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1744) compounds of compound numbers 1114 to 1194 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group at position 6 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by the (3R,1E)-3-hydroxy-1-octenyl group
    1745) (1S,5S,6R,7S)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1746) (1S,5S,6R,7S)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1747) (1R,5R,6S,7S)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1748) (1R,5R,6S,7S)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1749) (1R,5R,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1750) (1R,5R,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1751) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-hydroxy-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1752) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1753) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1754) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1755) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1756) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-hexenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1757) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-hexenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1758) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-heptenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1759) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-heptenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1760) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1761) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1762) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-decenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1763) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-1-decenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1764) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1765) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1766) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1767) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1768) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1769) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3(3-ethylcyclopentyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1770) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3(3-ethylcyclopentyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1771) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1772) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-cyclopentyl-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1773) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S, 1E)-3-hydroxy-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1774) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R, 1E)-3-hydroxy-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1775) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1776) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S, 1E)-3-hydroxy-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1777) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1778) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1779) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1780) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1781) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1782) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1783) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1784) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1785) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1786) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S, 1E)-3-hydroxy-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1787) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1788) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1789) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(p-tolyl)-1 butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1790) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopenty)-6-[(3S,1E)-3-hydroxy-5-(o-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1791) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl-6-[(3R,1E)-3-hydroxy-5-(o-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1792) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1793) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1794) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-5-(p-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1795) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-5-(β-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1796) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(4-methoxyphenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1797) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(4-methoxyphenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1798) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(4-methoxyphenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1799) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(4-N,N-dimethylaminophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1800) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(3-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1801) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(3-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1802) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(4-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1803) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(4-chlorophenyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1804) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1805) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1806) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1807) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-3-phenyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1808) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1809) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1810) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1811) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1812) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-3(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1813) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-3(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1814) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1815) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1816) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-3-methyl-5(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1817) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-3-methyl-5(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1818) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4,4-dimethyl-loctenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1819) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4,4-dimethyl-loctenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1820) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E,5Z)-3-hydroxy-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1821) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E,5Z)-3-hydroxy-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1822) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-6-octyn-1-enyl]7-hydroxybicyclo[3.3.0]-2-octene
    1823) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1824) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1825) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1826) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R, E)-3-hydroxy-4,4-dimethyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1827) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4,4-dimethyl-6-octyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1828) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,4S,1E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1829) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R,1E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1830) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4S, E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1831) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,4R, E)-3-hydroxy-4-methyl-6-nonyn-1-enyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1832) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-phenoxy-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1833) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-1-octynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1834) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-1-octynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1835) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S, 1Z)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1836) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1Z)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1837) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxyoctyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1838) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxyoctyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1839) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-3-methyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1840) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-3-methyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1841) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-4,4-dimethyloctyl-7-hydroxybicyclo[3.3.0]-2-octene
    1842) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-4,4-dimethyloctyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1843) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-3-phenylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1844) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-3-phenylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1845) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-4-phenylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1846) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-4-phenylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1847) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-4-(m-tolyl)butyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1848) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-4-(m-tolyl)butyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1849) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S)-3-hydroxy-3-cyclopentylpropyl]7-hydroxybicyclo[3.3.0]-2-octene
    1850) (1S,5S,6%,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R)-3-hydroxy-3-cyclopentylpropyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1851) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1852) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1853) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-hydroxy-4-butyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1854) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-butyl-1,5-hexadienyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1855) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-butyl-1,5-hexadienyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1856) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-cyclopentyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1857) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-cyclopentyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1858) (1S,5S,6R,7R)-3-(S—N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-cyclohexyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1859) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-cyclohexyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1860) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1861) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-4-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1862) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-(1-hydroxycyclopentyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1863) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-(1-hydroxycyclohexyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1864) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1865) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-4-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1866) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1867) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-1,3-octadienyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1868) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,8S)-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1869) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,9R)-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1870) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E,5S)-5-methyl-1,3-nonadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1871) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E,5R)-5-methyl-1,3-nonadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1872) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,4R)-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1873) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,4S)-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1874) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-4-methyl-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1875) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,4R)-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1876) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,4S)-4-ethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1877) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-4-ethyl-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1878) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-butyl-1,3-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1879) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,5Z)-1,5-octadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1880) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E,5Z)-1,3,5-octatrienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1881) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-cyclopentyliden-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1882) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-cyclohexyliden-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1883) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-2-phenylvinyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1884) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-2-(o-tolyl)vinyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1885) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-2-(m-tolyl)vinyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1886) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-2-(p-tolyl)vinyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1887) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-phenyl-1-propenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1888) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-phenyl-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene.
    1889) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-4-phenyl-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1890) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-4-phenyl-3-methyl-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1891) (1S,5S,6R,7%)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-(o-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1892) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1893) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4-(p-tolyl)-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1894) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-4-(m-tolyl)-1,3-butadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1895) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1896) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-5-(m-tolyl)-1,3-pentadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1897) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-4,4-bisphenylsulfonyl-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1898) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E,3E)-5-(m-tolyl)-1,3-hexadienyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1899) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(4-phenoxybutyl)-7-hydroxy bicyclo[3.3.0]-2-octene
    1900) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-propenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1901) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-butenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1902) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-pentenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1903) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-hexenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1904) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-heptenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1905) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-octenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1906) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-nonenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1907) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-1-decenyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1908) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-3-oxo-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1909) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4R,1E)-3-oxo-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1910) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4,4-dimethyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1911) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(5S,1E)-3-oxo-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1912) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(5R,1E)-3-oxo-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1913) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-cyclopentyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1914) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-cyclohexyl-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1915) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-cyclopentyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1916) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-cyclohexyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1917) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-phenyl-S-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1918) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-phenyl-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1919) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-5-phenyl-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1920) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-(o-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1921) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-(m-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1922) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-3-(p-tolyl)-1-propenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1923) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-(o-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1924) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1925) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-4-(p-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1926) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-5-(o-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1927) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-5-(m-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1928) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1E)-3-oxo-5-(p-tolyl)-1-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1929) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-hydroxymethyl-7-hydroxy bicyclo[3.3.0]-2-octene
    1930) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R)-1-hydroxyethyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1931) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S)-1-hydroxyethyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1932) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R)-1-hydroxypentyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1933) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S)-1-hydroxypentyl]-7-hydroxy bicyclo[3.3.0]-2-octene
    1934) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R)-1-hydroxy-1-methylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1935) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S)-1-hydroxy-1-methylbutyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1936) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R,2E)-1-hydroxy-2-nonenyl]-7- hydroxybicyclo[3.3.0]-2-octene
    1937) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S,2E)-1-hydroxy-2-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1938) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R,3S,2E)-1,3-dihydroxy-2-nonenyl]-7-hydroxybicyclo [3.3.0]-2-octene
    1939) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S,3S,2E)-1,3-dihydroxy-2-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1940) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R,3S,2E)-1,3-dihydroxy-4-cyclopentyl-2-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1941) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S,3S,2E)-1,3-dihydroxy-4-cyclopentyl-2-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1942) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R,3S,2E)-1,3-dihydroxy-5-phenyl-2-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1943) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S,3S,2E)-1,3-dihydroxy-5-phenyl-2-pentenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1944) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S)-1-hydroxy-2-pentynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1945) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R)-1-hydroxy-2-pentynyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1946) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1R)-1-hydroxy-5-phenoxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1947) (1S,5S,6S,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(1S)-1-hydroxy-5-phenoxypentyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1948) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxyphenylmethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1949) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxyphenylmethyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1950) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(o-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1951) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(o-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1952) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(m-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1953) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(m-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1954) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(p-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1955) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(p-tolyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1956) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(4-methoxyphenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1957) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(4-methoxyphenyl) methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1958) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(4-N,N-dimethylamino phenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1959) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(4-N,N-dimethylamino phenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1960) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(R)-hydroxy(3-chlorophenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1961) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(S)-hydroxy(3-chlorophenyl)methyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1962) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-formyl-7-hydroxybicyclo[3.3.0]-2-octene
    1963) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-acetyl-7-hydroxybicyclo[3.3.0]-2-octene
    1964) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopenty)-6-benzoyl-7-hydroxybicyclo[3.3.0]-2-octene
    1965) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(o-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    1966) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(m-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    1967) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(p-tolyl)-7-hydroxybicyclo[3.3.0]-2-octene
    1968) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminophenyl)-6-(4-methoxyphenylcarbonyl)-7-hydroxy bicyclo [3.3.0]-2-octene
    1969) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(4-N,N-dimethylaminophenyl carbonyl)-7-hydroxybicyclo[3.3.0]-2-octene
    1970) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-(3-chlorophenylcarbonyl)-7-hydroxy bicyclo[3.3.0]-2-octene
    1971) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2-phenylvinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1972) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2-(4-methoxyphenyl)vinyl carbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1973) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2-(4-N,N-dimethylaminophenyl) vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1974) (1,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2-(3-chlorophenyl)vinyl carbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1975) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2(2-thienyl)vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1976) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(2E)-2-(4-pyridyl)vinylcarbonyl]-7-hydroxybicyclo[3.3.0]-2-octene
    1977) compounds of compound numbers 1655 to 1976 of the examples given above, wherein the 5-N,N-dimethylaminopentyl group, which is a substitution group at position 3 in the structure of the bicyclo[3.3.0]-2-octene cycle, has been replaced by either of the 5-aminopentyl group, the 5-N,N-diethylaminopentyl group, the 5-N-(3-hydroxypropyl)aminopentyl group, the 5-N-(4-pyridylmethyl)aminopentyl group, the 5-N,N-diisopropylaminopentyl group, the 5-(1-pyrrolidinyl)pentyl group or the 5-piperidinopentyl group, the 5-morpholinopentyl group
    1978) (1S,2R,3R,5S)-7-[(E)-5-aminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxy bicyclo[3.3.0]octane
    1979) (1S,2R,3R,5S)-7-[(E)-5-N-methylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1980) (1S,2R,3R,5S)-7-[(E)-5-N-ethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0] octane
    1981) (1S,2R,3R,5S)-7-[(E)-5-N-propylaminopentylidene]-2-[(3S, 1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1982) (1S,2R,3R,5S)-7-[(E)-5-N-isopropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1983) (1S,2R,3R,5S)-7-[(E)-5-N-butylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1984) (1S,2R,3R,5S)-7-[(E)-5-N-t-butylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1985) (1S,2R,3R,5S)-7-[(E)-5-N-phenylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1986) (1S,2R,3R,5S)-7-[(E)-5-N-benzylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1987) (1S,2R,3R,5S)-7-[(E)-5-N-(4-pyridylmethyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1988) (1S,2R,3R,5S)-7-[(E)-5-(1-pyrrolidinyl)pentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1989) (1S,2R,3R,5S)-7-[(E)-5-piperidinopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1990) (1S,2R,3R,5S)-7-[(E)-5-morpholinopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1991) (1S,2R,3R,5S)-7-[(E)-5-(4-N-methyl-1-piperazinyl)pentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1992) (1S,2R,3R,5S)-7-[(E)-5-N-(2-pyridyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1993) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-loctenyl]-3-hydroxybicyclo[3.3.0]octane
    1994) (1S,2R,3R,5S)-7-[(E)-5-N,N-diethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1995) (1S,2R,3R,5S)-7-[(E)-5-N,N-dipropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-loctenyl]-3-hydroxybicyclo[3.3.0]octane
    1996) (1S,2R,3R,5S)-7-[(E)-5-N,N-diisopropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1997) (1S,2R,3R,5S)-7-[(E)-5-N,N-dibutylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1998) (1S,2R,3R,5S)-7-[(E)-5-N-t-butyl-N-methylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    1999) (1S,2R,3R,5S)-7-[(E)-5-N-(2-hydroxyethyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2000) (1S,2R,3R,5S)-7-[(E)-5-N-(3-hydroxypropyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2001) (1S,2R,3R,5S)-7-[(E)-4-aminobutylidene]-2-[(3S,1 E)-3-hydroxy-1-octenyl]-3-hydroxy bicyclo[3.3.0]octane
    2002) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylaminobutylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2003) (1S,2R,3R,5S)-7-[(E)-6-aminohexylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxy bicyclo[3.3.0]octane
    2004) (1S,2R,3R,5S)-7-[(E)-6-N,N-dimethylaminohexylidene]-2-[(3S, 1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2005) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-diisopropylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2006) (1S,2R,3R,5S)-7-[(E)-2-(2-N-t-butyl-N-methylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2007) (1S,2R,3R,5S)-7-[(E)-2-[2-(1-pyrrolidinyl)ethyl]oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2008) (1S,2R,3R,5S)-7-[(E)-2-(2-piperidinoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2009) (1S,2R,3R,5S)-7-[(E)-2-(2-morpholinoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0] octane
    2010) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)thioethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2011) (1S,2R,3R,5S)-7-[(E)-2-N-(2-N,N-dimethylaminoethyl)aminoethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2012) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)oxymethylene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2013) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)thiomethylene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2014) (1S,2R,3R,5S)-7-[(E)-N-(2-N,N-dimethylaminoethyl)aminomethylene]E-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2015) (1S,2R,3R,5S)-7-[(E)-5-aminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2016) (1S,2R,3R,5S)-7-[(E)-5-N-methylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2017) (1S,2R,3R,5S)-7-[(E)-5-N-ethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl]-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2018) (1S,2R,3R,5S)-7-[(E)-5-N-propylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2019) (1S,2R,3R,5S)-7-[(E)-5-N-isopropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo [3.3.0]octane
    2020) (1S,2R,3R,5S)-7-[(E)-5-N-butylaminopentylidene]-2-[(3S, E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2021) (1S,2R,3R,5S)-7-[(E)-5-N-t-butylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2022) (1S,2R,3R,5S)-7-[(E)-5-N-phenylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2023) (1S,2R,3R,5S)-7-[(E)-5-N-benzylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2024) (1S,2R,3R,5S)-7-[(E)-5-N-(4-pyridylmethyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2025) (1S,2R,3R,5S)-7-[(E)-5-(1-pyrrolidinyl)pentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2026) (1S,2R,3R,5S)-7-[(E)-5-piperidinopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2027) (1S,2R,3R,5S)-7-[(E)-5-morpholinopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2028) (1S,2R,3R,5S)-7-[(E)-5-(4-N-methyl-1-piperazinyl)pentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2029) (1S,2R,3R,5S)-7-[(E)-5-N-(2-pyridyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0] octane
    2030) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2031) (1S,2R,3R,5S)-7-[(E)-5-N,N-diethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2032) (1S,2R,3R,5S)-7-[(E)-5-N,N-dipropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2033) (1S,2R,3R,5S)-7-[(E)-5-N,N-diisopropylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2034) (1S,2R,3R,5S)-7-[(E)-5-N,N-dibutylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2035) (1S,2R,3R,5S)-7-[(E)-5-N-t-butyl-N-methylaminopentylidene]-2-[(3S,1E)-3-hydroxy-3- cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2036) (1S,2R,3R,5S)-7-[(E)-5-N-(2-hydroxyethyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2037) (1S,2R,3R,5S)-7-[(E)-5-N-(3-hydroxypropyl)aminopentylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2038) (1S,2R,3R,5S)-7-[(E)-4-aminobutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo [3.3.0]octane
    2039) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylaminobutylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2040) (1S,2R,3R,5S)-7-[(E)-6-aminohexylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1 propenyl]-3-hydroxybicyclo [3.3.0]octane
    2041) (1S,2R,3R,5S)-7-[(E)-6-N,N-dimethylaminohexylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2042) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2043) (1,2R,3R,5S)-7-[(E)-2-(2-N,N-diisopropylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2044) (1S,2R,3R,5S)-7-[(E)-2-(2-N-t-butyl-N-methylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2045) (1S,2R,3R,5S)-7-[(E)-2-[2-(1-pyrrolidinyl)ethyl]oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2046) (1S,2R,3R,5S)-7-[(E)-2-(2-piperidinoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2047) (1S,2R13R,5S)-7-[(E)-2-(2-morpholinoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2048) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)thioethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2049) (1S,2R,3R,5S)-7-[(E)-2-N-(2-N,N-dimethylaminoethyl)aminoethylidene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2050) (S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)oxymethylene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2051) (1S,2R13R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)thiomethylene]-2-[(3S, 1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2052) (1S,2R,3R,5S)-7-[(E)-N-(2-N,N-dimethylaminoethyl)aminomethylene]-2-[(3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl]-3-hydroxybicyclo[3.3.0]octane
    2053) (1S,2R,3R,5S)-7-[(E)-5-aminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0] octane
    2054) (1S,2R,3R,5S)-7-[(E)-5-N-methylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2055) (1S,2R,3R,5S)-7-[(E)-5-N-ethylaminopentylidene]-2-[(3S,4S, E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo [3.3.0] octane
    2056) (1S,2R,3R,5S)-7-[(E)-5-N-propylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2057) (1S,2R13R,5S)-7-[(E)-5-N-isopropylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2058) (1S,2R13R,5S)-7-[(E)-5-N-butylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl 6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]-octane
    2059) (1S,2R,3R,5S)-7-[(E)-5-N-t-butylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2060) (1S,2R,3R,5S)-7-[(E)-5-N-phenylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2061) (1S,2R,3R,5S)-7-[(E)-5-N-benzylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2062) (1S,2R,3R,5S)-7-[(E)-5-N-(4-pyridylmethyl)aminopentylidene]-2-[(3S,4S,0E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2063) (1S,2R,3R,5S)-7-[(E)-5-(1-pyrrolidinyl)pentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2064) (1S,2R,3R,5S)-7-[(E)-5-piperidinopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2065) (1S,2R,3R,5S)-7-[(E)-5-morpholinopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2066) (1S,2R,3R,5S)-7-[(E)-5-(4-N-methyl-1-piperazinyl)pentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2067) (1S,2R,3R,5S)-7-[(E)-5-N-(2-pyridyl)aminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2068) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2069) (1S,2R,3R,5S)-7-[(E)-5-N,N-diethylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2070) (1S,2R,3R,5S)-7-[(E)-5-N,N-dipropylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2071) (1S,2R,3R,5S)-7-[(E)-5-N,N-diisopropylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2072) (1S,2R,3R,5S)-7-[(E)-5-N,N-dibutylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2073) (1S,2R,3R,5S)-7-[(E)-5-N-t-butyl-N-methylaminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2074) (1S,2R,3R,5S)-7-[(E)-5-N-(2-hydroxyethyl)aminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2075) (1S,2R,3R,5S)-7-[(E)-5-N-(3-hydroxypropyl)aminopentylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2076) (1S,2R,3R,5S)-7-[(E)-4-aminobutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1 enyl]-3-hydroxybicyclo[3.3.0]octane
    2077) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylaminobutylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2078) (1S,2R,3R,5S)-7-[(E)-6-aminohexylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2079) (1S,2R,3R,5S)-7-[(E)-6-N,N-dimethylaminohexylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2080) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2081) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-diisopropylaminoethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2082) (1S,2R,3R,5S)-7-[(E)-2-(2-N-t-butyl-N-methylaminoethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2083) (1S,2R,3R,5S)-7-[(E)-2-[2-(1-pyrrolidinyl)ethyl]oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2084) (1S,2R,3R,5S)-7-[(E)-2-(2-piperidinoethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2085) (1S,2R,3R,5S)-7-[(E)-2-(2-morpholinoethyl)oxyethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2086) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)thioethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2087) (1S,2R,3R,5S)-7-[(E)-2-N-(2-N,N-dimethylaminoethyl)aminoethylidene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2088) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)oxymethylene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2089) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)thiomethylene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2090) (1S,2R,3R,5S)-7-[(E)-N-(2-N,N-dimethylaminoethyl)aminomethylene]-2-[(3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2091) (1S,2R,3R,5S)-7-[(E)-5-aminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2092) (1S,2R,3R,5S)-7-[(E)-5-N-methylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2093) (1S,2R,3R,5S)-7-[(E)-5-N-ethylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2094) (1S,2R,3R,5S)-7-[(E)-5-N-propylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2095) (1S,2R,3R,5S)-7-[(E)-5-N-isopropylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2096) (1S,2R,3R,5S)-7-[(E)-5-N-butylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2097) (1S,2R,3R,5S)-7-[(E)-5-N-t-butylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2098) (1S,2R,3R,5S)-7-[(E)-5-N-phenylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2099) (1S,2R,3R,5S)-7-[(E)-5-N-benzylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2100) (1S,2R,3R,5S)-7-[(E)-5-N-(4-pyridylmethyl)aminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2101) (1S,2R,3R,5S)-7-[(E)-5-(1-pyrrolidinyl)pentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2102) (1S,2R,3R,5S)-7-[(E)-5-piperidinopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2103) (1S,2R,3R,5S)-7-[(E)-5-morpholinopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2104) (1S,2R,3R,5S)-7-[(E)-5-(4-N-methyl-1-piperazinyl)pentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane.
    2105) (1S,2R,3R,5S)-7-[(E)-5-N-(2-pyridyl)aminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2106) (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2107) (1S,2R,3R,5S)-7-[(E)-5-N,N-diethylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2108) (1S,2R,3R,5S)-7-[(E)-5-N,N-dipropylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2109) (1S,2R,3R,5S)-7-[(E)-5-N,N-diisopropylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2110) (1S,2R,3R,5S)-7-[(E)-5-N,N-dibutylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2111) (1S,2R,3R,5S)-7-[(E)-5-N-t-butyl-N-methylaminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2112) (1S,2R,3R,5S)-7-[(E)-5-N-(2-hydroxyethyl)aminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2113) (1S,2R,3R,5S)-7-[(E)-5-N-(3-hydroxypropyl)aminopentylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2114) (1S,2R,3R,5S)-7-[(E)-4-aminobutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2115) (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylaminobutylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2116) (1S,2R,3R,5S)-7-[(E)-6-aminohexylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2117) (1S,2R,3R,5S)-7-[(E)-6-N,N-dimethylaminohexylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2118) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2119) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-diisopropylaminoethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2120) (1S,2R,3R,5S)-7-[(E)-2-(2-N-t-butyl-N-methylaminoethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2121) (1 S,2R,3R,5S)-7-[(E)-2-[2-(1-pyrrolidinyl)ethyl]oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2122) (1S,2R,3R,5S)-7-[(E)-2-(2-piperidinoethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2123) (1S,2R,3R,5S)-7-[(E)-2-(2-morpholinoethyl)oxyethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2124) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)thioethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2125) (1S,2R,3R,5S)-7-[(E)-2-N-(2-N,N-dimethylaminoethyl)aminoethylidene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2126) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)oxymethylene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2127) (1S,2R,3R,5S)-7-[(E)-(2-N,N-dimethylaminoethyl)thiomethylene]-2-[(3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2128) (1S,2R,3R,5S)-7-[(E)-N-(2-N,N-dimethylaminoethyl)aminomethylene]-2-[(3S,4R,1E)3-hydroxy-4-methyl-6-octyn-1-enyl]-3-hydroxybicyclo[3.3.0]octane
    2129) compounds of compound numbers 1978 to 2014 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group or the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group, the 2-(1-hydroxycyclohexyl)ethynyl group
    2130) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(4-aminobutyl)-1H-cyclopenta [b]benzofuran
    2131) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2132) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-ethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2133) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-propylaminobutyl)-1H-cyclopenta[b]benzofuran
    2134) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-isopropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2135) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2136) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-(4-N-t-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2137) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-phenylaminobutyl)-1H-cyclopenta[b]benzofuran
    2138) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-benzylaminobutyl)-1H-cyclopenta[b]benzofuran
    2139) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[4-N-(4-pyridylmethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2140) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5[4-(1-pyrrolidinyl)butyl]-1H-cyclopenta[b]benzofuran
    2141) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-piperidinobutyl)-1H-cyclopenta[b]benzofuran
    2142) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-morpholinobutyl)-1H-cyclopenta[b]benzofuran
    2143) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5[4-(4-N-methyl-1-piperazinyl)butyl]-1H-cyclopenta[b]benzofuran
    2144) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[4-N-(2-pyridyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2145) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-dimethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2146) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-diethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2147) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-dipropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2148) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-diisopropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2149) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N,N-dibutylaminobutyl)-1H-cyclopenta[b]benzofuran
    2150) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(4-N-t-butyl-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2151) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[4-N-(2-hydroxyethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2152) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydro y-1-[(3S,1E)-3-hydroxy-1-octenyl]-5-[4-N-(3-hydroxypropyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2153) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-aminopropyl)-1H-cyclopenta[b]benzofuran
    2154) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-dimethylaminopropyl)-1H-cyclopenta[b]benzofuran
    2155) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(5-aminopentyl)-1H-cyclopenta[b]benzofuran
    2156) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(5-N,N-dimethylaminopentyl)-1H-cyclopenta[b]benzofuran
    2157) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-1-octenyl]-5(3-N,N-dimethylaminopropyloxy)-1H-cyclopenta[b]benzofuran
    2158) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-aminobutyl)-1H-cyclopenta[b]benzofuran
    2159) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2160) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-ethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2161) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-propylaminobutyl)-1H-cyclopenta [b]benzofuran
    2162) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-isopropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2163) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2164) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-t-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2165) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-phenylaminobutyl)-1H-cyclopenta [b]benzofuran
    2166) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-benzylaminobutyl)-1H-cyclopenta[b] benzofuran
    2167) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(4-pyridylmethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2168) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-(1-pyrrolidinyl)butyl]-1H-cyclopenta[b]benzofuran
    2169) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-piperidinobutyl)-1H-cyclopenta[b]benzofuran
    2170) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-morpholinobutyl)-1H-cyclopenta[b]benzofuran.
    2171) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-(4-N-methyl-1-piperazinyl)butyl]-1H-cyclopenta[b]benzofuran
    2172) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(2-pyridyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2173) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dimethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2174) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-diethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2175) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dipropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2176) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-diisopropylaminobutyl)-1H-cyclopenta [b]benzofuran
    2177) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dibutylaminobutyl)-1H-cyclopenta[b]benzofuran
    2178) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-t-butyl-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2179) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(2-hydroxyethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2180) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(3-hydroxypropyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2181) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-aminopropyl)-1H-cyclopenta[b]benzofuran
    2182) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dimethylaminopropyl)-1H-cyclopenta [b]benzofuran
    2183) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(5-aminopentyl)-1H-cyclopenta[b]benzofuran
    2184) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(5-N,N-dimethylaminopentyl)-1H-cyclopenta[b]benzofuran
    2185) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4R,1E)-3-hydroxy-4-methyl-1* octen-6-ynyl]-5-(3-N,N-dimethylaminopropyloxy)-1H-cyclopenta[b]benzofuran
    2186) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-aminobutyl)-1H-cyclopenta[b]benzofuran
    2187) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2188) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-ethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2189) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-propylaminobutyl)-1H-cyclopenta[b]benzofuran
    2190) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-isopropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2191) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2192) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-t-butylaminobutyl)-1H-cyclopenta[b]benzofuran
    2193) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-phenylaminobutyl)-1H-cyclopenta[b]benzofuran
    2194) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S, 1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-benzylaminobutyl)-1H-cyclopenta[b]benzofuran
    2195) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(4-pyridylmethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2196) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-(1-pyrrolidinyl)butyl]-1H-cyclopenta[b]benzofuran
    2197) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-piperidinobutyl)-1H-cyclopenta[b]benzofuran
    2198) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-morpholinobutyl)-1H-cyclopenta[b]benzofuran
    2199) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-(4-N-methyl-1-piperazinyl)butyl]-1H-cyclopenta[b]benzofuran
    2200) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(2-pyridyl)aminobutyl]-1H-cyclopenta [b]benzofuran
    2201) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dimethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2202) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-diethylaminobutyl)-1H-cyclopenta[b]benzofuran
    2203) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N,N-dipropylaminobutyl)-1H-cyclopenta [b]benzofuran
    2204) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1 N octen-6-ynyl]-5-(4-N,N-diisopropylaminobutyl)-1H-cyclopenta[b]benzofuran
    2205) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1 octen-6-ynyl]-5-(4-N,N-dibutylaminobutyl)-1H-cyclopenta[b]benzofuran
    2206) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1′-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(4-N-t-butyl-N-methylaminobutyl)-1H-cyclopenta[b]benzofuran
    2207) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(2-hydroxyethyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2208) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-[4-N-(3-hydroxypropyl)aminobutyl]-1H-cyclopenta[b]benzofuran
    2209) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-aminopropyl)-1H-cyclopenta[b]benzofuran
    2210) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dimethylaminopropyl)-1H-cyclopenta[b]benzofuran
    2211) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(5-aminopentyl)-11H-cyclopenta[b]benzofuran
    2212) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(5-N,N-dimethylaminopentyl)-1H-cyclopenta[b]benzofuran
    2213) (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,4S,1E)-3-hydroxy-4-methyl-1-octen-6-ynyl]-5-(3-N,N-dimethylaminopropyloxy)-1H-cyclopenta[b]benzofuran
    2214) compounds of compound numbers 2130 to 1256 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenyl group or the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl
    2215) (1S,2R,3R,5S)-7-[(Z)-5-N,N-dimethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2216) (1R,5S,7R,8R)-3-(5-N,N-dimethylaminopentyl)-8-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
    2217) (1S,2R,3R,5S,7R)-7-(5-N,N-dimethylaminopentyl)-2-[(3S, 1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane
    2218) (1 S,2R,3R,5S,7R)-7-[2-(2-N,N-dimethylaminoethoxy)ethyl]-2-[(3R,5 S,1E)-3-hydroxy-5-methyl-1-nonenyl]-3-hydroxybicyclo[3.3.0]octane
    2219) (1S,3S,5R,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-oxabicyclo[3.3.0]octane
    2220) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-oxabicyclo[3.3.0]-3-octen
    2221) (1S,5R,6R,7R)-3-[(Z)-5-N,N-dimethylaminopentylidene]-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-4-oxo-2-oxabicyclo[3.3.0]octane
    2222) (1S,3S,5R,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-thiabicyclo[3.3.0]octane
    2223) (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-azabicyclo[3.3.0]-2-octene
    2224) (1S,3S,5R,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-1-octenyl]-7-hydroxy-2-azabicyclo[3.3.0]octane
    2225) compunds of compound numbers 2215 to 1224 of the examples given above, wherein the (3S,1E)-3-hydroxy-1-octenyl group, which is a substitution group bonded to the carbon at position 12 of the prostacyclin carbon identification number, has been replaced by either of the (3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (3S,5R,1E)-3-hydroxy-5-methyl-1-nonenyl group, the (4S,1E)-4-hydroxy-4-methyl-1-octenyl group, the (4R,1E)-4-hydroxy-4-methyl-1-octenyl group, the (3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl group, the (E)-4-(m-tolyl)-1-butenyl group, the (3S,4S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group, the (3S,4R,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl group, the (3S,1E)-3-hydroxy-3-cyclopentyl-1-propenyl group, the (3S,1E)-3-hydroxy-3-cyclohexyl-1-propenyl group, the (3S,1E)-3-hydroxy-4-cyclopentyl-1-butenyl group, the (3R,1E)-3-hydroxy-3-phenyl-1-propenylgroup or the (3R,1E)-3-hydroxy-4-phenoxy-1-butenyl group
    2226) compunds of compound numbers 1 to 174, 262 to 435, 523 to 532, 543 to 728, 855 to 1104, 1105 to 1284, 1375 to 1554, 1645 to 1654, 1665 to 1850 and 1977 to 2225 of the examples given above, wherein the hydroxyl groups/group, which are/is bonded to the carbon at position 11 and/or at position 15 of the prostacyclin carbon identification number, has/have been substituted for either of the acetoxy group, t-butyldimethylsilyloxy group, trimethylsilyloxy group or the tetrahydropyran-2-yloxy group
    2227) compunds of compound numbers 175 to 261, 533 to 542, 729 to 743, 855, 1008, 1093, 1104, 1285 to 1374, 1655 to 1664, 1851 to 1865, 1977, 2129, 2214 and 2225 of the examples given above, wherein the hydroxyl groups/group, which are/is bonded to the carbon at position 11 and/or at position 16 of the prostacyclin carbon identification number, has/have been substituted for either of the acetoxy group, the t-butyldimethylsilyloxy group, the trimethylsilyloxy group or the tetrahydropyran-2-yloxy group
    2228) compunds of compound numbers 436 to 522, 744 to 855, 1008, 1093, 1104, 1555 to 1644, 1866 to 1977, 2129, 2214 and 2225 of the examples given above, wherein the hydroxyl group, which is bonded to the carbon at position 11 of the prostacyclin carbon identification number, has been substituted for either of the acetoxy group, the t-butyldimethylsilyloxy group, the trimethylsilyloxy group or the tetrahydropyran-2-yloxy group 2229) (1S,2R,3R,5S)-7-[(E)-2-(2-N,N-dimethylaminoethyl)oxyethylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane.


The nitrogen-containing compound represented by the above Formula (1) has an activity for the remedy of neural damage. Therefore, the nitrogen-containing compound of the present invention can be used as an agent for the treatment of disorders due to neural damage, or and agent for the treatment of lesion of nerves due to external injuries.
Among the nitrogen-containing compound represented by the above Formula (1) of the present invention, those having an amido group at the extremity of the α-chain of prostacyclin analog structure, in other words, those whose A4 in the above Formula (1) is a carbonyl group are derived from functional groups such as a carboxyl group, an alkoxycarbonyl group or a cyano group, by the method described in pages 137 through 173 of the “Fourth Edition of the Experimental Chemistry Course” by the Chemical Society of Japan, Volume 220 (Maruzen Co., Ltd.). In other words, the target amide can be obtained by inserting a functional group such as a carboxyl group, an alkoxycarbonyl group or a cyano group at the site corresponding to the α-chain of the synthetic intermediate having the prostacyclin analog structure indicated by G in the above Formula (1), and by adding the appropriate chemical modification. For example, as indicated in Scheme 1 below,




by converting the carboxyl group at position 1 of an isocarbacyclin into an imidazolylcarbonyl group using 1,1′-carbonyldiimidazole, then reacting with an amine to convert into an amide group, the target amide can be obtained. Usually, the reaction uses polar aprotic solvents such as dimethylformamide, N-methylpyrrolidone, hexamethyl phosphoric triamide, dimethyl sulfoxide. However, dimethylformamide and N-methylpyrrolidone are used preferably. The reaction is performed at a temperature range of 0 to 100° C. with a timeframe of 10 minutes to 24 hours. However, it is performed preferably at a temperature range of 10 to 60° C. with a timeframe of 15 minutes to 18 hours.

Among the nitrogen-containing compound represented by the above Formula (1) of the present invention, those having an amino group at the extremity of the α-chain of prostacyclin analog structure, in other words, those whose A4 in the above Formula (1) represents a single bond, or an aliphatic hydrocarbon group having 1 to 3 carbon atoms, are derived from functional groups such as an amide group, an imino group, a halogen group, a carbonyl group, a cyano group or an azide group by the method described in pages 279 through 317 of the “Fourth Edition of the Experimental Chemistry Course” by the Chemical Society of Japan, Volume 20 (Maruzen Co., Ltd.). In other words, the target amines can be obtained by inserting a functional group such as an amide group, an imino group, a halogen group, a carbonyl group, a cyano group or an azide group at the site corresponding to the α-chain of the synthetic intermediate having the prostacyclin analog structure indicated by G in the above Formula (1), and by adding an adequate chemical modification. For example, as indicated in Scheme 2 below,




from an amide obtained using a method, for example, indicated in Scheme 1, the target amine can be obtained with reducing agents such as lithium aluminium hydride or borane. Usually, the reaction uses ether solvents such as tetrahydrofurane, dioxane, dimethoxyethane, and preferably uses tetrehydrofurane. The reaction is performed at a temperature range of 0 to 100° C. and with a timeframe of 10 minutes to 24 hours. However, it is performed preferably at a temperature range of 10 to 60° C. with a timeframe of 15 minutes to 18 hours.

In addition, modifications at sites on the cyclic structure and at sites on the ω-chain of the nitrogen-containing compound represented by the above Formula (1) of the present invention can be achieved following routes indicated for example in Scheme 3, Scheme 4 and Scheme 5, but are not limited to the these.




[In the above, R45, R55, R65 in Scheme 3, Scheme 4 and Scheme 5 are functional groups chosen among those exemplified by R4, R5, R6, respectively.]

The nitrogen-containing compound of the present invention is produced by combining the modifications of the sites on the α-chain, the sites on the cyclic structure and the site on the ω-chain.
Since the nitrogen-containing compound of the present invention has an activity for the remedy of nerve damage, it can be used as an agent for the treatment of disorders caused by nerve damage, or for the treatment of lesions of the nerves due to external injuries. There are no particular limitations on the scope of application of such an agent for treating neural damage or lesion of nerves due to external injuries. The drug agent of the present invention is particularly useful for mammals, and can be suitably used for livestock, laboratory animals, pets and humans, among others.
The agent for the treatment of disorders caused by nerve damage, or for the treatment of lesions of the nerves due to external injuries of the present invention, can be used for the treatment of animal or human disorders or lesions. There are no particular limitations on the scope of disorders, which must be caused by a neural damage. The following can be cited as concrete examples,

    1) Neuro-degenerative disorders such as Alzheimer's disease, Pick's disease, Lewy body disease, Parkinson's disease, Huntington's chorea, spinocerebellar degeneration and amyotrophic lateral sclerosis,
    2) demyelinating disorders such as acute disseminated encephalomyelitis and multiple sclerosis,
    3) metabolic disorders such as brain lipidosis and Wilson's Disease,
    4) infectious disorders such as meningitis and Creutzfeld-Jacob disease,
    5) peripheral neural damage such as polyneuritis and Guillain-Barre Syndrome,
    6) cerebrovascular disorders such as cerebral infarction and transient ischemia,
    7) nervous disorders (neuropathies) associated with diabetes and renal diseases and
    8) brain tumors.

However, it is preferably used in disorders cited from 1) through 5).



No particular restriction exists on the method of administration. However, oral administration, percutaneous administration, nasal administration, intravenous injection, intraperitoneal administration, rectal administration or intracerebroventricular administration are preferred.
For the clinical application of the nitrogen-containing compound or the salts thereof of the present invention, or clathrate compounds, it is desirable to produce a pharmaceutical preparation formed by the nitrogen-containing compound and a pharmaceutically accepted solid or liquid carrier, and to further add diluents, in other words additives such as excipients and stabilizers, as necessary. The amine injectable preparation of the present invention to be used for therapeutic administration must be sterile. Sterilization can be easily achieved by filtration through a sterilization filter membrane such as a membrane filter having a pore diameter of 0.2 μm.
In such pharmaceutical composition, the proportion of the above-mentioned active ingredient with respect to the constituents of the carrier can be modulated, for example, between 0.000001 and 90% W/W. Therapeutic effective dose depends on the method of administration, age, and the disorder considered, however, 0.01% g to 1000 mg/day/individual is possible, and 0.01 μg to 10 mg/day/individual is preferred. For each administration route, it is desirable to determine the efficacy of absorption into the body for each compound, separately.
Concerning the formulation and the administration form, oral administration is possible by making formulations such as granules, subtle granules, powders, pills, tablets, capsules or liquids, or, parenteral administration is possible by making agents for local applications such as suppositories, aerosols, or ointments and skin patches. As injectable agents, intravenous administration, intra-arterial administration, intramuscular administration, subcutaneous administration are possible. In addition, prior to use, powders for injectable solution can be prepared. In addition, nasal administration, intraperitoneal administration, rectal administration or intracerebroventricular administration are possible.
Organic or inorganic, solid or liquid carriers or diluents can also be used to prepare the nitrogen-containing compound of the current invention to serve as a pharmaceutical preparation suited for oral, enteral or parenteral administration.
Binding agents such as acacia, corn starch, or gelatin, excipients such as microcrystalline cellulose, disintegrants such as cornstarch and alginic acid, lubricants such as magnesium stearate, and sweeteners such as saccharose and lactose can be cited as representative carriers or diluents entering in the composition of tablets and capsules. If the formulation is a capsule, in addition to the above substances, liquid carriers such as lipid oils may be included. Various sorts of other substances may be used as coating agents or agents for improving the physical state of the dose units. Sterile compositions for injection, may be formulated according to a pharmaceutical method of the art. For example, it is desirable to dissolve or suspend the active compound in an excipient such as water or natural vegetal oil or synthetic lipid excipient such as ethyl oleate. It is also possible to include buffers such as citrate, acetate, phosphate, and antioxydants such as ascorbate, according to accepted pharmaceutical methods.
The tablet form can be obtained by the usual method, for example it can be made by using excipients such as lactose, starch or crystalline cellulose; binding agents such as carboxymethyl cellulose, methyl cellulose or polyvinyl pyrrolidone; disintegrants such as sodium alginate, sodium bicarbonate and sodium lauryl sulfate.
Likewise, pills, powders, granules can be made by the usual method using the above-mentioned excipients. Liquid agents and suspensions can be made by the usual method using, for example, glycerin esters such as tricaprilyn or triacetin, or alcohols such as ethanol. Capsules can be obtained by filling capsules, for instance, made of gelatin with granules, powders, or liquids.
As a formulation for oral administration, the nitrogen-containing compound of the present invention, can be converted into a cyclodextrin clathrate compound. The clathrate can be prepared by adding a solution made by dissolving cyclodextrin in water and/or an organic solvent capable of mixing easily with water, to a solution made by dissolving the nitrogen-containing compound in an organic solvent capable of mixing easily with water. The mixture is heated, then vacuum concentrated under refrigeration, filtered or decanted to separate the product and isolate the target cyclodextrin clathrate compound. The proportion of organic solvent and water varies with the solubility of the starting material and of the product. It is desirable that the temperature when preparing cyclodextrin clathrate compound does not exceed 70° C. α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin or any combination of the above, can be used for the preparation of cyclodextrin clathrate compound. The stability of the nitrogen-containing compound can be increased by a conversion into a cyclodextrin clathrate compound.
As formulation for subcutaneous, intramuscular and intravenous administration, injectable agents exist in the form of aqueous and non-aqueous solutions. For example, physiological saline can be used for aqueous solutions. For non-aqueous solution, for example, propyleneglycol, polyethylene glycol, olive oil, ethyl oleate can be used, and anticeptic agents and stabilizers can be added to the above, as needed. Injectable agents are sterilized by suitably performing treatments such as filtration through bacterial retention filters or mixing with bactericides.
As formulations for percutaneous administration, ointments and creams can be cited as examples. Ointments can be made by the usual method with fats such as castor oil and olive oil, and emulsifiers such as diethyleneglycol, sorbitan monofatty acid ester; creams can be made using vaseline with grease oil and emulsifiers such as diethyleneglycol, sorbitan monofatty acid ester.
For rectal administration, a usual suppository such as a gelatin soft capsule may be used.
Preparations for parenteral administration can be administered as emulsions. In other words, water is added to a homogenous solution made of vegetal oils such as soybean oil, phospholipids such as lecithins and the nitrogen-containing compound of the present invention, and homogenized by homogenizers such as, for example, pressure injection homogenizer or ultrasonic homogenizer, to give lipid emulsion which can also be used as an injectable agent.
EMBODIMENTS
In the following, the present invention will be explained more concretely by giving examples and reference examples. However, the present invention is not limited to these examples and reference examples.
REFERENCE EXAMPLE 1
Preparation of (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene




73 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and dissolved in 2 mL of dimethylformamide. After addition of 49 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was then cooled to ambient temperature, 5 mL of 25% ammonium hydroxide in water was added, and stirred for 1 hour. An aqueous solution saturated with potassium hydrogen sulfate was added and extracted with ethyl acetate. The organic layer was washed with an aqueous solution saturated with sodium bicarbonate, then with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 29 mg of the compound presented in the title (40% yield).
1H-NMR (270 MHz, CDCl3): δ 0.91 (brt, 3H, J=7.1 Hz), 1.17 (s, 3H), 1.2–1.7 (m, 15H), 1.8–2.5 (m, 11H), 2.9–3.1 (m, 1H), 3.7–3.9 (m, 1H), 5.30 (brs, 1H), 5.3–5.5 (m, 1H), 5.5–5.7 (m, 1H).
REFERENCE EXAMPLE 2
The compound shown in Table 1 was obtained with a method identical to Reference example 1.











TABLE 1





Ref.






Ex.



NMR data


No.
starting material
product
Yield %
δ







2
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(4-
36
0.7–1.0(m, 3H), 1.0–2.5



carboxybutyl)-6-
carbamoylbutyl)-6-

(m, 24H), 2.9–3.1(m,



[(3S,1E)-3-hydroxy-
[(3S,1E)-3-hydroxy-

1H), 3.7–3.9(m, 1H),



1-octenyl]-7-
1-octenyl]-7-

4.0–4.2(m, 1H), 5.29(brs,



hydroxybicyclo[3.3.0]-
hydroxybicyclo[3.3.0]-

1H), 5.3–5.6(m, 2H),



2-octene
2-octene

6.0–6.1(m, 1H), 6.6–6.9(m, 1H)









REFERENCE EXAMPLE 3
Preparation of (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,5S,1 E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydrodroxybicyclo[3.3.0]-2-octene




59 mg of (1S,5S,6R,7R)-3-(4-methoxycarbonylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and dissolved in 3 mL acetonitrile, under stirring, 10 mL of 25% ammonium hydroxide in water was added and stirred for 6 days. After concentration, it was subjected to a silicagel column chromatography, to obtain 34 mg of the compound presented in the title(60% yield).
1H-NMR (270 MHz, CDCl3):δ0.88 (d, 3H, J=6.5 Hz), 0.7–1.0 (m, 3H), 1.0–2.5 (m, 25H), 2.9–3.1 (m, 1H), 3.7–3.9 (q, 1H, J=8.9 Hz), 4.0–4.2 (m, 1H), 5.29 (brs, 1H), 5.3–5.6 (m, 2H), 6.0–6.1 (m, 1H), 6.6–6.9 (m, 1H).
REFERENCE EXAMPLE 4
Preparation of (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene




36 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and dissolved in 1.5 mL of dimethylformamide. After addition of 32 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was then cooled to ambient temperature, 25 mg of imidazole and 33 mg of methylamine hydrochloride were added, and stirred at 50° C. for 1.5 hours. An aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 22 mg of the compound presented in the title (57% yield).
1H-NMR (270 MHz, CDCl3): δ 0.91 (brt, 3H, J=6.8 Hz), 1.16 (s, 3H), 1.2–1.7 (m, 15H), 1.8–2.5 (m, 9H), 2.9–3.1 (m, 1H), 2.94 (s, 3H), 3.00 (s, 3H), 3.7–3.9 (m, 1H), 5.30 (brs, 1H), 5.3–5.5 (m, 1H), 5.5–5.7 (m, 1H).
REFERENCE EXAMPLES 5–8
The compounds shown in Table 2 were obtained with a method identical to Reference example 4.











TABLE 2





Ref.






Ex.



NMR data


No.
starting material
product
Yield %
δ







5
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(4-N,N-
35
1.2–1.8(m, 6H), 2.33(s,



carboxybutyl)-6-
dimethylcarbamoylbutyl)-

3H), 1.9–2.5(m, 12H),



[(3S,1E)-3-hydroxy-4-
6-[(3S,1E)-3-hydroxy-

2.7–3.1(m, 1H), 2.94(s,



(m-tolyl)-1-butenyl]-7-
4-(m-tolyl)-1-butenyl]-

3H), 3.01(s, 3H), 3.5–3.7



hydroxybicyclo[3.3.0]-
7-hydroxybicyclo[3.3.0]-

(m, 1H), 4.2–4.5(m, 1H),



2-octene
2-octene

5.27 (brs, 1H), 5.45–5.65






(m, 2H), 6.9–7.1(m, 3H),






7.1–7.2(m, 1H)


6
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(4-
78
1.2–1.75(m, 6H), 2.33(s,



carboxybutyl)-6-
N,N-dimethylcarbamoyl-

3H), 1.75–2.5(m, 12H),



[(3R,1E)-3-hydroxy-4-
butyl)-6-[(3R,1E)-3-

2.94(s, 3H), 3.00(s, 3H),



(m-tolyl)-1-butenyl]-7-
hydroxy-4-(m-tolyl)-1-

2.9–3.1(m, 1H), 3.5–3.7



hydroxybicyclo[3.3.0]-
butenyl]-7-hydroxy-

(m, 1H), 4.34, (q, 1H,



2-octene
bicyclo[3 3.0]-2-octene

J=6.2Hz), 5.27(brs, 1H),






5.3–5.5(m, 1H), 5.5–5.7






(m, 1H), 6.9–7.1(m, 3H),






7.1–7.2(m, 1H)


7
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(4-
60
1.2–2.1(m, 12H), 2.33(s,



carboxybutyl)-6-[(E)-
N,N-dimethylcarbamoyl-

3H), 2.1–2.5(m, 5H),



4-(m-tolyl)-1-butenyl]-
butyl)-6-[(E)-4-

2.5–2.8(m, 2H), 2.94(s,



7-hydroxybicyclo-
(m-tolyl)-1-butenyl]-7-

3H), 3.00(s, 3H), 2.9–3.1



[3.3.0]-2-octene
hydroxybicyclo[3.3.0]-

(m, 1H), 3.5–3.7(m, 1H),




2-octene

5.2–5.3(m, 2H), 5.4–5.6






(m, 1H), 6.9–7.1(m, 3H),






7.1–7.2(m, 1H)


8
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(4-
35
1.2–1.9(m, 7H), 1.95–2.2



carboxybutyl)-6-
N,N-dimethylcarbamoyl-

(m, 4H), 2.32(s, 3H),



[4-(m-tolyl)-1,3-
butyl)-6-[4-(m-tolyl)-

2.2–2.5(m, 4H), 2.95(s,



butadienyl]-7-hydroxy
1,3-butadienyl]-7-

3H), 3.01(s, 3H), 2.9–3.1



bicyclo[3.3.0]-2-octene
hydroxybicyclo[3.3.0]-

(m, 1H), 3.7–3.9(m, 1H),




2-octene

5.31(brs, 1H), 5.65–5.8






(m, 1H), 6.15–6.55(m,






2H), 6.65–6.8(m, 1H),






6.95–7.1(m, 1H), 7.1–7.3






(m, 3H)









REFERENCE EXAMPLE 9
Preparation of (1S,5S,6R,7R)-3-[4-N-(2-ethoxycarbonylethyl)carbamoylbutyl]-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene




36 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and dissolved in 1 mL of dimethylformamide. After addition of 24 mg of 1,1′-carbonyldiimidazole, it was stirred for 20 hours. 14 mg of imidazole and 31 mg of ethyl 3-aminopropionate were added and stirred for 8 hours. An aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to silicagel column chromatography, to obtain 36 mg of the compound presented in the title (79% yield).
1H-NMR (270 MHz, CDCl3):δ0.91 (brt, 3H, J=6.1 Hz), 1.16 (s, 3H), 1.27 (t, 3H, J=7.2 Hz), 1.2–1.7 (m, 13H), 2.53 (t, 2H, J=5.9 Hz), 1.8–2.6 (m, 11H), 2.9–3.1 (m, 1H), 3.51 (q, 2H, J=5.8 Hz), 3.77 (q, 1H, J=7.0 Hz), 4.15 (q, 2H, J=7.1 Hz), 5.28 (brs, 1H), 5.3–5.5 (m, 1H), 5.5–5.7 (m, 1H), 6.0–6.2 (m, 1H).
REFERENCE EXAMPLE 10
Preparation of (1S,5S,6R,7R)-3-(4-piperidinocarbonylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene




3 ml of toluene and 1 mL of 15% trimethylaluminium-hexane solution were added to a nitrogen exchanged flask. 148 μL of piperidine was added and stirred at ambient temperature for 3 hours. 59 mg of (1S,5S,6R,7R)-3-(4-methoxycarbonylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene was dissolved and added in 4 mL of toluene, and stirred at 60° C. for 18 hours. An aqueous solution saturated with potassium hydrogen sulfate was added, extracted with ethyl acetate. The organic layer was washed with an aqueous solution saturated with sodium bicarbonate, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 62 mg of the compound presented in the title (93% yield).
1H-NMR (270 MHz, CDCl3):δ0.8–0.95 (m, 3H), 0.90 (d, 3H, J=6.2 Hz), 1.1–1.7 (m, 22H), 1.8–2.5 (m, 9H), 2.9–3.1 (m, 1H), 3.3–3.5 (m, 2H), 3.5–3.6 (m, 2H), 3.77 (q, 1H, J=6.8 Hz), 4.1–4.25 (m, 1H), 5.29 (brs, 1H), 5.45–5.6 (m, 2H).
REFERENCE EXAMPLES 11–13
The compounds shown in Table 3 were obtained with a method identical to Reference example 10.









TABLE 3







Ref.
starting material













Ex.
carboxylic acid



NMR data


No.
derivatives
amine
product
Yield %
δ





11
(1S,5S,6R,7R)-3-
diethylamine
(1S,5S,6R,7R)-3-
42
0.7–1.0(m, 6H), 1.11(t,



(4-methoxy-

(4-N,N-diethyl-

3H, J=7.0Hz), 1.17(t, 3H,



carbonylbutyl)-6-

carbamoylbutyl)-6-

J=7.2Hz), 1.0–1.8(m,



[(3S,5S,1E)-3-

[(3S,5S,1E)-3-

13H), 1.8–2.1(m, 4H),



hydroxy-5-methyl-

hydroxy-5-methyl-1-

2.1–2.5(m, 5H), 2.9–3.1



1-nonenyl]-7-

nonenyl]-7-hydroxy-

(m, 1H), 3.30(q, 2H,



hydroxybicyclo-

bicyclo[3.3.0]-2-

J=7.2Hz), 3.37(q, 2H,



[3.3.0]-2-octene

octene

J=7.1Hz), 3.7–3.8(m,







1H), 4.1–4.2(m, 1H), 5.29







(brs, 1H), 5.4–5.6(m, 2H)


12
(1S,5S,6R,7R)-3-
morpholine
(1S,5S,6R,7R)-3-(4-
92
0.7–1.0(m, 6H), 1.0–2.1



(4-methoxy

morpholinocarbonyl-

(m, 21H), 2.1–2.5(m,



carbonylbutyl)-6-

butyl)-6-[(3S,5S,1E)-

4H), 2.9–3.1(m, 1H),



[(3S,5S,1E)-3-

3-hydroxy-5-methyl-

3.4–3.5(m, 2H), 3.5–3.7



hydroxy-5-methyl-

1-nonenyl]-7-hydroxy

(m, 6H), 3.7–3.8(m, 1H),



1-nonenyl]-7-

bicyclo[3.3.0]-2-

4.1–4.2(m, 1H), 5.29(brs,



hydroxybicyclo-

octene

1H), 5.4–5.6(m, 2H)



[3.3.0]-2-octene


13
(1S,5S,6R,7R)-3-
4-amino-
(1S,5S,6R,7R)-3-[4-
71
0.7–1.0(m, 6H), 1.0–2.5



(4-methoxy-
methyl-
N-(4-pyridylmethyl)

(m, 25H), 2.9–3.1(m,



carbonylbutyl)-6-
pyridine
carbamoylbutyl]-6-

1H), 3.7–3.85(m, 1H),



[(3S,5S,1E)-3-

[(3S,5S,1E)-3-

4.1–4.2(m, 1H)4.45(d,



hydroxy-5-methyl-

hydroxy-5-methyl-

2H, J=6.2Hz), 5.27(brs,



1-nonenyl]-7-

1-nonenyl]-7-

1H), 5.4–5.6(m, 2H),



hydroxybicyclo-

hydroxybicyclo-

6.0–6.2(m, 1H), 7.20(d,



[3.3.0]-2-octene

[3.3.0]-2-octene

2H, J=5.9Hz), 8.53(d,







2H, J=5.9Hz)









REFERENCE EXAMPLE 14
Preparation of (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-(tetrahydropyran-2-yloxy)-bicyclo[3.3.0]-2-octene




40 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-(tetrahydropyran-2-yloxy)-bicyclo[3.3.0]-2-octene was dissolved in 4 mL of dimethylformamide, and 27 mg of 1-hydroxybenzotriazole monohydrate was added. While stirring on ice, 71 μL of diisopropylamine was added and stirred at 0° C. for 20 minutes. 38 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide monohydrochloride was added, and stirred for 13 hours. An aqueous solution of ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 29 mg of the compound presented in the title (56% yield).
1H-NMR (270 MHz, CDCl3):δ 1.22 (d, 6H, J=5.0 Hz), 1.37 (d, 6H, J=5.0 Hz), 1.1–1.8 (m, 13H), 2.34 (s, 3H), 1.8–2.7 (m, 11H), 2.9–3.1 (m, 1H), 3.5–4.0 (m, 5H), 4.1–4.3 (m, 1H), 5.15–5.3 (m, 2H), 5.45–5.9 (m, 1H), 6.9–7.05 (m, 3H), 7.1–7.25 (m, 1H).
REFERENCE EXAMPLE 15
Preparation of (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane.




59 mg of (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane was taken and was dissolved in 2 mL of dimethylformamide. 25 mg of 1,1′-carbonyldiimidazole was added and, stirred at ambient temperature for 5 hours. 20 mg of imidazole and 23 mg of dimethylamine hydrochloride were added, and stirred at ambient temperature for 18 hours. An aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 17 mg of the compound presented in the title (26% yield).
1H-NMR (270 MHz, CDCl3):δ0.96 and 1.00 (d, 3H, J=6.9 Hz), 1.1–1.3 (m, 1H), 1.5–2.5 (m, 22H), 2.94 (s, 3H), 3.0 (s, 3H), 3.65–3.8 (m, 1H), 3.9–4.05 and 4.1–4.2 (m, 1H), 5.2–5.3 (m, 1H), 5.45–5.65 (m, 2H).
REFERENCE EXAMPLE 16
Preparation of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(3-N,N-dimethylcarbamoylpropyl)-1H-cyclopenta[b] benzofuran




20 mg of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(3-carboxypropyl)-1H-cyclopenta[b] benzofuran was taken and dissolved in 2 mL of dimethylformamide. 16 mg of 1,1′-carbonyldiimidazole was added and stirred at 50° C. for 1 hour. 13 mg of imidazole and 16 mg of dimethylamine hydrochloride was added, and stirred at 50° C. for 1 hour. An aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to a silicagel column chromatography, to obtain 5 mg of the compound presented in the title (23% yield).
1H-NMR (270 MHz, CDCl3): δ 0.9–1.1 (m, 3H), 1.2–1.7 (m, 5H), 1.79 (brs, 3H), 1.9–2.8 (m, 9H), 2.96 (s, 3H), 3.0 (s, 3H), 3.49 (t, 1H, J=8.5 Hz), 3.9–4.3 (m, 2H), 5.0–5.2 (m, 1H), 5.5–5.8 (m, 2H), 6.7–6.85 (m, 1H), 6.9–7.05 (m, 2H).
EXAMPLE 1
Preparation of (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene




29 mg of (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene obtained in Reference example 3 was taken and dissolved in 4 mL of tetrahydrofurane. 20 mg of lithium aluminium hydride was added, and stirred for 4 hours. 100 μL of an aqueous solution saturated with sodium sulfate was added, then 500 mg of anhydrous sodium sulfate was added, and stirred for 18 hours. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 8 mg of the compound presented in the title (29% yield).
1H-NMR (270 MHz, CDCl3): δ 0.7–1.0 (m, 6H), 1.0–1.6 (m, 16H), 1.8–2.1 (m, 4H), 2.2–2.5 (m, 3H), 2.72 (t, 2H, J=7.0 Hz), 2.7–3.1 (m, 5H), 3.76 (q, 1H, J=8.6 Hz), 4.0–4.15 (m, 1H), 5.27 (brs, 1H), 5.4–5.6 (m, 2H).
EXAMPLE 2
The compound shown in Table 4 was obtained with a method identical to Example 1.











TABLE 4









NMR data


Example No.
starting material
product
Yield %
δ







2
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
17
0.7–1.0(m, 3H), 1.0–1.6



carbamoylbutyl)-6-
aminopentyl)-6-

(m, 15H), 1.8–2.1(m,



[(3S,1E)-3-hydroxy-1-
[(3S,1E)-3-hydroxy-1-

4H), 2.2–2.5(m, 3H), 2.73



octenyl]-7-hydroxy-
octenyl]-7-hydroxy

(t, 2H, J=7.0Hz), 2.7–3.1



bicyclo[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

(m, 5H), 3.6–3.85(m,






1H), 4.0–4.15(m, 1H),






5.26(brs, 1H), 5.4–5.6(m, 2H)









EXAMPLE 3
Preparation of (1S,5S,6R,7R)-3-(5-N-acetylaminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene




20 μL of acetic acid was dissolved in 2 mL of dimethylformamide. After adding 60 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was cooled to ambient temperature, and 18 mg of (1S,5S,6R,7R)-3-(5-aminopentyl)-6-[(3S,5S,1E)-3-hydroxy-5-methyl-1-nonenyl]-7-hydroxybicyclo[3.3.0]-2-octene was added, and stirred for 18 hours. An aqueous solution saturated with potassium hydrogen sulfate was added and extracted with ethyl acetate. The organic layer was washed with an aqueous solution saturated with sodium bicarbonate, then with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, it was subjected to silicagel column chromatography, to obtain 3.5 mg of the compound presented in the title (22% yield).
1H-NMR (270 MHz, CDCl3): δ 0.7–1.0 (m, 6H), 1.0–1.6 (m, 16H), 1.96 (s, 3H), 1.8–2.1 (m, 4H), 2.2–2.5 (m, 3H), 2.7–3.1 (m, 3H), 3.1–3.4 (m, 2H), 3.76 (q, 1H, J=8.6 Hz), 4.0–4.15 (m, 1H), 5.27 (brs, 1H), 5.4–5.6 (m, 2H), 6.6–6.8 (m, 1H).
EXAMPLE 4
The compound shown in Table 5 was obtained with a method identical to Example 3.











TABLE 5









starting material

NMR data












Example No.
amine
acid
product
Yield %
δ





4
(1S,5S,6R,7R)-3-
benzoic
(1S,5S,6R,7R)-3-(5-
37
0.7–1.0(m, 6H), 1.0–1.6



(5-aminopentyl)-6-
acid
N-benzoylamino-

(m, 16H), 1.8–2.1(m,



[(3S,5S,1E)-3-

pentyl)-6-[(3S,5S,1E)-

4H), 2.2–2.5(m, 3H),



hydroxy-5-methyl-

3-hydroxy-5-methyl-

2.7–3.1(m, 3H), 3.3–3.5



1-nonenyl]-7-

1-nonenyl]-7-hydroxy-

(m, 2H), 3.77(q, 1H,



hydroxybicyclo-

bicyclo[3.3.0]-2-

J=8.5Hz), 4.0–4.15(m,



[3.3.0]-2-octene

octene

1H), 5.27(brs, 1H),







5.4–5.6(m, 2H), 7.0–7.2







(m, 1H), 7.2–7.5(m, 3H),







7.7–7.85(m, 2H)









EXAMPLE 5
Preparation of (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene




36 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and was dissolved in 1.5 mL of dimethylformamide. After addition of 32 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was then cooled to ambient temperature, 27 mg of imidazole was added, and 33 mg of dimethylamine hydrochloride was further added. After stirring at 50° C. for 1.5 hours, an aqueous solution saturated with ammonium chloride was added and extraction was performed with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 1.5 mL of tetrahydrofurane was added. While stirring on ice, 38 mg of lithium aluminium hydride was added and stirring continued at 0° C. for 15 minutes, then at 50° C. for 1.5 hours. While stirring at ambient temperature, 200 μL of an aqueous solution saturated with sodium sulfate was added, then 800 mg of anhydrous sodium sulfate and 4 mL of ethyl acetate were added, and stirred for 1 hour. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to silicagel column chromatography, to obtain 19 mg of the compound presented in the title (51% yield).
1H-NMR (270 MHz, CDCl3):δ0.91 (brt, 3H, J=6.9 Hz), 1.16 (s, 3H), 1.2–1.6 (m, 15H), 1.8–2.5 (m, 11H), 2.24 (s, 6H), 2.9–3.1 (m, 1H), 3.7–3.9 (m, 1H), 5.27 (brs, 1H), 5.3–5.5 (m, 1H), 5.5–5.7 (m, 1H).
EXAMPLES 6–16
The compounds shown in Table 6 were obtained with a method identical to Example 5.











TABLE 6









NMR data


Example No.
starting material
product
Yield %
δ



















6
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
46
0.92(brt, 3H, J=6.8Hz),



carboxybutyl)-6-
N,N-dimethylamino-

1.2–1.6(m, 15H), 1.8–2.5



[(3S,1E)-3-hydroxy-
pentyl)-6-[(3S,1E)-3-

(m, 11H), 2.23(s, 6H),



1-octenyl]-7-hydroxy-
hydroxy-1-octenyl]-7-

2.9–3.1(m, 1H), 3.7–3.9



bicyclo[3.3.0]-2-octene
hydroxybicyclo[3.3.0]-

(m, 1H), 4.1–4.2(m, 1H),




2-octene

5.27(brs, 1H), 5.4–5.6(m, 2H)


7
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
47
0.7–1.0(m, 6H), 1.1–1.7



carboxybutyl)-6-
N,N-dimethylamino-

(m, 15H), 1.75–2.2(m,



[(3S,5S,1E)-3-hydroxy-
pentyl)-6-[(3S,5S,1E)-3-

7H), 2.23(s, 6H), 2.1–2.5



5-methyl-1-nonenyl]-
hydroxy-5-methyl-1-

(m, 5H), 2.9–3.1(m, 1H),



7-hydroxybicyclo-
nonenyl]-7-hydroxy-

3.7–3.8(m, 1H), 4.1–4.2



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

(m, 1H), 5.27(brs, 1H),






5.4–5.6(m, 2H)


8
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
38
0.7–1.0(m, 6H), 1.1–1.6



carboxybutyl)-6-
N,N-dimethylamino-

(m, 15H), 1.75–2.2(m,



[(3S,5R,1E)-3-hydroxy-
pentyl)-6-[(3S,5R,1E)-3-

7H), 2.23(s, 6H), 2.2–2.5



5-methyl-1-nonenyl]-7-
hydroxy-5-methyl-1-

(m, 5H), 2.9–3.1(m, 1H),



hydroxybicyclo[3.3.0]-
nonenyl]-7-hydroxy

3.7–3.8(m, 1H), 4.1–4.2



2-octene
bicyclo[3.3.0]-2-octene

(m, 1H), 5.26(brs, 1H),






5.4–5.6(m, 2H)


9
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
17
0.92(brt, 3H, J=7.0Hz),



carboxybutyl)-6-
N,N-dimethylamino-

1.16(s, 3H), 1.2–1.6(m,



[(4R,1E)-4-hydroxy-
pentyl)-6-[(4R,1E)-4-

15H), 1.8–2.5(m, 11H),



4-methyl-1-octenyl]-
hydroxy-4-methyl-1-

2.24(s, 6H), 2.9–3.1(m,



7-hydroxybicyclo-
octenyl]-7-hydroxy

1H), 3.7–3.9(m, 1H), 5.26



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

(brs, 1H), 5.3–5.5(m, 1H),






5.5–5.7(m, 1H)


10
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
34
0.95 and 1.00(d, 3H,



carboxybutyl)-6-
N,N-dimethylamino-

J=2.3Hz), 1.1–1.7(m,



[(3S,1E)-3-hydroxy-4-
pentyl)-6-[(3S,1E)-3-

10H), 1.8–2.5(m, 14H),



methyl-6-octyne-1-
hydroxy-4-methyl-6-

2.24(s, 6H), 2.9–3.1(m,



enyl]-7-hydroxy-
octyne-1-enyl]-7-

1H), 3.7–3.9(m, 1H),



bicyclo[3.3.0]-2-octene
hydroxybicyclo-

4.1–4.2(m, 1H), 5.26(brs,




[3.3.0]-2-octene

1H), 5.4–5.6(m, 2H)


11
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
50
1.1–1.6(m, 16H), 1.8–2.5



carboxybutyl)-6-
N,N-dimethylamino-

(m, 11H), 2.24(s, 6H),



[(3S,1E)-3-hydroxy-
pentyl)-6-[(3S,1E)-3-

2.9–3.1(m, 1H), 3.7–3.9



3-cyclopentyl-1-
hydroxy-3-cyclopentyl-

(m, 1H), 4.1–4.2(m, 1H),



propenyl]-7-hydroxy
1-propenyl]-7-hydroxy-

5.25(brs, 1H), 5.35–5.7



bicyclo[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

(m, 2H)


12
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
39
1.1–1.6(m, 18H), 1.8–2.5



carboxybutyl)-6-
N,N-dimethylamino

(m, 11H), 2.24(s, 6H),



[(3S,1E)-3-hydroxy-3-
pentyl)-6-[(3S,1E)-3-

2.9–3.1(m, 1H), 3.7–3.9



cyclohexyl-1-propenyl]-
hydroxy-3-cyclohexyl-

(m, 1H), 4.1–4.2(m, 1H),



7-hydroxybicyclo-
1-propenyl]-7-hydroxy-

5.24(brs, 1H), 5.3–5.7(m, 2H)



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene


13
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
43
1.1–1.75(m, 18H), 1.8–2.6



carboxybutyl)-6-
N,N-dimethylamino

(m, 11H), 2.24(s, 6H),



[(3S,1E)-3-hydroxy-4-
pentyl)-6-[(3S,1E)-3-

2.9–3.1(m, 1H), 3.7–3.9



cyclopentyl-1-butenyl]-
hydroxy-4-cyclopentyl-

(m, 1H), 4.1–4.2(m, 1H),



7-hydroxybicyclo-
1-butenyl]-7-hydroxy-

5.25(brs, 1H), 5.4–5.6(m, 2H)



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene


14
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
44
0.93(brt, 3H, J=6.9Hz),



carboxybutyl)-6-
N,N-dimethylamino-

1.2–1.7(m, 15H), 1.8–2.5



[(3R,1E)-3-hydroxy-1-
pentyl)-6-[(3R,1E)-3-

(m, 11H), 2.24(s, 6H),



octenyl]-7-hydroxy-
hydroxy-1-octenyl]-7-

2.9–3.1(m, 1H), 3.7–3.9



bicyclo[3.3.0]-2-octene
hydroxybicyclo-

(m, 1H), 4.1–4.2(m, 1H),




[3.3.0]-2-octene

5.28 (brs, 1H), 5.4–5.6(m, 2H)


15
(1S,5S,6R,7R)-3-(2-
(1S,5S,6R,7R)-3-[2-(2-
21
0.94(brt, 3H, J=6.9Hz),



carboxymethyloxy-
N,N-dimethylamino-

1.2–1.6(m, 9H), 1.8–2.5



ethyl)-6-[(3S,1E)-3-
ethyl)oxyethyl]-6-[(3S,1E)-

(m, 11H), 2.24(s, 6H),



hydroxy-1-octenyl]-7-
3-hydroxy-1-

2.8–3.1(m, 1H), 3.4–4.2



hydroxybicyclo-
octenyl]-7-hydroxy

(m, 6H), 5.28(brs, 1H),



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

5.4–5.7(m, 2H)


16
(1S,5S,6R,7R)-3-(2-
(1S,5S,6R,7R)-3-[2-(2-
15
0.91(brt, 3H, J=6.8Hz),



carboxymethylthio-
N,N-dimethylamino-

1.2–1.6(m, 9H), 1.8–2.5



ethyl)-6-[(3S,1E)-3-
ethyl)thioethyl]-6-

(m, 11H), 2.23(s, 6H),



hydroxy-1-octenyl]-7-
[(3S,1E)-3-hydroxy-1-

2.9–3.4(m, 5H), 3.7–3.9



hydroxybicyclo-
octenyl]-7-hydroxy

(m, 1H), 4.1–4.2(m, 1H),



[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

5.26(brs, 1H), 5.4–5.6(m, 2H)









EXAMPLE 17
Preparation of (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene




39 mg of (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene obtained in Reference example 6 was taken, 4 mL of tetrahydrofuran was added, then 36 mg of lithium aluminium hydride was added, and stirred at ambient temperature for 5 hours. While stirring at ambient temperature, 100 μL of an aqueous solution saturated with sodium sulfate was added, then 300 mg of anhydrous sodium sulfate was added, and stirred for 1.5 hours. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 26 mg of the compound presented in the title (70% yield).
1H-NMR (270 MHz, CDCl3): δ 1.2–1.6 (m, 7H), 1.7–2.1 (m, 7H), 2.22 (s, 6H), 2.33 (s, 3H), 2.2–2.5 (m, 4H), 2.7–2.9 (m, 2H), 2.9–3.1 (m, 1H)3.55–3.7 (m, 1H), 4.34 (q, 1H, J=6.5 Hz), 5.26 (brs, 1H), 5.45 (dd, 1H, J=15.8, 8.2 Hz), 5.59 (dd, 1H, J=15.5, 6.6 Hz), 6.9–7.1 (m, 3H), 7.1–7.25 (m, 1H).
EXAMPLES 18–26
The compounds shown in Table 7 were obtained with a method identical to Example 17.











TABLE 7









NMR data


Example No.
starting material
product
Yield %
δ







18
(1S,5S,6R,7R)-3-[4-N-
(1S,5S,6R,7R)-3-
68
0.91(brt, 3H, J=6.6Hz),



(2-ethoxycarbonylethyl)-
[5-N-(3-hydroxypropyl)-

1.16(s, 3H), 1.1–2.5(m,



carbamoylbutyl]-6-
aminopentyl]-6-

29H), 2.9–3.1(m, 1H),



[(4S,1E)-4-hydroxy-4-
[(4S,1E)-4-hydroxy-4-

3.41(q, 2H, J=6.1Hz),



methyl-1-octenyl]-7-
methyl-1-octenyl]-7-

3.63(t, 2H, J=5.4Hz),



hydroxybicyclo[3.3.0]-
hydroxybicyclo-

4.7–4.9(m, 1H), 5.29(brs,



2-octene
[3.3.0]-2-octene

1H), 5.41(dd, 1H, J=15.4,






8.4Hz), 5.5–5.7(m, 1H),






5.9–6.0(m, 1H)


19
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-
43
0.7–1.0(m, 6H), 1.04(t,



N,N-diethylcarbamoyl-
(5-N,N-diethylamino-

6H, J=7.2Hz), 1.1–1.6(m,



butyl)-6-[(3S,5S,1E)-
pentyl)-6-[(3S,5S,1E)-

15H), 1.75–2.2(m, 7H),



3-hydroxy-5-methyl-1-
3-hydroxy-5-methyl-1-

2.2–2.5(m, 5H), 2.56(q,



nonenyl]-7-hydroxy-
nonenyl]-7-hydroxy-

4H, J=6.4Hz), 2.9–3.1(m,



bicyclo[3.3.0]-2-octene
bicyclo[3.3.0]-2-octene

1H), 3.7–3.8(m, 1H),






4.1–4.2(m, 1H), 5.27(brs,






1H), 5.4–5.6(m, 2H)


20
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-(5-
50
0.7–1.0(m, 6H), 1.0–1.6



morpholinocarbonyl-
morpholinopentyl)-6-

(m, 15H), 1.75–2.1(m,



butyl)-6-[(3S,5S,1E)-
[(3S,5S,1E)-3-hydroxy-

5H), 2.1–2.65(m, 10H),



3-hydroxy-5-methyl-1-
5-methyl-1-nonenyl]-

2.9–3.1(m, 1H), 3.6–3.8



nonenyl]-7-hydroxy-
7-hydroxybicyclo-

(m, 6H), 4.0–4.2(m, 1H),



bicyclo[3.3.0]-2-octene
[3.3.0]-2-octene

5.26(brs, 1H), 5.4–5.6(m, 2H)


21
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-
81
0.7–1.0(m, 6H), 1.0–1.7



piperidinocarbonylbutyl)-
(5-piperidinopentyl)-6-

(m, 21H), 1.7–2.1(m,



6-[(3S,5S,1E)-3-hydroxy-
[(3S,5S,1E)-3-hydroxy-

9H), 2.2–2.5(m, 7H),



5-methyl-1-nonenyl]-7-
5-methyl-1-nonenyl]-7-

2.9–3.1(m, 1H), 3.7–3.85



hydroxybicyclo[3.3.0]-2-
hydroxybicyclo-

(m, 1H), 4.1–4.25(m,



octene
[3.3.0]-2-octene

1H), 5.27(brs, 1H),






5.45–5.6(m, 2H)


22
(1S,5S,6R,7R)-3-[4-
(1S,5S,6R,7R)-3-[5-N-
89
0.8–0.95(m, 6H), 1.0–2.1



N-(4-pyridylmethyl)-
(4-pyridylmethyl)amino-

(m, 18H), 2.04(t, 2H,



carbamoylbutyl]-6-
pentyl]-6-[(3S,5S,1E)-

J=8.5Hz), 2.27(t, 2H,



[(3S,5S,1E)-3-hydroxy-
3-hydroxy-5-methyl-1-

J=7.4Hz), 2.2–2.5(m,



5-methyl-1-nonenyl]-
nonenyl]-7-hydroxy-

5H), 2.9–3.1(m, 1H),



7-hydroxybicyclo-
bicyclo[3.3.0]-2-octene

3.7–3.85(m, 1H), 4.1–4.2



[3.3.0]-2-octene


(m, 1H), 4.46 (d, 2H,






J=5.9Hz), 5.27(brs, 1H),






5.45–5.6(m, 2H), 5.9–6.0






(m, 1H), 7.20(d, 2H,






J=5.9Hz), 8.54(d, 2H, J=5.9Hz)


23
(1S,5S,6R,7R)-3-(4-
(1S,5S,6R,7R)-3-
43
1.2–1.55(m, 7H), 1.8–2.1



N,N-dimethyl-
(5-N,N-dimethylamino-

(m, 7H), 2.23(s, 6H),



carbamoylbutyl)-6-
pentyl)-6-[(3S,1E)-3-

2.33(s, 3H), 2.1–2.5(m,



[(3S,1E)-3-hydroxy-4-
hydroxy-4-(m-tolyl)-1-

4H), 2.7–2.9(m, 2H),



(m-tolyl)-1-butenyl]-7-
butenyl]-7-hydroxy

2.9–3.1(m, 1H), 3.6–3.8



hydroxybicyclo-
bicyclo[3.3.0]-2-octene

(m, 1H), 4.32(q, 1H,



[3.3.0]-2-octene


J=6.5Hz), 5.26(brs, 1H),






5.49(dd, 1H, J=15.3,






8.5Hz), 5.60(dd, 1H,






J=15.4, 6.2Hz), 6.9–7.1






(m, 3H), 7.1–7.25(m, 1H)


24
(1S,5S,6R,7R)-3-
(1S,5S,6R,7R)-3-
70
1.2–1.55(m, 7H), 1.6–2.1



(4-N,N-dimethyl-
(5-N,N-dimethylamino-

(m, 7H), 2.22(s, 6H),



carbamoylbutyl)-6-
pentyl)-6-[(3R,1E)-3-

2.33(s, 3H), 2.1–2.5(m,



[(3R,1E)-3-hydroxy-4-
hydroxy-4-(m-tolyl)-1-

4H), 2.75–2.9(m, 2H),



(m-tolyl)-1-butenyl]-7-
butenyl]-7-hydroxy-

2.9–3.1(m, 1H), 3.5–3.7



hydroxybicyclo-
bicyclo[3.3.0]-2-octene

(m, 1H), 4.33(q, 1H,



[3.3.0]-2-octene


J=6.5Hz), 5.26(brs, 1H),






5.45(dd, 1H, J=15.8,






8.2Hz), 5.59(dd, 1H,






J=15.5, 6.6Hz), 6.9–7.1






(m, 3H), 7.1–7.2(m, 1H)


25
(1S,5S,6R,7R)-3-
(1S,5S,6R,7R)-3-
81
1.2–2.1(m, 13H), 2.22(s,



(4-N,N-dimethyl-
(5-N,N-dimethylamino-

6H), 2.33(s, 3H),



carbamoylbutyl)-6-
pentyl)-6-[(E)-4-

2.15–2.5(m, 6H), 2.5–2.7



[(E)-4-(m-tolyl)-1-
(m-tolyl)-1-butenyl]-7-

(m, 2H), 2.9–3.05(m,



butenyl]-7-hydroxy-
hydroxybicyclo-

1H), 3.5–3.7(m, 1H),



bicyclo[3.3.0]-2-octene
[3.3.0]-2-octene

5.2–5.3(m, 2H), 5.45–5.6






(m, 1H), 6.9–7.1(m, 3H),






7.1–7.2(m, 1H)


26
(1S,5S,6R,7R)-3-
(1S,5S,6R,7R)-3-
 7
1.2–1.7(m, 7H), 2.33(s,



(4-N,N-dimethyl-
(5-N,N-dimethylamino-

9H), 1.7–2.7(m, 14H),



carbamoylbutyl)-6-
pentyl)-6-[(1E,3E)-6-

2.9–3.1(m, 1H), 3.5–3.7



[(1E,3E)-6-(m-tolyl)-
(m-tolyl)-1,3-hexa-

(m, 1H), 5.30(brs, 1H),



1,3-hexadienyl]-7-
dienyl]-7-hydroxy-

5.35–5.55(m, 1H),



hydroxybicyclo-
bicyclo[3.3.0]-2-octene

5.55–5.75(m, 1H), 5.9–6.2



[3.3.0]-2-octene


(m, 2H), 6.8–7.05(m,






3H), 7.05–7.2(m, 1H)









EXAMPLE 27
Preparation of (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene




24 mg of (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene was taken and dissolved in 2 mL of dimethylformamide. 25 mg of 1,1′-carbonyldiimidazole was added and stirred at 50° C. for 1.5 hours. It was then cooled to ambient temperature and 100 mg pyrrolidine was added. After stirring at 50° C. for 2 hours, an aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 3 mL of tetrahydrofurane was added. While stirring on ice, 112 mg of lithium aluminium hydride was added, and stirring continued at 50° C. for 3 hours. While stirring at ambient temperature, 200 μL of an aqueous solution saturated with sodium sulfate was added, then 1 g of anhydrous sodium sulfate was added- and stirred for 16 hours. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to silicagel column chromatography, to obtain 18 mg of the compound presented in the title (65% yield).
1H-NMR (270 MHz, CDCl3): δ1.2–1.6 (m, 7H), 1.7–2.1 (m, 10H), 2.33 (s, 3H), 2.15–2.7 (m, 12H), 2.8–3.1 (m, 1H), 3.5–3.7 (m, 1H), 5.15–5.3 (m, 2H), 5.45–5.65 (m, 1H), 6.9–7.1 (m, 3H), 7.1–7.2 (m, 1H).
EXAMPLES 28–33
The compounds shown in Table 8 were obtained with a method identical to Example 27.











TABLE 8









starting material

NMR data












Example No.
carboxylic acid
amine
product
Yield %
δ





28
(1S,5S,6R,7R)-3-
methylamine
(1S,5S,6R,7R)-3-
33
0.94(brt, 3H, J=6.9Hz),



(4-carboxybutyl)-

(5-N-methylamino-

1.2–1.6(m, 16H), 1.8–2.6



6-[(3S,1E)-3-

pentyl)-6-[(3S,1E)-

(m, 11H), 2.42(s, 3H),



hydroxy-1-octenyl]-

3-hydroxy-1-octenyl]-

2.9–3.1(m, 1H), 3.7–3.9



7-hydroxybicyclo-

7-hydroxybicyclo-

(m, 1H), 4.1–4.2(m, 1H),



[3.3.0]-2-octene

[3.3.0]-2-octene

5.28(brs, 1H), 5.4–5.6(m, 2H)


29
(1S,5S,6R,7R)-3-
cyclohexylamine
(1S,5S,6R,7R)-3-
14
0.93(brt, 3H, J=6.9Hz),



(4-carboxybutyl)-

(5-N-cyclohexyl-

0.9–2.5(m, 37H), 2.9–3.1



6-[(3S,1E)-3-

aminopentyl)-6-

(m, 1H), 3.7–3.9(m, 1H),



hydroxy-1-octenyl]-

[(3S,1E)-3-hydroxy-

4.1–4.2(m, 1H), 5.26(brs,



7-hydroxybicyclo-

1-octenyl]-7-hydroxy-

1H),5.4–5.6(m, 2H)



[3.3.0]-2-octene

bicyclo[3.3.0]-2-octene


30
(1S,5S,6R,7R)-3-
benzylamine
(1S,5S,6R,7R)-3-
33
0.92(brt, 3H, J=6.7Hz),



(4-carboxybutyl)-

(5-N-benzylamino-

1.1–1.7(m, 16H), 1.8–2.7



6-[(3S,1E)-3-

pentyl)-6-[(3S,1E)-

(m, 11H), 2.9–3.1(m,



hydroxy-1-octenyl]-

3-hydroxy-1-octenyl]-

1H), 3.77(s, 2H), 3.7–3.9



7-hydroxybicyclo-

7-hydroxybicyclo-

(m, 1H), 4.1–4.2(m, 1H),



[3.3.0]-2-octene

[3.3.0]-2-octene

5.27(brs, 1H), 5.4–5.6(m,







2H), 7.1–7.3(m, 5H)


31
(1S,5S,6R,7R)-3-
N-methylpiperazine
(1S,5S,6R,7R)-3-
23
0.92(brt, 3H, J=6.8Hz),



(4-carboxybutyl)-

[5-(4-N-methyl-1-

1.2–1.6(m, 15H), 1.8–2.9



6-[(3S,1E)-3-

piperazinyl)pentyl]-6-

(m, 19H), 2.29(s, 3H),



hydroxy-1-octenyl]-

[(3S,1E)-3-hydroxy-

2.9–3.1(m, 1H), 3.7–3.9



7-hydroxybicyclo-

1-octenyl]-7-hydroxy-

(m, 1H), 4.1–4.2(m, 1H),



[3.3.0]-2-octene

bicyclo[3.3.0]-2-octene

5.28(brs, 1H), 5.4–5.6(m, 2H)


32
(1S,5S,6R,7R)-3-
Butylamine
(1S,5S,6R,7R)-3-
41
0.7–1.0(m, 6H), 1.17(s,



(4-carboxybutyl)-

(5-N-butylamino-

3H), 1.2–1.6(m, 19H),



6-[(4R,1E)-4-

pentyl)-6-[(4R,1E)-4-

1.8–2.7(m, 14H), 2.9–3.1



hydroxy-4-methyl-

hydroxy-4-methyl-1-

(m, 1H), 3.7–3.9(m, 1H),



1-octenyl]-7-

octenyl]-7-hydroxy-

5.27(brs, 1H), 5.3–5.5(m,



hydroxybicyclo-

bicyclo[3.3.0]-2-

1H), 5.5–5.7(m, 1H)



3.3.0]-2-octene

octene


33
(1S,5S,6R,7R)-3-
morpholine
(1S,5S,6R,7R)-3-
87
1.2–1.6(m, 6H), 1.6–2.1



(4-carboxybutyl)-6-

(5-morpholinopentyl)-

(m, 11H), 2.33(s, 3H),



[(E)-4-(m-tolyl)-1-

6-[(E)-4-(m-tolyl)-1-

2.1–2.5(m, 6H), 2.5–2.75



butenyl]-7-hydroxy-

butenyl]-7-hydroxy-

(m, 2H), 2.8–3.1(m, 1H),



bicyclo[3.3.0]-2-octene

bicyclo[3.3.0]-2-

3.5–3.75(m, 5H)5.2–5.3





octene

(m, 2H)5.4–5.6(m, 1H),







6.9–7.05(m, 3H), 7.1–7.2(m, 1H)









EXAMPLE 34
Preparation of (1S,5S,6R,7R)-3-(5-N,N-diisopropylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene




29 mg of (1S,5S,6R,7R)-3-(4-N,N-diisopropylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-(tetrahydropyran-2-yloxy)-bicyclo[3.3.0]-2-octene obtained in Reference example 14 was dissolved in 5 mL of tetrahydrofuran and 118 mg of lithium aluminium hydride was added. After stirring at 50° C. for 2 hours, 150 μL of an aqueous solution saturated with sodium sulfate was added, then anhydrous sodium sulfate was further added, and stirred for 18 hours. After filtration and concentration, the obtained oily matter was dissolved in 5 mL of methanol, and 20 mg of p-toluene sulfonic acid monohydrate was added. After stirring for 1.5 hours, an aqueous solution of potassium carbonate was added. After concentration extraction was performed with ethyl acetate, and the organic layer was washed with a saturated saline solution. It was then dried with anhydrous sodium sulfate, filtered, concentrated, and subjected to a silicagel column chromatography, to obtain 3 mg of the compound presented in the title (12% yield).
1H-NMR (270 MHz, CDCl3): δ 1.03 (d, 12H, J=6.2 Hz), 1.2–2.1 (m, 14H), 2.2–2.5 (m, 5H), 2.33 (s, 3H), 2.55–2.75 (m, 2H), 2.8–3.2 (m, 3H), 3.6–3.7 (m, 1H), 5.2–5.3 (m, 2H), 5.4–5.7 (m, 1H), 6.9–7.1 (m, 3H), 7.1–7.25 (m, 1H).
EXAMPLE 35
Preparation of (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S, 1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane




14 mg of (1S,2R,3R,5S)-7-[(E)-4-N,N-dimethylcarbamoylbutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane obtained in Reference example 15 was taken and 4 mL of tetrahydrofuran was added. In addition, while stirring on ice, 15 mg of lithium aluminium hydride was added and stirred at ambient temperature for 4 hours. While stirring at ambient temperature, 100 μL of an aqueous solution saturated with sodium sulfate was added, 300 mg anhydrous sodium sulfate was added, and stirred for 16 hours. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 9 mg of the compound presented in the title (65% yield).
1H-NMR (270 MHz, CDCl3): δ 0.96 and 1.01 (d, 3H, J=6.8 Hz), 1.1–1.6 (m, 7H), 1.79 (t, 3H, J=2.4 Hz), 2.24 (s, 6H), 1.7–2.5 (m, 15H), 3.7–3.9 (m, 1H), 3.9–4.2 (m, 1H), 5.2–5.3 (m, 1H), 5.4–5.6 (m, 2H).
EXAMPLE 36
Preparation of (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane




28 mg of (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3,1E)-3-hydroxy-1-octenyl]-3-hydroxybicyclo[3.3.0]octane was taken and was dissolved in 1.5 mL of dimethylformamide. 35 mg of 1,1′-carbonyldiimidazole was added and stirred at 50° C. for 1 hour. It was then cooled to ambient temperature, 27 mg of imidazole was added, and 33m of dimethylamine hydrochloride was also added. After stirring at 50° C. for 1.5 hours, an aqueous solution saturated with ammonium chloride was added and extraction was performed with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 1.5 mL of tetrahydrofurane was added. While stirring on ice, 38 mg of lithium aluminium hydride was added and stirring continued at 0° C. for 15 minutes, then at 50° C. for 1.5 hours. While stirring at ambient temperature, 200 μL of an aqueous solution saturated with sodium sulfate was added, then 800 mg of anhydrous sodium sulfate and 4 mL of ethyl acetate were added, and stirred for 1 hour. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 11 mg of the compound presented in the title (41% yield).
1H-NMR (270 MHz, CDCl3): δ 0.93 (brt, 3H, J=6.8 Hz), 1.1–1.6 (m, 12H), 2.24 (s, 6H), 1.7–2.5 (m, 15H), 3.7–3.9 (m, 1H), 3.9–4.2 (m, 1H), 5.2–5.3 (m, 1H), 5.4–5.6 (m, 2H).
EXAMPLE 37
The compound shown in Table 9 was obtained with a method identical to Example 36.











TABLE 9









NMR data


Example No.
starting material
product
Yield %
δ







37
(1S,2R,3R,5S)-7-[(E)-
(1S,2R,3R,5S)-7-[(E)-
37
1.0–1.7(m, 13H), 2.23(s,



4-carboxybutylidene]-
5-N,N-dimethylamino-

6H), 1.7–2.5(m, 15H),



2-[(3S,1E)-3-hydroxy-
pentylidene]-2-[(3S,1E)-

3.7–3.9(m, 1H), 3.9–4.2



3-cyclopentyl-1-
3-hydroxy-3-cyclopentyl-

(m, 1H), 5.2–5.3(m, 1H),



propenyl]-3-hydroxy-
1-propenyl]-3-hydroxy-

5.4–5.6(m, 2H)



bicyclo[3.3.0]octane
bicyclo[3.3.0]octane









EXAMPLE 38
Preparation of (1S,2R,3R,5S)-7-[(E)-5-morpholinopentylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane




20 mg of (1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane was taken and dissolved in 2 mL of dimethylformamide. After addition of 20 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1.5 hours. It was then cooled to ambient temperature, and 100 mg of morpholine was added. After stirring at 50° C. for 2 hours, an aqueous solution saturated with ammonium chloride was added and extraction was performed with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 3 mL of tetrahydrofurane was added. While stirring, 100 mg of lithium aluminium hydride was added, and stirring continued at 50° C. for 3 hours. While stirring at ambient temperature, 200 μL of an aqueous solution saturated with sodium sulfate was added, then 1 g of anhydrous sodium sulfate was added, and stirred for 16 hours. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 7 mg of the compound presented in the title (40% yield).
1H-NMR (270 MHz, CDCl3):δ 0.96 and 1.01 (d, 3H, J=6.8 Hz), 1.1–1.6 (m, 7H), 1.79 (t, 3H, J=2.4 Hz), 1.7–2.7 (m, 19H), 3.6–3.9 (m, 5H), 3.9–4.2 (m, 1H), 5.2–5.3 (m, 1H), 5.4–5.6 (m, 2H).
EXAMPLES 39–40
The compounds shown in Table 10 were obtained with a method identical to Example 38.











TABLE 10









starting material

NMR data












Example No.
carboxylic acid
amine
product
Yield %
δ





39
(1S,2R,3R,5S)-7-
diethylamine
(1S,2R,3R,5S)-7-
35
0.96 and 1.01(d, 3H,



[(E)-4-carboxy-

[(E)-5-N,N-diethyl-

J=6.8Hz), 1.05(t, 6H,



butylidene]-2-

aminopentylidene]-2-

J=7.1Hz), 1.1–1.6(m,



[(3S,1E)-3-hydroxy-

[(3S,1E)-3-hydroxy-

7H), 1.79(t, 3H,



4-methyl-6-octyne-1-

4-methyl-6-octyne-

J=2.4Hz), 1.7–2.5(m,



enyl]-3-hydroxy-

1-enyl]-3-hydroxy-

15H), 2.55(q, 4H,



bicyclo[3.3.0]octane

bicyclo[3.3.0]octane

J=6.5Hz), 3.7–3.9(m,







1H), 3.9–4.2(m, 1H),







5.2–5.3(m, 1H), 5.4–5.6(m, 2H)


40
(1S,2R,3R,5S)-7-
pyrrolidine
(1S,2R,3R,5S)-7-
42
0.96 and 1.01(d, 3H,



[(E)-4-carboxybutyli-

[(E)-5-(1-pyrrolidinyl)-

J=6.7Hz), 1.1–1.7(m,



dene]-2-[(3S,1E)-3-hy-

pentylidene]-2-

11H), 1.7–2.7(m, 22H),



droxy-4-methyl-6-octyne-

[(3S,1E)-3-hydroxy-

3.7–3.9(m, 1H), 3.9–4.2



1-enyl]-3-hydroxy-

4-methyl-6-octyne-1-

(m, 1H), 5.2–5.3(m, 1H),



bicyclo[3.3.0]octane

enyl]-3-hydroxy-

5.4–5.6(m, 2H)





bicyclo[3.3.0]octane









REFERENCE EXAMPLE 17
Preparation of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1′-octene-6-ynyl]-5-(4-N,N-dimethylaminobutyl)-1H-cyclopenta[b]benzofuran




10 mg of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-37-hydroxy-4-methyl-1-octene-6-ynyl]-5-(3-carboxypropyl)-1H-cyclopenta[b]benzofuran was taken and was dissolved in 2 mL of dimethylformamide. After addition of 8.1 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was then cooled to ambient temperature, 6.8 mg of imidazole was added, 8.2 mg dimethylamine hydrochloride was further added. After stirring at 50° C. for 1 hour, an aqueous solution saturated with ammonium chloride was added and extraction was performed with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 2 mL of tetrahydrofurane was added. While stirring on ice, 9.5 mg of lithium aluminium hydride was added, and stirring continued at 0° C. for 15 minutes, and at 50° C. for 1 hour. While stirring at ambient temperature, 100 μL of an aqueous solution saturated with sodium sulfate was added, 400 mg of anhydrous sodium sulfate was added, and stirred for 1 hour. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 7.5 mg of the compound presented in the title (73% yield).
1H-NMR (270 MHz, CDCl3): δ 0.9–1.1 (m, 3H), 1.2–1.7 (m, 7H), 1.79 (brs, 3H), 1.9–2.7 (m, 9H), 2.24 (s, 6H), 3.49 (t, 1H, J=8.5 Hz), 3.9–4.3 (m, 2H), 5.0–5.2 (m, 1H), 5.5–5.8 (m, 2H), 6.7–6.85 (m, 1H), 6.9–7.05 (m, 2H).
EXAMPLE 41
Preparation of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(4-morpholinobutyl)-1H-cyclopenta[b]benzofuran




10 mg of (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(3-carboxypropyl)-1H-cyclopenta[b]benzofuran was taken and was dissolved in 2 mL of dimethylformamide. After addition of 8.1 mg of 1,1′-carbonyldiimidazole, it was stirred at 50° C. for 1 hour. It was cooled to ambient temperature, and 50 mg morpholine was added. After stirring at 50° C. for 1 hour, an aqueous solution saturated with ammonium chloride was added and extracted with ethyl acetate. The organic layer was washed with a saturated saline solution, and dried with anhydrous sodium sulfate. After filtration and concentration, 2 mL of tetrahydrofurane was added. While stirring on ice, 9.5 mg of lithium aluminium hydride was added and stirring continued at 0° C. for 15 minutes, then at 50° C. for 1 hour. While stirring at ambient temperature, 100 μL of an aqueous solution saturated with sodium sulfate was added, then 400 mg of anhydrous sodium sulfate was added, and stirred for 1 hour. A filtration was performed over celite, and after washing the residue with ethyl acetate, the filtrate was concentrated and subjected to a silicagel column chromatography, to obtain 5.3 mg of the compound presented in the title (48% yield).
1H-NMR (270 MHz, CDCl3): δ 0.9–1.1 (m, 3H), 1.2–1.7 (m, 7H), 1.78 (brs, 3H), 1.9–2.7 (m, 13H), 3.3–3.6 (m, 1H), 3.6–4.3 (m, 6H), 5.0–5.2 (m, 1H), 5.5–5.8 (m, 2H), 6.7–6.85 (m, 1H), 6.9–7.05 (m, 2H).
EXAMPLES 42–43
The compounds shown in Table 11 were obtained with a method identical to Example 41.











TABLE 11









NMR data


Example No.
starting material
product
Yield %
δ







42
(1R,2R,3aS,8bS)-
(1R,2R,3aS,8bS)-
54
0.9–1.1(m, 3H), 1.2–1.7



2,3,3a,8b-tetrahydro-2-
2,3,3a,8b-tetrahydro-2-

(m, 13H), 1.79(brs, 3H),



hydroxy-1-[(3S,1E)-3-
hydroxy-1-[(3S,1E)-3-

1.8–2.7(m, 13H), 3.3–3.6



hydroxy-4-methyl-1-
hydroxy-4-methyl-1-

(m, 1Hz), 3.9–4.3(m, 2H),



octene-6-ynyl]-5-(3-
octene-6-ynyl]-5-(4-

5.0–5.2(m, 1H), 5.5–5.8



carboxypropyl)-1H-
piperidinobutyl)-1H-

(m, 2H), 6.7–6.85(m,



cyclopenta[b]benzofuran
cyclopenta[b]benzofuran

1H), 6.9–7.05(m, 2H)


43
(1R,2R,3aS,8bS)-
(1R,2R,3aS,8bS)-
43
0.9–1.1(m, 3H), 1.2–1.7



2,3,3a,8b-tetrahydro-2-
2,3,3a,8b-tetrahydro-2-

(m, 13H), 1.80(brs, 3H),



hydroxy-1-[(3S,1E)-3-
hydroxy-1-[(3S,1E)-3-

1.8–2.7(m, 11H), 3.3–3.6



hydroxy-4-methyl-1-
hydroxy-4-methyl-1-

(m, 1Hz), 3.9–4.3(m, 2H),



octene-6-ynyl]-5-(3-
octene-6-ynyl]-5-[4-(1-

5.0–5.2(m, 1H), 5.5–5.8



carboxypropyl)-1H-
pyrrolidinyl)butyl]-1H-

(m, 2H), 6.7–6.85(m,



cyclopenta[b]benzofuran
cyclopenta[b]benzofuran

1H), 6.9–7.05(m, 2H)









REFERENCE EXAMPLE 18
Method for Measuring The Ability of Learning and Memory in a Rat by the Step-Through Passive Avoidance Test
A step-through passive avoidance instrument made of two chambers separated by a guillotine door was used as the experimental apparatus. One chamber is an illuminated chamber made of transparent acrylic boards (floor: 15 cm×25 cm, height: 15 cm), the other chamber is a dark chamber made of black acryl boards (same dimensions). In addition, the floor of the dark chamber was equipped with a grid made of 4 mm diameter stainless steel pieces separated by 15 mm spacing. The grid was connected to an apparatus for delivering electric shocks (shock generator scrambler).
First, the guillotine door was opened for one minute to let a rat freely explore the interior of the apparatus. Then, for acquisition trials, the door was closed and the rat was put into the illuminated chamber. 30 seconds later, the door was opened and immediately after the four legs of the rat were put inside the dark chamber, the door was closed and an electric shock was delivered. The strength of the electric shock was 0.5 mA for 5 seconds. The training was repeated until the rat remained in the illuminated chamber for more than 120 seconds when the rat was placed in the illuminated chamber immediately after the electric shock and the door was opened in a similar way. 24 hours after the acquisition trials, the rat was put into the illuminating chamber for retention trials, 30 seconds after, the guillotine door was opened, and the time taken for the four legs of the rat to enter the dark chamber was measured (step-through latency). The maximum observation time during retention trials was set to 300 seconds.
REFERENCE EXAMPLE 19
Method for Measuring the Ability of Learning and Memory in a Rat by the Y-Maze Test (Spontaneous Alternation Behavior Test)
A Y-shaped maze made by connecting three arms having a length of 35 cm each, a wall height of 25 cm and a floor width of 10 cm at an angle of 120° with respect to each other. The apparatus was settled on the laboratory floor.
A rat was placed at the extremity of one of the arms, was allowed to freely explore the maze for 8 minutes, and a record was taken of the order in which the arms were explored by the rat. By calling (A) the “Total arm entries”, and among them, by calling (B) the “Number of spontaneous alternations” which is the number of cases where 3 different arms were selected in sequence, the “Percentage of spontaneous alternations” was calculated with: (B/(A−2))×100.
REFERENCE EXAMPLE 20
Preparation of a Model for Alzheimer's Disease by the Continuous Intracerebroventricular Administration of β-Amyloid Proteins
7 week old Wistar male rats (weight 220 to 250 g) were used (N=5 to 10).
β-amyloid protein (1–42) was dissolved in 35% acetonitrile-0.1% trifluoroacetic acid in water, injected in a mini-osmotic pump, which had been set to deliver 300 pmol/day (volume: 230 μL, flow: 0.5 μL/hour), and connected to a dental syringe needle through a polyethylene tube. Animals in control group were connected to a pump to which β-amyloid protein (40–1) orvehicleonly was injected. After anesthetizing the rats with pentobarbital (50 mg/Kg, i.p.), an incision was performed in each of their scalps, and following the brainatlas, holes were drilled in the cranium. The syringe needle was inserted so that the tip of the needle was inside the lateral ventricle (A=−0.3 mm, L=1.2 mm, H=4.5 mm), and fixed with dental cement. The osmotic pump was then implanted under the dorsal skin.
Taking the day when the mini-osmotic pump was implanted as day 0, on day 5, a Y-maze test was performed following the method indicated in Reference example 2, on day 13 and day 14, a passive avoidance test was performed following the method indicated in Reference example 1, and a decrease in the ability of learning and memory was observed in the group which was administered β-amyloid protein (1–42) in comparison to the group which was administered β-amyloid protein (40–1) or the group which was administered vehicle only.
REFERENCE EXAMPLE 21
Method for Evaluating the Promotion Activity on the Neurite Outgrowth (1)
Mouse neuroblastoma Neuro2A cells (obtained from DAINIPPON PHARMACEUTICAL CO., LTD.) were suspended with a density of 2.5×104 cells/mL in DMEM containing 10% FCS and 2 mM of Gln, and were plated on commercially available 24-well tissue culture plates with a quantity of 400 μL/well. After an overnight culture under the conditions where the temperature was 37° C., and the carbon dioxide content of the air was 5%, the media was exchanged to an identical media containing the test compound, and the culture was further continued for 24 hours. Then microscope photographs were taken with a 20× lens. Using the photographs, by counting the total number of cells in the field of view and the number of cells with extended neurite, the proportion of cells with extended neurite is calculated.
REFERENCE EXAMPLE 22
Method for Evaluating the Promotion Activity on the Neurite Outgrowth (2)
The cells used and the performed culture method were identical to those in Reference example (1). After being cultured in a media containing the test compound for 24 hours, microscope photographs were taken with a 20× lens. Transparent sheets were used to cover the latter photographs, in order to copy neural projections with a uniform thickness. The copied sheets were imported into a personal computer as image data, using a scanner. Using image processing software, the area covered by the neurites were calculated, and, since the thickness used to mark the neurite was uniform, the analysis was performed considering that the area was proportional to the length, and allowing to compute the length of neurite per cell.
REFERENCE EXAMPLE 23
Method for Measuring the Activity of Decreasing Blood Pressure
A catheter for monitoring the blood pressure was inserted and placed in the femoral artery, and a catheter for the administration of drug solution was inserted and placed in the femoral vein of male Wistar rats (10–11 weeks old, Charles River) under ether anesthesia. The animals were placed in a Ballman cage, and awakened. After the blood pressure stabilized, a solvent containing ethanol and Tween80 adjusted to the same amount as those in each administered solution was injected by bolus administration. After monitoring blood pressure and heart rate for 60 minutes to verify the absence of effects, the test compound was administered and the blood pressure and the heart rate were further monitored for 60 minutes. The doses of the solvent and the test compound were all 1 mL/Kg. The measurements of the blood pressure and the heart rate were performed immediately before administration (0 minutes), at 3, 5, 10, 15, 30 and 60 minutes after administration. For each animal, the blood pressure value measured at each time point was normalized by defining the blood pressure at 0 minute as 100.
The test compound was used once it had been dissolved with ethanol and diluted in physiological saline containing Tween80, with, the quantity of test compound, the concentration of ethanol and Tween80 in the administration solution for each group as indicated in Table 12 below.









TABLE 12





Dose
Concentration of Ethanol
Concentration of Tween80


(mg/kg)
(%)
(%)

















0.1
1
0.198


1
10
0.18









REFERENCE EXAMPLE 24
Measurement of the Permeability of the Compound Through the Blood Brain Barrier
Bovine cerebral capillary endothelial cells were cultured on a 100 mm diameter plate (coated with collagen I) to obtain confluency. The cells were cultured for 15 minutes in an incorporation media (141 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM H2SO4, 10 mM HEPES, 10 mM D-glucose) containing the test compound (1 μM), to incorporate the test compound into the cells. Then, the test compound incorporated into the cells was extracted with ethanol extraction, and quantified by HPLC. The rate of incorporation was calculated with the equation below.

amount of test compound in the ethanol-extracted fraction/amount of test compound in the incorporation solution×100(%)

EXAMPLE 44
Measurement of the Ameliorating Effect on Learning and Memory Deficit (1)
Test compound: (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 18 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 13 below.









TABLE 1







Time taken to move into the dark chamber



during retention trials



mean value ± standard error



(unit: seconds)

















β-amyloid protein(40-1)
207.3 ± 51.5 (n = 6)


300 pmol/day group


β-amyloid protein(1-42)
140.2 ± 53.8 (n = 5)


300 pmol/day group


β-amyloid protein(1-42)
217.8 ± 44.9 (n = 6)


300 pmol/day and test


compound 12 fmol/day group









The time taken to move into the dark chamber was extended for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate the learning and memory deficit.
EXAMPLE 45
Measurement of the Ameliorating Effect on Learning and Memory Deficit (2)
Test compound: (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 18 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 14 below.









TABLE 14







Time taken to move into the dark chamber



during retention trials



mean value ± standard error



(unit: seconds)

















β-amyloid protein(40-1)
263.3 ± 36.7 (n = 3)


300 pmol/day group


β-amyloid protein(1-42)
132.8 ± 58.1 (n = 5)


300 pmol/day group


β-amyloid protein(1-42)
212.2 ± 58.5 (n = 5)


300 pmol/day and test


compound 12 fmol/day group









The time taken to move into the dark chamber was extended for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 46
Measurement of the Ameliorating Effect on Learning and Memory Deficit (3)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 18 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 15 below.









TABLE 15







Time taken to move into the dark chamber



during retention trials



mean value ± standard error



(unit: seconds)

















β-amyloid protein(40-1)
263.3 ± 36.7 (n = 3)


300 pmol/day group


β-amyloid protein(1-42)
132.8 ± 58.1 (n = 5)


300 pmol/day group


β-amyloid protein(1-42)
242.0 ± 36.3 (n = 4)


300 pmol/day and test


compound 12 fmol/day group









The time taken to move into the dark chamber was extended for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to amliorate learning and memory deficit.
EXAMPLE 47
Measurement of the Ameliorating Effect on Learning and Memory Deficit (4)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 18 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 16 below.









TABLE 16







Time taken to move into the dark chamber



during retention trials mean value ± standard



error (unit: seconds)


















Vehicle only group
286.7 ± 13.3
(n = 6)


β-amyloid protein (1-42)
191.7 ± 49.0
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
300.0 ± 0.0 
(n = 5)


300 pmol/day and test


compound 12 fmol/day


group









The time taken to move into the dark chamber was extended for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 48
Measurement of the Ameliorating Effect on Learning and Memory Deficit (5)
Test compound: (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 19 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 17 below.









TABLE 17







Occurrence of spontaneous alternation behavior



mean value ± standard error (unit: %)


















β-amyloid protein (40-1)
72.2 ± 2.9
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
65.6 ± 3.4
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
74.1 ± 2.5
(n = 6)


300 pmol/day and test


compound 12 fmol/day


group









The occurrence of spontaneous alternation behavior increased for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 49
Measurement of the Ameliorating Effect on Learning and Memory Deficit (6)
Test compound: (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 19 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 18 below.









TABLE 18







Occurrence of spontaneous alternation behavior



mean value ± standard error (unit: %)


















β-amyloid protein (40-1)
76.3 ± 4.9
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
66.5 ± 4.7
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
72.1 ± 3.7
(n = 6)


300 pmol/day and test


compound 12 fmol/day


group









The occurrence of spontaneous alternation behavior increased for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 50
Measurement of the Ameliorating Effect on Learning and Memory Deficit (7)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 19 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 19 below.









TABLE 19







Occurrence of spontaneous alternation behavior



mean value ± standard error (unit: %)


















β-amyloid protein (40-1)
76.3 ± 4.9
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
66.5 ± 4.7
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
73.2 ± 5.1
(n = 6)


300 pmol/day and test


compound 12 fmol/day


group









The occurrence of spontaneous alternation behavior increased for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 51
Measurement of the Ameliorating Effect on Learning and Memory Deficit 8)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The ameliorating effect on learning and memory deficit was evaluated with the evaluation methods of Reference examples 19 and 20. The test compound was dissolved in the β-amyloid protein solution, and injected at the same time as the β-amyloid protein, using an osmotic pump. The results are shown in Table 20 below.









TABLE 20







Occurrence of spontaneous alternation behavior



mean value ± standard error (unit: %)


















Vehicle only group
68.2 ± 2.3
(n = 6)


β-amyloid protein (1-42)
59.1 ± 3.0
(n = 6)


300 pmol/day group


β-amyloid protein (1-42)
71.7 ± 4.0
(n = 6)


300 pmol/day and test


compound 12 fmol/day


group









The occurrence of spontaneous alternation behavior increased for the test compound group when compared to the β-amyloid protein(1–42) only group. In other words, in the present experiment, the test compound displayed an activity to ameliorate learning and memory deficit.
EXAMPLE 52
Evaluation of the Promotion Activity on the Neurite Outgrowth (1)
Test compound: (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The promotion activity on the neurite outgrowth was evaluated with the method of Reference example 21.
In addition to the test compound, PGE1, whose promotion activity on the neurite outgrowth is known in other neuroblastoma cell strain (Miki et al., Drugs and treatments, Vol. 21, No.1, p93), was administered to an additional group for comparison. The results are shown in Table 21 below.










TABLE 21








Proportion of cells with neurite (%)



Compound
mean value ± standard error









Test compound not added
 8.8 ± 1.3



PGE1 (10 nM)
26.0 ± 3.0



Test compound (10 nM)
40.3 ± 3.5










This experiment shows that a promotion activity on the neurite outgrowth was detected for the test compound (level of significance: p<0.01). In addition, test compound showed a strong promotion activity when compared to PGE1 which is known to have a promotion activity on the neurite outgrowth (level of significance: p<0.05).
EXAMPLE 53
Evaluation of the Promotion Activity on the Neurite Outgrowth (2)
Test compound: (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The promotion activity on the neurite outgrowth was evaluated with the method of Reference example 22.
In addition to the test compound, as in Example 52, PGE1 was administered to an additional group for comparison. The results are shown in Table 22 below.








TABLE 22






Length of neurite per single cell (pixel/cell)


Compound
mean value ± standard error







Test compound not added
 6.1 ± 0.9


PGE1 (1 nM)
14.2 ± 1.5


Test compound (1 nM)
22.6 ± 3.0









This experiment shows that a promotion activity on the neurite outgrowth was detected for the test compound level of significance: p<0.01). In addition, test compound showed a strong promotion activity when compared to PGE1 which is known to have a promotion activity on the neurite outgrowth (level of significance: p<0.05).
EXAMPLE 54
Evaluation of the Promotion Activity on the Neurite Outgrowth (3)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The promotion activity on the neurite outgrowth was evaluated with the method of Reference example 21.
In addition to the test compound, as in Example 52, PGE1 was administered to an additional group for comparison. The results are shown in Table 23 below.










TABLE 23








Proportion of cells with neurite (%)



Compound
mean value ± standard error









Test compound not added
 6.1 ± 0.9



PGE1 (10 nM)
19.5 ± 1.9



Test compound (10 nM)
38.7 ± 6.6










This experiment shows that a promotion activity on the neurite outgrowth was detected for the test compoundlevel of significance: p<0.01). In addition, test compound showed a strong promotion activity when compared to PGE1 which is known to have a promotion activity on the neurite outgrowth (level of significance: p<0.05).
EXAMPLE 55
Evaluation of the Promotion Activity on the Neurite Outgrowth (4)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene
The promotion activity on the neurite outgrowth was evaluated with the method of Reference example 22.
In addition to the test compound, as in Example 52, PGE, was administered to an additional group for comparison. The results are shown in Table 24 below.








TABLE 24






Length of neurite per single cell (pixel/cell)


Compound
mean value ± standard error







Test compound not added
1.2 ± 0.13


PGE1 (100 nM)
5.7 ± 1.03


Test compound (100 nM)
8.0 ± 1.37









This experiment shows that a promotion activity on the neurite outgrowth was detected for the test compound.(level of significance: p<0.01).
EXAMPLE 56
Evaluation of the Promotion Activity on the Neurite Outgrowth (5)
Test compound A: (1R,2R,3aS,8bS)-2,3,3a,8b-tetrahydro-2-hydroxy-1-[(3S,1E)-3-hydroxy-4-methyl-1-octene-6-ynyl]-5-(4-N,N-dimethylaminobutyl)-1H-cyclopenta[b]benzofuran.
Test compound B: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound C: (1S,2R,3R,5S)-7-[(E)-5-N,N-dimethylaminopentylidene]-2-[(3S, 1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane.
Test compound D: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(3S,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound E: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The promotion activity on the neurite outgrowth was evaluated with the method of Reference example 21.
In parallel to the test compounds, as in Example 52, PGE1 was administered to an additional group for comparison. The results are shown in Table 25 below.









TABLE 25







Promotion activity on the



Concentration of test
neurite outgrowth


Compound
compound (μM)
(value relative to PGE1)







Vehicle
—
0.79


PGE1
10
1.00


Test compound A
10
1.17


Test compound B
10
1.63


Test compound C
10
1.15


Test compound D
10
1.31


Test compound E
10
1.58









EXAMPLE 57
Evaluation of the Promotion Activity on the Neurneurite Outgrowth (6)
Test compound A: (1S,5S,6R,7R)-3-(5-morpholinopentyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound B: (1S,5S,6R,7R)-3-[5-N,N-diisopropylaminopentyl]-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound C: (1S,5S,6R,7R)-3-[5-(1-pyrrolidinyl)pentyl]-6-[(3R,1E)-3-hydroxy-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The promotion activity on the neurneurite outgrowth was evaluated using the method of Reference example 21.
In parallel to the test compounds, as in Example 52, PGE1 was administered to an additional group for comparison. The results are shown in Table 26 below.









TABLE 26







Promotion activity on the



Concentration of
neurite outgrowth


Compound
compound (μM)
(value relative to PGE1)







Vehicle
—
0.45


PGE1
10
1.00


Test compound A
10
1.15


Test compound B
0.1
1.12


Test compound C
10
1.25









EXAMPLE 58
Evaluation of the Promotion Activity on the Neurneurite Outgrowth (7)
Test compound A: (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound B: (1S,5S,6R,7R)-3-(4-N,N-dimethylcarbamoylbutyl)-6-[(E)-4-(m-tolyl)-1-butenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The promotion activity on the neurneurite outgrowth was evaluated with the method of Reference example 21.
In parallel to the test compounds, as in Example 52, PGE1 was administered to an additional group for comparison. The results are shown in Table 27 below.









TABLE 27







Promotion activity on the



Concentration of
neurite outgrowth


Compound
compound (μM)
(value relative to PGE1)







Vehicle
—
0.53


PGE1
10
1.00


Test compound A
10
1.39


Test compound B
10
1.50









EXAMPLE 59
Measurement of the Blood Pressure Decreasing Activity (1)
Test compound: (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The effect on the blood pressure was evaluated with the method of Reference example 23. The variation in the blood pressure after administration of the test compound was as indicated in Table 28 below.










TABLE 28










Blood pressure (values normalized to 100 at 0 minute)



Dose
(± standard error)
















mg/kg
0 min
3 min
5 min
10 min
15 min
30 min
60 min



















Solvent only
0
100
98.4
97.5
102.6
100.6
102.2
98.8





(2.0)
(0.9)
(2.3)
(1.1)
(4.8)
(3.6)


Test compound
0.1
100
102.2
101.1
100.0
101.5
97.3
101.1





(1.0)
(0.4)
(1.9)
(1.9)
(1.9)
(2.8)


Solvent only
0
100
101.8
99.2
98.5
100.0
99.8
97.0





(1.1)
(0.5)
(1.5)
(1.2)
(1.7)
(1.2)


Test compound
1
100
93.7
95.7
101.0
100.9
101.1
104.8





(5.6)
(5.7)
(4.8)
(3.2)
(2.0)
(3.2)









In the 1 mg/Kg group, the test compound exerted a decrease in blood pressure immediately after administration. However, it was observed that recovery was fast, only a slight decrease existed after 3 minutes, and after 10 minutes, the blood pressure returned to normal values. No significant variations were observed in the 0.1 mg/Kg group. In other words, it is clear that the test compound is a compound having an extremely small activity on the circulatory system.
EXAMPLE 60
Measurement of the Blood Pressure Decreasing Activity (2)
Test compound: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
The effect on the blood pressure was evaluated with the method of Reference example 23. The variation in the blood pressure after administration of the test compound was as indicated in Table 28 below.










TABLE 29










Blood pressure (values normalized to 100 at 0 minute)



Dose
(± standard error)
















mg/kg
0 min
3 min
5 min
10 min
15 min
30 min
60 min



















Solvent only
0
100
101.1
99.7
103.7
105.2
101.4
98.3





(0.8)
(1.8)
(3.0)
(3.2)
(3.0)
(2.7)


Test compound
0.1
100
100.8
99.7
102.1
101.7
101.2
101.5





(2.2)
(2.9)
(1.7)
(2.8)
(1.3)
(3.7)


Solvent only
0
100
101.7
98.5
97.8
98.7
98.2
94.0





(1.0)
(1.1)
(1.0)
(1.5)
(2.8)
(3.5)


Test compound
1
100
108.1
105.1
105.9
105.9
105.0
99.9





(1.6)
(1.1)
(0.8)
(1.8)
(1.8)
(2.5)









In other words, it is clear that, since no significant variations were observed in the 0.1 mg/Kg dose and the 1 mg/Kg dose, the test compound is a compound having an extremely small activity on the circulatory system.
EXAMPLE 61
Measurement of the Permeability Through the Blood Brain Barrier (1)
Test compound A: (1S,5S,6R,7R)-3-(4-carbamoylbutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound B: (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Permeability through the blood brain barrier was measured with the method of Reference example 24. As a reference, measurements were also performed for the well-known isocarbacyclin derivative (test compound B), and compared. The results are shown in Table 30 below.








TABLE 30






Rate of incorporation into bovine capillary endothelial


Compound
cells (mean value of two experiments)







Test compound A
5.09%


Test compound B
below detection limit









It is clear from this experiment that the test compound has a high permeability through the blood brain barrier.
EXAMPLE 62
Measurement of the Permeability Through the Blood Brain Barrier (2)
Test compound A: (1S,5S,6R,7R)-3-(5-N,N-dimethylaminopentyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Test compound B: (1S,5S,6R,7R)-3-(4-carboxybutyl)-6-[(4S,1E)-4-hydroxy-4-methyl-1-octenyl]-7-hydroxybicyclo[3.3.0]-2-octene.
Permeability through the blood brain barrier was measured with the method of Reference example 24. As a reference, measurements were also performed for the well-known isocarbacyclin derivative (test compound B), and compared. The results are shown in Table 31 below.








TABLE 31






Rate of incorporation into bovine capillary endothelial


Compound
cells (mean value of two experiments)







Test compound A
15.8%


Test compound B
below detection limit









In other words, it is clear that the test compound A has a high permeability through the blood brain barrier.
USABILITY IN THE INDUSTRY
The nitrogen-containing compound of the present invention represented by the above equation (1) has an activity for the remedy of nerve damage. Therefore, the compound of the present invention can be used as a therapeutic agent for diorders due to nerve damage or nerve lesions due to external injuries.

## Claims

1. A nitrogen-containing compound represented by Formula (2) shown below or a salt thereof:



In Formula (2), the symbol  represents a single bond or a double bond
G represents one functional group chosen from the group consisting of the Formulae (G1), (G2), (G3), (G4) and (G5) shown below:







(In Formula (G 1), Formula (G2), Formula (G3), Formula (G4) and Formula (G5), the symbol  represents the site of linkage with A10;
R4 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group or a functional group forming the acetal bond together with the oxygen atom bonded to R4;
W represents a single bond, —CH2—, —(CH2)2—, —(CH2)3—, —CH═CH—, —CH═CHCH2—, —C═C—of —C═CCH2—;
m may be either 0 or 1, however, when W is a single bond, m is equal to 1;
R5 and R6 are either identical or different and, either represent one functional group chosen from the following items 1) to 4):
1) a hydrogen atom,
2) a substituted or an unsubstituted aliphatic hydrocarbon group having 1 to 10 carbon atoms, when the substituents are selected from the group consisting of:
fluorine atom,
chlorine atom,
bromine atom,
iodine atom,
hydroxyl group,
alkoxy group having 1 to 4 carbon atoms,
aryloxy group having 6 to 10 carbon atoms,
aralkoxy group having 7 to 9 carbon atoms,
acyloxy group having 2 to 10 carbon atoms,
sulfonyloxy group having 1 to 8 carbon atoms,
oxo group,
carboxyl group,
alkoxycarbonyl group having 2 to 10 carbon atoms,
carbamoyl group having 1 to 15 carbon atoms,
amino group having 0 to 14 carbon atoms,
acylamino group having 1 to 10 carbon atoms,
sulfonylamino group having 1 to 8 carbon atoms,
imino group having 1 to 10 carbon atoms,
cyano group,
nitro group,
sulfide group having 1 to 6 carbon atoms,
sulfinyl group having 1 to 6 carbon atoms, and
sulfonyl group having 1 to 6 carbon atoms,
substituted or unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms, wherein the substituents are selected from the group consisting of:
aliphatic hydrocarbon group having 1 to 6 carbon atoms,
fluorine atom,
chlorine atom,
bromine atom,
iodine atom,
hydroxyl group,
alkoxy group having 1 to 4 carbon atoms,
aryloxy group having 6 to 10 carbon atoms,
aralkoxy group having 7 to 9 carbon atoms,
acyloxy group having 2 to 10 carbon atoms,
sulfonyloxy group having 1 to 8 carbon atoms,
oxo group,
acyl group having 1 to 10 carbon atoms,
carboxyl group,
alkoxycarbonyl group having 2 to 10 carbon atoms,
carbamoyl group having 1 to 15 carbon atoms,
amino group having 0 to 14 carbon atoms,
acylamino group having 1 to 10 carbon atoms,
sulfonylamino group having 1 to 8 carbon atoms,
imino group having 1 to 10 carbon atoms,
cyano group,
nitro group,
sulfide group having 1 to 6 carbon atoms,
sulfinyl group having 1 to 6 carbon atoms, and
sulfonyl group having 1 to 6 carbon atoms, and

substituted or unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms, wherein the substituents are selected from the group consisting of:
alkyl group having 1 to 4 carbon atoms,
fluorine atom,
chlorine atom,
bromine atom,
iodine atom,
hydroxyl group,
alkoxy group having 1 to 4 carbon atoms,
aryloxy group having 6 to 10 carbon atoms,
aralkoxy group having 7 to 9 carbon atoms,
acyloxy group having 2 to 10 carbon atoms,
sulfonyloxy group having 1 to 8 carbon atoms,
acyl group having 1 to 10 carbon atoms,
carboxyl group,
alkoxycarbonyl group having 2 to 10 carbon atoms,
carbamoyl group having 1 to 15 carbon atoms,
amino group having 0 to 14 carbon atoms,
acylamino group having 1 to 10 carbon atoms,
sulfonylamino group having 1 to 8 carbon atoms,
cyano group,
nitro group,
sulfide group having 1 to 6 carbon atoms,
sulfinyl group having 1 to 6 carbon atoms, and
sulfonyl group having 1 to 6 carbon atoms,


3) a substituted or an unsubstituted alicyclic hydrocarbon group having 3 to 8 carbon atoms wherein the substituents are selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms,
4) a substituted or an unsubstituted aromatic hydrocarbon group having 6 to 10 carbon atoms, wherein the substituents are selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms,
or, when R5 and R6 are bonded to each other, they represent a substituted or an unsubstituted alicyclic hydrocarbon chain having 4 to 7 carbon atoms wherein the substituents are selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and, sulfonyl group having 1 to 6 carbon atoms;
R7 represents a hydrogen atom, an acyl group having 2 to 10 carbon atoms, a tri(hydrocarbon group having 1 to 7 carbon atoms) silyl group, an alkoxycarbonyl group having 2 to 5 carbon atoms, a sulfonyl group having 1 to 8 carbon atoms, a functional group forming the acetal bond together with the oxygen atom bound to R7, or, when R7 and R5 are bonded to each other, it represents one portion of the bond forming the carbonyl group together with the carbon atom bonded to R5 and the oxygen atom bonded to R7;
A20 represents a single bond, a Formula (A2A) shown below, a Formula (A2B) shown below or a Formula (A2C) shown below:




(in the formula, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 10 carbon atoms)




(in the formula, n represents 0, 1, or 2)
A10 represents the items 1) or 2) below:
1) a single bond,
2) a functional group which bridges G and A20 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group selected from the group consisting of morpholino, pyrrolidinyl, and piperidino, and a phenylene group;
A30 represents the items 1) or 2) below:
1) a single bond,
2) a functional group which bridges A20 and A40 through an identical atom or through different atoms, and chosen from: an aliphatic hydrocarbon group having 1 to 3 carbon atoms, an alicyclic hydrocarbon group having 3 to 8 carbon atoms, a heterocyclic group selected from the group consisting of morpholino, pyrrolidinyl, and piperidino, and a phenylene group;
A40 represents any of the items 1) to 3) below:
1) a single bond,
2) an aliphatic hydrocarbon group having 1 to 3 carbon atoms, which bridges the nitrogen atom, bonded to R10 and R20, and A30 through an identical atom or through different atoms;
3) when A40 and R10 are bonded to each other, a functional group forming a 5 to 8 membered ring together with the nitrogen atom they are bonded to (when A40 or R10 and the nitrogen atom they are bonded to are bonded through a double bond, R20 represents the bond between A40 or R10 and the nitrogen atom);
however, in the combination of G, A10, A20, A30, and A40, when G represents the Formula (G1) and either of A10 or A30 is a phenylene group, A20 may not be a single bond and when A20 represents a single bond, then G and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between; in addition, when A20 represents one of the Formula (A2A), Formula (A2B) or Formula (A2C), A20 and the nitrogen atom bonded to R10 and R20 must be bonded with more than two carbon atoms in between;
R10 and R20 are either identical or different, and either represents one functional group chosen from the following items 1) to 7):
1) a hydrogen atom (however, when R10 and R20 both represent a hydrogen atom, only in the case where G is equal to Formula (G1)),
2) a substituted or an unsubstituted alkyl group having 1 to 10 carbon atoms, wherein the substituents are selected from the group consisting of fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, sulfonyl group having 1 to 6 carbon atoms, cycloalkyl group having 3 to 8 carbon atoms, and phenyl group,
3) a substituted or an unsubstituted cycloalkyl group having 3 to 8 carbon atoms, wherein the substituents are selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, an acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms,
4) a substituted or an unsubstituted phenyl group, wherein the substituents are selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms,
5) a substituted or an unsubstituted heterocyclic group selected from the group consisting of morpholino, pyrrolidinyl, and piperidino and, alkyl group having 1 to 4 carbon atoms, wherein the substituents are selected from the group consisting of fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms,
6) an acyl group having 1 to 10 carbon atoms,
7) a sulfonyl group having 1 to 8 carbon atoms; however, when either R10 or R20 represents a sulfonyl group having 1 to 8 carbon atoms, the other may neither be an acyl group having 1 to 10 carbon atoms nor a sulfonyl group having 1 to 8 carbon atoms,
or, when R10 and R20 are bonded together, they represent a functional group forming a cyclic amino group having 4 to 8 carbon atoms together with the nitrogen atom they are bonded to, wherein said cyclic amino group having 4 to 8 carbon atoms may be substituted with one or more substituents selected from the group consisting of alkyl group having 1 to 4 carbon atoms, fluorine atom, chlorine atom, bromine atom, iodine atom, hydroxyl group, alkoxy group having 1 to 4 carbon atoms, aryloxy group having 6 to 10 carbon atoms, aralkoxy group having 7 to 9 carbon atoms, acyloxy group having 2 to 10 carbon atoms, sulfonyloxy group having 1 to 8 carbon atoms, oxo group, acyl group having 1 to 10 carbon atoms, carboxyl group, alkoxycarbonyl group having 2 to 10 carbon atoms, carbamoyl group having 1 to 15 carbon atoms, amino group having 0 to 14 carbon atoms, acylamino group having 1 to 10 carbon atoms, sulfonylamino group having 1 to 8 carbon atoms, imino group having 1 to 10 carbon atoms, cyano group, nitro group, sulfide group having 1 to 6 carbon atoms, sulfinyl group having 1 to 6 carbon atoms, and sulfonyl group having 1 to 6 carbon atoms.

2. A nitrogen-containing compound or a salt thereof of claim 1, wherein G in the above Formula (2) is one functional group chosen from the group consisting of the Formulae (G1E), (G2E), (G3E), (G4E), and (G5E) shown below:






In the above Formula (G1E), Formula (G2E), Formula (G3E), Formula (G4E) and Formula (G5E), the symbol  indicates that the bond is in the β position with respect to the carbon atom forming the cyclic structure it is bonded to, and the symbol  indicates that the bonds are in the a position with respect to the carbon atoms forming the cyclic structures they are bonded to.

3. A nitrogen-containing compound or a salt thereof of claim 1, wherein G in the above Formula (2) is a functional group having the Formula (G1).

4. A nitrogen-containing compound or a salt thereof of claim 2, wherein G in the above Formula (2) is a functional group having the Formula (G1E).

5. A nitrogen-containing compound or a salt thereof of claim 2, wherein G in the above Formula (2) is one functional group chosen from the group consisting of the above Formulae (G2E), (G3E), (G4E) and (G5E).

6. A nitrogen-containing compound of a salt thereof of claim 2, wherein G in the above Formula (2) is a functional group having the Formula (G3E).